Heteroaromatic ring compound, pharmaceutical composition thereof and use thereof
By developing a heteroaromatic ring compound with novel structure, the problem of insufficient types of existing FGFR2 inhibitors was solved, effective inhibition and selectivity of FGFR2 abnormalities was achieved, significantly slowing down cancer cell proliferation, reducing adverse reactions and tolerance Drug properties risk.
Patent Information
- Application Number
- PCT/CN2024/095527
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-14
- Filing Date
- 2024-05-27
- Publication Date
- 2024-12-05
AI Technical Summary
The lack of existing FGFR2 inhibitors leads to insufficient inhibitory activity and selectivity for abnormal FGFR2, and there are serious adverse reactions and drug resistance problems, which limits its application in treatment.
A novel structure heteroaromatic ring compound has been developed, which has good inhibitory activity and selectivity for FGFR2 abnormalities, and has the ability to treat human gastric cancer cells SNU-16, human small cell lung cancer cells DMS114, and human bladder cancer cells RT112/84. Good selectivity.
This compound effectively inhibits FGFR2 abnormality, significantly slows the proliferation of cancer cells, provides a safe and effective selective small molecule inhibitor, reducing the risk of adverse reactions and drug resistance.
Smart Images

Figure PCTCN2024095527-FTAPPB-I100001 
Figure PCTCN2024095527-FTAPPB-I100002 
Figure PCTCN2024095527-FTAPPB-I100003
Abstract
Description
Heteroaromatic ring compounds, pharmaceutical compositions and applications thereof
[0001] This application claims priority to Chinese Patent Application No. 202310612074X filed on May 26, 2023, Chinese Patent Application No. 202310725862X filed on June 16, 2023, Chinese Patent Application No. 2023107918403 filed on June 29, 2023, and Chinese Patent Application No. 2023115206627 filed on November 14, 2023. The entire contents of the aforementioned Chinese patent applications are incorporated herein by reference. Technical Field
[0002] The present invention relates to a heteroaromatic ring compound, a pharmaceutical composition and application thereof. Background Art
[0003] The fibroblast growth factor receptor (FGFR) family belongs to the receptor tyrosine kinase (RTK) family and includes four receptor subtypes (FGFR1, FGFR2, FGFR3, and FGFR4). In the FGF signaling pathway, fibroblast growth factor binds to the FGFR receptor, inducing FGFR dimerization and phosphorylating tyrosine residues at the cytoplasmic end of the FGFR, activating the downstream FRS2-Ras-MAPK, PLCγ, and PI3K-AKT / PKB signaling pathways. Under physiological conditions, the FGFR signaling pathway is involved in regulating multiple processes, including embryonic development, cell proliferation and migration, and angiogenesis.
[0004] The FGFs in the human body are divided into six subfamilies, which are divided into two major categories: classical FGFs and hormonal FGFs. Classical FGFs include FGF1-10, 16-18, 20, and 22, which can bind to FGFR1-4. Hormonal FGFs include FGF19, 21, and 23, which primarily bind to FGFR1 and FGFR4. FGF19-FGFR4 regulates bile acid metabolism, while FGF23-FGFR1 regulates blood calcium, phosphorus, and vitamin D levels (C. Degirolamo et al., Nat Rev Drug Discov. 2016;15:51-69). This makes inhibition of FGFR1 and FGFR4 potentially target-related toxicity, leading to serious adverse reactions such as hyperphosphatemia and diarrhea.
[0005] FGFR mutation activation or high expression is closely related to the occurrence and development of human tumors. FGFR activation mutations or overexpression in cells can lead to the persistence and excessive activation of the FGFR signaling pathway, causing cells to acquire carcinogenic functions such as excessive proliferation and apoptosis escape. Studies have shown that 7% of cancers have FGFR abnormalities, including FGFR1 (49%), FGFR2 (19%), FGFR3 (26%) and FGFR4 (7%). Among them, the incidence of FGFR2 abnormalities is higher in endometrial cancer, bile duct cancer and gastric cancer (T. Helsten et al., Clin Cancer Res. 2016, 22: 259-267).
[0006] Currently, several FGFR inhibitors are on the market, such as the pan-FGFR inhibitors erdatinib and pemigatinib. Both can cause severe adverse reactions such as hyperphosphatemia and diarrhea due to their inhibition of FGFR1 and FGFR4. In addition to target-related toxicities, pan-FGFR inhibitors can also develop drug resistance during treatment. These adverse reactions and acquired drug resistance have significantly limited the application of pan-FGFR inhibitors.
[0007] RLY-4008 is the first selective FGFR2 inhibitor developed by RELAY THERAPEUTICS, INC. and is currently in clinical development. Its structure is disclosed in WO2020231990 A1 as follows:
[0008] Although some progress has been made in this field, no FGFR2 selective inhibitor drugs have been approved for marketing, so there is still a need to continue to develop effective and safe selective small molecule FGFR2 inhibitors.
[0009] Summary of the Invention
[0010] The present invention aims to overcome the shortage of FGFR2 inhibitors in the prior art by providing novel heteroaromatic compounds, pharmaceutical compositions thereof, and their applications. The compounds of the present invention exhibit excellent inhibitory activity and selectivity against FGFR2 abnormalities, as well as potent proliferation inhibition against human gastric cancer cells SNU-16 and good selectivity against human small cell lung cancer cells DMS114 and human bladder cancer cells RT112 / 84.
[0011] The present invention solves the above technical problems through the following methods.
[0012] The present invention provides a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
[0013] in:
[0014] X is CR X or N;
[0015] R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl;
[0016] Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl;
[0017] or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group;
[0018] Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0019] R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl;
[0020] Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl;
[0021] Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0022] Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0023] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 2a replace;
[0024] Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0025] Each R 2-a are independently hydrogen or C 1-6 alkyl;
[0026] m is 0, 1, 2, 3, 4 or 5;
[0027] Each R 8 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl;
[0028] Each R 8a and R 8b are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 8-a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group or one or more R 8-b Substituted C 3-8 Cycloalkyl;
[0029] Each R 8-a and R 8-b are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0030] Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene;
[0031] Each R 3are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 3a replace;
[0032] Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0033] n is 0, 1, 2, 3 or 4;
[0034] L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L)-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-;
[0035] Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl;
[0036] Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0037] R 7 For halogen, cyano,
[0038] R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl;
[0039] Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl, -OC 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0040] R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl;
[0041] Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0042] R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C( O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9)2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 )、-P(O)(R 18 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl;
[0043] Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl;
[0044] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0045] Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl;
[0046] Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group;
[0047] Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 Deuterium, C 1-6 Alkyl, halogen, cyano, hydroxyl or -N(R 12 )2;
[0048] Each R 12 are each independently hydrogen or C 1-6 alkyl;
[0049] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl;
[0050] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0051] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0052] Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f Each is independently -S(O)2(R 19 ), deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Substituted C 3-8 Cycloalkyl;
[0053] Each R 9-a 、R 9-b 、R 9-c and R 9-d Deuterium, C 1-6 Alkyl, hydroxyl, halogen, cyano, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2;
[0054] Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11esubstituted 5-10 membered heteroaryl;
[0055] Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl;
[0056] Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0057] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0058] Each R 16 Independently C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0059] Each R 17 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0060] Each R 18 are independently hydrogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0061] Each R 19 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0062] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2, 3 or 4;
[0063] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0064] The present invention provides a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
[0065] in:
[0066] X is CR X or N;
[0067] R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl;
[0068] Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl;
[0069] or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group;
[0070] Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0071] R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl;
[0072] Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl;
[0073] Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0074] Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0075] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 2a replace;
[0076] Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0077] Each R 2-a are independently hydrogen or C 1-6 alkyl;
[0078] m is 0, 1, 2, 3, 4 or 5;
[0079] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl;
[0080] Each R 8a are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0081] Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene;
[0082] Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N( R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 3a replace;
[0083] Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0084] n is 0, 1, 2, 3 or 4;
[0085] L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-;
[0086] Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl;
[0087] Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0088] R 7 For halogen, cyano,
[0089] R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl;
[0090] Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-gare independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl or -OC 1-6 alkyl;
[0091] R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl;
[0092] Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0093] R 5 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 )、-P(O)(R 18 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl;
[0094] Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl;
[0095] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0096] Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl;
[0097] Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4substituted 3-12 membered heterocyclic hydrocarbon group;
[0098] Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 are each independently deuterium, halogen, cyano, hydroxyl or -N(R 12 )2;
[0099] Each R 12 are each independently hydrogen or C 1-6 alkyl;
[0100] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl;
[0101] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0102] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0103] Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f Each is independently -S(O)2(R 19 ), deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Substituted C 3-8 Cycloalkyl;
[0104] Each R 9-a 、R 9-b 、R 9-c and R 9-d Deuterium, C 1-6 Alkyl, hydroxyl, halogen, cyano, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2;
[0105] Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl;
[0106] Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl;
[0107] Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0108] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0109] Each R 16 Independently C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0110] Each R 17 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0111] Each R 18 are independently hydrogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0112] Each R 19 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0113] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0114] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0115] The present invention provides a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
[0116] in:
[0117] X is CR X or N;
[0118] R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl;
[0119] Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl;
[0120] or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group;
[0121] Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0122] R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl;
[0123] Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C 6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl;
[0124] Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0125] Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10Aryl or 5-10 membered heteroaryl;
[0126] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 2a replace;
[0127] Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0128] Each R 2-a are independently hydrogen or C 1-6 alkyl;
[0129] m is 0, 1, 2, 3, 4 or 5;
[0130] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl;
[0131] Each R 8a are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0132] Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene;
[0133] Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N( R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 3a replace;
[0134] Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0135] n is 0, 1, 2, 3 or 4;
[0136] L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-;
[0137] Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl;
[0138] Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0139] R 7 For halogen, cyano,
[0140] R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl;
[0141] Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl or -OC 1-6 alkyl;
[0142] R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl;
[0143] Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0144] R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl;
[0145] Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl;
[0146] Each R 15Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0147] Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl;
[0148] Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group;
[0149] Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 are each independently deuterium, halogen, cyano, hydroxyl or -N(R 12 )2;
[0150] Each R 12 are each independently hydrogen or C 1-6 alkyl;
[0151] Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl;
[0152] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0153] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0154] Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo, C 1- 6-alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Substituted C 3-8 Cycloalkyl;
[0155] Each R 9-a 、R 9-b 、R 9-c and R 9-d are each independently deuterium, hydroxyl, halogen, cyano or -NH2;
[0156] Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl;
[0157] Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl;
[0158] Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0159] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0160] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0161] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0162] The present invention provides a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
[0163] in:
[0164] X is CR X or N;
[0165] R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen1-6 alkyl;
[0166] Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl;
[0167] or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group;
[0168] Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0169] R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl;
[0170] Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C 6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl;
[0171] Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-hare independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0172] Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0173] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more R 2a replace;
[0174] Each R 2aare independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0175] Each R 2-a are independently hydrogen or C 1-6 alkyl;
[0176] m is 0, 1, 2, 3, 4 or 5;
[0177] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl;
[0178] Each R 8a are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0179] Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene;
[0180] Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more R 3a replace;
[0181] Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0182] n is 0, 1, 2, 3 or 4;
[0183] L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-;
[0184] Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl;
[0185] Each R La 、R Lb 、R Lc 、RLd and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl;
[0186] R 7 For halogen, cyano,
[0187] R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl;
[0188] Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl or -OC 1-6 alkyl;
[0189] R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl;
[0190] Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl;
[0191] R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R5h substituted 5-10 membered heteroaryl;
[0192] Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl;
[0193] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0194] Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl;
[0195] Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group;
[0196] Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 are each independently deuterium, halogen, cyano, hydroxyl or -N(R 12 )2;
[0197] Each R 12 are each independently hydrogen or C 1-6 alkyl;
[0198] Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl;
[0199] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0200] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0201] Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo, C 1- 6-alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Substituted C 3-8 Cycloalkyl;
[0202] Each R 9-a 、R 9-b 、R 9-cand R 9-d are each independently deuterium, hydroxyl, halogen, cyano or -NH2;
[0203] Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl;
[0204] Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl;
[0205] Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl;
[0206] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0207] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0208] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0209] In a certain embodiment, in the compound represented by formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, certain groups have the following definitions, and the definitions of the unmentioned groups are as described in any embodiment of the present invention (this paragraph is hereinafter referred to as "in a certain embodiment").
[0210] In one scenario, each C 6-10Aryl groups may independently be phenyl or naphthyl, for example phenyl.
[0211] In one scenario, each C 6-10 Arylene groups can independently be phenylene or naphthylene, for example phenylene, for example
[0212] In one embodiment, each halogen can independently be fluorine, chlorine, bromine or iodine, for example fluorine or chlorine, for example fluorine.
[0213] In one scenario, each C 1-6 Alkyl groups may independently be C 1-4 Alkyl may in turn be methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl or sec-butyl, for example methyl, ethyl, isopropyl or isobutyl.
[0214] In one scenario, each -OC 1-6 The alkyl groups may independently be -OC 1-4 Alkyl can also be -O-methyl, -O-ethyl, -O-n-propyl, -O-isopropyl, -O-n-butyl, -O-tert-butyl, -O-isobutyl or -O-sec-butyl, for example -O-methyl, -O-ethyl or -O-isobutyl, for example -O-methyl.
[0215] In a certain embodiment, each 3-12 membered heterocycloalkyl group can independently be a 3-10 membered heterocycloalkyl group, and the 3-10 membered heterocycloalkyl group can be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0216] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0217] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0218] In a certain embodiment, each 3-12 membered heterocycloalkyl group can independently be a 3-10 membered heterocycloalkyl group, and the 3-10 membered heterocycloalkyl group can be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0219] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0220] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0221] In a certain embodiment, each 3-10 membered heterocycloalkyl group can independently be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0222] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0223] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0224] In a certain embodiment, each 3-12 membered heterocycloalkyl group may independently be a 3-10 membered heterocycloalkyl group, and the 3-10 membered heterocycloalkyl group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0225] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0226] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two, or more of N, O, or S, and the number of heteroatoms is 1, 2, or 3.
[0227] In a certain embodiment, each 3-10 membered heterocycloalkyl group can independently be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0228] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0229] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two, or more of N, O, or S, and the number of heteroatoms is 1, 2, or 3.
[0230] In a certain embodiment, each 3-12 membered heterocycloalkyl group can independently be a 3-10 membered heterocycloalkyl group, and the 3-10 membered heterocycloalkyl group can be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0231] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0232] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2, 3 or 4. Further example
[0233] In a certain embodiment, each 3-10 membered heterocycloalkyl group can independently be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group;
[0234] The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example
[0235] The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2, 3 or 4. Further example
[0236] In one scenario, R 7b and R 7c In the embodiment, each 3-10 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic alkyl group or a 3-10 membered heterocyclic alkenyl group, and the 3-10 membered heterocyclic alkyl group may be a 3-6 membered monocyclic heterocyclic alkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocyclic alkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0237] In one scenario, R 7b and R 7c In the embodiment, each 3-10 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic alkyl group or a 3-10 membered heterocyclic alkenyl group, and the 3-10 membered heterocyclic alkyl group may be a 3-6 membered monocyclic heterocyclic alkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocyclic alkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0238] In one scenario, R 7b 、R 7c 、R 7-a and R 11 In the embodiment, each 3-10 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic alkyl group or a 3-10 membered heterocyclic alkenyl group, and the 3-10 membered heterocyclic alkyl group may be a 3-6 membered monocyclic heterocyclic alkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocyclic alkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3. Further example
[0239] In one scenario, R 5 、R 5a 、R 5-f 、R 9 、R 9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic or bridged) heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0240] In one scenario, R 5 、R 5a 、R 5-f 、R9 、R 9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic or bridged) heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., fused, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3.
[0241] In one scenario, R 5 、R 5a 、R 5-f 、R 9 、R 9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two, or more of N, O, or S, and the number of heteroatoms is 1, 2, or 3.
[0242] In one scenario, R 5 、R 5a 、R 5-b 、R 5-f 、R 9 、R 9a 、R9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2, 3 or 4. Further example
[0243] In one scenario, each C 3-8 The cycloalkyl groups may be independently C 3-8 Cycloalkyl or C 3-8 Cycloalkenyl, such as C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl can be C 3-8 Monocyclic cycloalkyl or C 6-8 Polycyclic (eg, cyclo, spiro or bridged) cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, such as cyclopropyl; the C 3-8 Cycloalkenyl can be C 3-8 Monocyclic cycloalkenyl or C 6-8 Polycyclic (eg, fused, spiro, or bridged) cycloalkenyl.
[0244] In one scenario, each C 1-6 The alkylene group may independently be methylene, ethylene, n-propylene, isopropylene, n-butylene, tert-butylene, isobutylene or sec-butylene, and is preferably methylene.
[0245] In one scenario, each C 2-6 The alkenyl group may independently be ethenyl, propenyl, butenyl or pentenyl.
[0246] In one scenario, each C 2-6 Alkynyl may independently be ethynyl, propynyl, butynyl or pentynyl, for example
[0247] In a certain embodiment, each 5-10 membered heteroaryl group can independently be a 5-6 membered monocyclic heteroaryl group or an 8-10 membered polycyclic (e.g., cyclic, spiro or bridged) heteroaryl group, wherein the heteroatom species is N and the number of heteroatoms is 1, 2 or 3, such as pyridyl, and
[0248] In one embodiment, each 5-10 membered heteroarylene group can independently be a 5-6 membered monocyclic heteroarylene group or an 8-10 membered polycyclic (e.g., fused, spiro, or bridged) heteroarylene group, wherein the heteroatom species is N and the number of heteroatoms is 1, 2, or 3.
[0249] In one scenario, each C 3-8 The cycloalkylene groups may independently be C 3-8 Cycloalkylene or C 3-8 Cycloalkenylene, the C 3-8 Cycloalkylene can be C 3-8 Monocyclic cycloalkylene or C 6-8 Polycyclic (eg, cyclic, spiro or bridged) cycloalkylene, the C 3-8 Cycloalkenylene can be C 3-8 Monocyclic cycloalkenylene or C 6-8 Polycyclic (eg, cyclopentyl, spirocyclopentyl or bridged) cycloalkenylene.
[0250] In a certain embodiment, each 3-10 membered heterocycloalkylene group may independently be a 3-10 membered heterocycloalkylene group or a 3-10 membered heterocycloalkenylene group, the 3-10 membered heterocycloalkylene group may be a 3-6 membered monocyclic heterocycloalkylene group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkylene group, wherein the heteroatoms are one or both of N and O, and the number of heteroatoms is 1, 2 or 3; the 3-10 membered heterocycloalkenylene group may be a 3-6 membered monocyclic heterocycloalkenylene group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkenylene group, wherein the heteroatoms are one or both of N and O, and the number of heteroatoms is 1, 2 or 3.
[0251] In one scenario, each -SC 1-6 The alkyl group may independently be -S-C1-4 alkyl, or may be methylmercapto, ethylmercapto, n-propylmercapto, isopropylmercapto, n-butylmercapto, isobutylmercapto, sec-butylmercapto or tert-butylmercapto.
[0252] In one solution, X is CR X .
[0253] In one scenario, R X For hydrogen.
[0254] In one scenario, R 1 -N(R6 )2.
[0255] In one scheme, each R 6 are independently hydrogen.
[0256] In one embodiment, ring A is C 6-10 Aryl or 5-10 membered heteroaryl, preferably C 6-10 Aryl.
[0257] In one scheme, each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, preferably halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, more preferably -OC 1-6 Alkyl or -C(O)N(R 8 )2.
[0258] In one scheme, each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; preferably each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a More preferably, each R 2 Independently -OC 1-6 Alkyl or -C(O)N(R8 )2.
[0259] In one scheme, each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; preferably each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl, -N(R 8 )2 or -C(O)N(R 8 )2, where C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a More preferably, each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, where -OC 1-6 Alkyl is unsubstituted or substituted with one or more R 2a replace.
[0260] In one embodiment, m is 1, 2 or 3, preferably 2.
[0261] In one embodiment, m is 1, 2 or 3, preferably 2 or 3, more preferably 2.
[0262] In one scheme, each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl.
[0263] In one scheme, each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 Alkyl; preferably, each R 8 are independently hydrogen or replaced by one or more R8a Substituted C 1-6 alkyl.
[0264] In one scheme, each R 8a are independently deuterium, halogen or hydroxyl; preferably, each R 8a is independently deuterium or a halogen.
[0265] In one scheme, each R 8 are independently hydrogen, C 1-6 Alkyl, one or more R 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl; preferably, each R 8 are independently hydrogen, 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cyclic hydrocarbon group.
[0266] In one scheme, each R 8a and R 8b Each independently represents deuterium, halogen, hydroxyl, one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cycloalkyl; preferably, each R 8a are independently deuterium, halogen, or one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cyclic hydrocarbon group, each R 8b are independently halogen or are replaced by one or more R 8-a Substituted C 1-6 alkyl.
[0267] In one scheme, each R 8-a and R 8-b It is a halogen.
[0268] In one scheme, each R 8a are independently halogen or hydroxy, preferably halogen.
[0269] In one scheme, each R 2a are independently deuterium, halogen or hydroxy, preferably deuterium or halogen, more preferably deuterium.
[0270] In one embodiment, ring B is C 6-10 Arylene or 5-10 membered heteroarylene, preferably C 6-10Arylene.
[0271] In one scenario, R 3 Halogen or C 1-6 alkyl.
[0272] In one embodiment, n is 0, 1 or 2, preferably 0.
[0273] In one embodiment, n is 0 or 1.
[0274] In one embodiment, L is -N(R L )C(O)-.
[0275] In one scenario, R L is hydrogen or C 1-6 Alkyl, preferably hydrogen.
[0276] In one scenario, R 7 for
[0277] In one scenario, R 7a is hydrogen, halogen or C 1-6 Alkyl, preferably halogen.
[0278] In one scenario, R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, preferably hydrogen or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, more preferably hydrogen.
[0279] In one scenario, R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, preferably R 7b is hydrogen, is replaced by one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group.
[0280] In one scenario, R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, preferably hydrogen or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, more preferably hydrogen.
[0281] In one scenario, R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, preferably R 7c is hydrogen, is replaced by one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group.
[0282] In one scheme, each R 7-e are independently halogen, hydroxy or C 1-6 Alkyl, preferably C 1-6 alkyl.
[0283] In one scheme, each R 7-a and R 7-e are independently halogen, hydroxy, C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group, preferably each R 7-a and R 7-e Each independently is C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group.
[0284] In one scheme, each R 7-a and R 7-e are each independently halogen, hydroxyl or C 1-6 Alkyl; preferably, each R 7-a and R 7-e Each independently is C 1-6 alkyl.
[0285] In one scenario, R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 Alkyl, preferably C 1-6 alkyl.
[0286] In one scheme, each R 4a are independently halogen or cyano.
[0287] In one scenario, R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R5f The substituted 3-12 membered heterocyclic hydrocarbon group is preferably substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, more preferably substituted by one or more R 5a Substituted C 1-6 Alkyl or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0288] In one scenario, R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; preferably one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; more preferably one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3- 8-cyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0289] In one scenario, R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; For example, R 5 -C(O)(R 11 )、-C(O)N(R9 )2、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group; for example, R 5 -C(O)(R 11 )、-C(O)N(R 9 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0290] In one scenario, R 5 -C(O)(R 11 )、-C(O)N(R 9 )2、-P(O)(R 18 )2, 3-12 membered heterocyclic hydrocarbon group, one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group; for example, R 5 -C(O)(R 11 )、-C(O)N(R 9 )2, 3-12 membered heterocyclic hydrocarbon group, one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0291] In one scheme, each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-fSubstituted 3-12 membered heterocyclic hydrocarbon group, preferably hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group, more preferably -NR 9 R 10 or a 3-12 membered heterocyclic hydrocarbon group.
[0292] In one scheme, each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group; preferably hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; more preferably hydroxyl, -NR 9 R 10 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5- f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0293] In one scheme, each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 5a are independently hydroxyl, -NR 9R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0294] In a certain scheme, when R 5a is a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 5-f The substituted 3- to 12-membered heterocyclic hydrocarbon group is preferably a 3- to 6-membered monocyclic heterocyclic alkyl group or a 6- to 10-membered polycyclic heterocyclic alkyl group (eg, a bridged ring).
[0295] In a certain scheme, when R 5a is a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 5-f A substituted 3- to 12-membered heterocyclic hydrocarbon group, wherein the heteroatoms in the 3- to 12-membered heterocyclic hydrocarbon group are selected from one or both of N and O, and the number of the heteroatoms is 1 or 2.
[0296] In a certain scheme, when R 5a is a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, when at least one hetero atom in the 3-12 membered heterocyclic hydrocarbon group is N, the 3-12 membered heterocyclic hydrocarbon group is preferably connected to R 5 C 1-6 Alkyl linkage.
[0297] In one scheme, each R 5-b are independently halogen, hydroxy or -OC 1-6 Alkyl, preferably hydroxy or -OC 1-6 alkyl.
[0298] In one scheme, each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; more preferably, each R 5-b are independently hydroxy or -OC 1-6 alkyl.
[0299] In one scheme, each R 5-a-4 C 1-6 alkyl.
[0300] In one scheme, each R 15 Independently C 3-8 cycloalkyl or 3-12 membered heterocycloalkyl, preferably 3-12 membered heterocycloalkyl.
[0301] In one scheme, each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b Substituted 3-12 membered heterocyclic hydrocarbon group.
[0302] In one scheme, each R 15b are independently halogen or C 1-6 alkyl.
[0303] In one scheme, each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, preferably halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl.
[0304] In one scheme, each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, preferably halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, more preferably halogen, hydroxy or C 1-6 alkyl.
[0305] In one scheme, each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, preferably halogen, hydroxy, -N(R 12 )2 or C 1-6 alkyl.
[0306] In one scheme, each R 5-a-1 are independently halogen or hydroxy, preferably hydroxy.
[0307] In one scheme, each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 , preferably -NR 9 R 10 .
[0308] In one scheme, each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 , preferably halogen or -NR 9 R 10 , more preferably -NR 9 R 10 .
[0309] In one scheme, each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 , preferably hydroxyl or -NR 9 R 10 , more preferably -NR 9 R 10 .
[0310] In one scheme, each R 5f For hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 .
[0311] In one scheme, each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R9a Substituted C 1-6 Alkyl, preferably hydrogen or C 1-6 alkyl;
[0312] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f Substituted 3-12 membered heterocyclic hydrocarbon group, preferably R 9 and R 10 Together with the nitrogen atom to which they are commonly attached, they form a 3-12 membered heterocyclic hydrocarbon group.
[0313] In one scheme, each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0314] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0315] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0316] For example, each R 9 and R 10 Each independently represents hydrogen, hydroxy, 3-12 membered heterocyclic hydrocarbon, one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group or C 1-6 alkyl;
[0317] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0318] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0319] In one scheme, each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0320] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0321] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f Substituted 3-12 membered heterocyclic hydrocarbon group.
[0322] In one scheme, each R 9a are independently halogen or hydroxy, preferably hydroxy.
[0323] In one scheme, each R 9a are independently halogen, hydroxy, 3-12 membered heterocyclic hydrocarbon or -N(R 14 )2.
[0324] In one scheme, each R 9a are independently halogen, hydroxy, -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 9a are independently -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group.
[0325] In one scheme, each R 9-c Independently C 1-6 alkyl.
[0326] In one scheme, each R 9b are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl or C 1-6 alkyl.
[0327] In one scheme, each R 9c Independently C 1-6 alkyl.
[0328] In one scheme, each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cyclic hydrocarbon groups, preferably halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group.
[0329] In one scheme, each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cyclic hydrocarbon group, preferably, halogen, hydroxyl, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group, more preferably halogen, hydroxyl or C 1-6 alkyl.
[0330] In one scheme, each R 9f are independently halogen, hydroxy, oxo (=O), -N(R 14 )2、C 1-6 Alkyl, -S(O)2(R 19 ), C3-8 Cycloalkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; for example, each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 3-8 Cycloalkyl, oxo (=O), C 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group.
[0331] In one scheme, each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -S(O)2(R 19 ), by one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cyclic hydrocarbon group.
[0332] In one scheme, each R 9-a are independently hydroxy, halogen or -NH2, preferably hydroxy.
[0333] In one scheme, each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ), halogen, -NHR 16 、-N(R 16 )2 or -NH2, for example, each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ) or -N(R 16 )2, preferably, each R 9-a Each independently is C 1- 6 alkyl or hydroxyl.
[0334] In one scheme, each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2; Preferably, each R 9-a are independently hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2.
[0335] In one scheme, each R11 Independently C 1-6 alkyl.
[0336] In one scheme, each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c Substituted 3-10 membered heterocyclic hydrocarbon group; for example, each R 11 is independently a 3-10 membered heterocyclic hydrocarbon group or is replaced by one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group.
[0337] In one scheme, each R 11c are independently -NH2, hydroxyl or C 1-6 Alkyl; for example, each R 11c are independently hydroxy or C 1-6 Alkyl groups, such as C 1-6 alkyl.
[0338] In one scheme, each R 12 are independently hydrogen.
[0339] In one scheme, each R 12 Independently C 1-6 alkyl.
[0340] In one scheme, each R 13 are independently hydrogen or C 1-6 alkyl.
[0341] In one scheme, each R 14 are independently hydrogen.
[0342] In one scheme, each R 14 Independently C 1-6 alkyl.
[0343] In one scheme, each R 16 Independently C 1-6 alkyl.
[0344] In one scheme, each R 17 Independently C 1-6 alkyl.
[0345] In one scheme, each R 18 Independently C 1-6 alkyl.
[0346] In one scheme, each R 19 Independently C 1-6 alkyl.
[0347] In one embodiment, the stereoisomer refers to a configurational isomer, a conformational isomer, or a mixture thereof, such as an enantiomer, a diastereomer, or a mixture thereof (eg, an enantiomer).
[0348] In a certain embodiment, when the compound represented by formula (I) contains a chiral center, the compound represented by formula (I) is each stereoisomer or a mixture thereof. For example, when it contains one chiral center, the compound represented by formula (I) is R configuration and / or S configuration.
[0349] In one solution, X is CR X ;
[0350] R X is hydrogen;
[0351] R 1 -N(R 6 )2;
[0352] Each R 6 are independently hydrogen;
[0353] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0354] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2;
[0355] m is 1, 2, or 3;
[0356] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0357] Each R 8a are independently halogen or hydroxy;
[0358] Ring B is C 6-10 Arylene or 5-10 membered heteroarylene;
[0359] n is 0, 1, or 2;
[0360] L is -N(R L )C(O)-;
[0361] R L is hydrogen or C 1-6alkyl;
[0362] R 7 for
[0363] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0364] R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0365] R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0366] Each R 7-e are independently halogen, hydroxy or C 1-6 alkyl;
[0367] R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 alkyl;
[0368] Each R 4a are independently halogen or cyano;
[0369] R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group;
[0370] Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0371] Each R5-b are independently halogen, hydroxy or -OC 1-6 alkyl;
[0372] Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl;
[0373] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0374] Each R 5-a-1 are independently halogen or hydroxy;
[0375] Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0376] Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0377] Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl;
[0378] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0379] Each R 9a are independently halogen or hydroxy;
[0380] Each R 9f are independently halogen, hydroxy, oxo, -N(R14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl;
[0381] Each R 9-a are independently hydroxy, halogen or -NH2;
[0382] Each R 11 Independently C 1-6 alkyl;
[0383] Each R 12 are independently hydrogen;
[0384] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0385] Each R 14 are independently hydrogen. (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0386] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0387] In one solution, X is CR X ;
[0388] R X is hydrogen;
[0389] R 1 -N(R 6 )2;
[0390] Each R 6 are independently hydrogen;
[0391] Ring A is C 6-10 aryl;
[0392] Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2;
[0393] m is 2;
[0394] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C1-6 alkyl;
[0395] Each R 8a are independently halogen;
[0396] Ring B is C 6-10 arylene;
[0397] n is 0;
[0398] L is -N(R L )C(O)-;
[0399] R L is hydrogen;
[0400] R 7 for
[0401] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0402] R 7b is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0403] R 7c is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0404] Each R 7-e Independently C 1-6 alkyl;
[0405] R 4 C 1-6 alkyl;
[0406] R 5 For one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group;
[0407] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0408] Each R 5-b are independently hydroxy or -OC 1-6 alkyl;
[0409] Each R 15 are independently 3-12 membered heterocyclic hydrocarbon groups;
[0410] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0411] Each R 5-a-1 are independently hydroxyl groups;
[0412] Each R 5e are independently -NR 9 R 10 ;
[0413] Each R 5f are independently hydroxy or -NR 9 R 10 ;
[0414] Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl;
[0415] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0416] Each R 9a are independently hydroxyl groups;
[0417] Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group;
[0418] Each R 9-a are independently hydroxyl groups;
[0419] Each R 11 Independently C 1-6 alkyl;
[0420] Each R 12 are independently hydrogen;
[0421] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0422] Each R 14 are independently hydrogen. (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0423] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0424] In one plan,
[0425] X is CR X ;
[0426] R X is hydrogen;
[0427] R 1 -N(R 6 )2;
[0428] Each R 6 are independently hydrogen;
[0429] Ring A is C 6-10 aryl;
[0430] Each R 2 Independently -OC 1-6 Alkyl or -C(O)N(R 8 )2;
[0431] m is 2;
[0432] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0433] Each R 8a are independently halogen (e.g., fluorine);
[0434] Ring B is C 6-10 arylene;
[0435] n is 0;
[0436] L is -N(R L )C(O)-;
[0437] R L is hydrogen;
[0438] R 7 for
[0439] R 7a is a halogen (e.g., fluorine);
[0440] R 7b is hydrogen;
[0441] R 7c is hydrogen;
[0442] R 4 C 1-6 Alkyl groups (e.g., methyl);
[0443] R 5 For one or more R 5a Substituted C 1-6 Alkyl or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group;
[0444] Each R 5a are independently -NR 9 R 10 or a 3-12 membered heterocyclic hydrocarbon group;
[0445] Each R 5f are independently -NR 9 R 10 ;
[0446] Each R 9 and R 10 are each independently hydrogen or C 1-6 alkyl;
[0447] or R 9 and R 10 Together with the nitrogen atom to which they are commonly attached, they form a 3-12 membered heterocyclic hydrocarbon group. (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0448] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0449] In one solution, X is CRX ;
[0450] R X is hydrogen;
[0451] R 1 -N(R 6 )2;
[0452] Each R 6 are independently hydrogen;
[0453] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0454] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0455] m is 1, 2, or 3;
[0456] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0457] Each R 8a are independently halogen or hydroxy;
[0458] Each R 2a are independently deuterium, halogen or hydroxyl;
[0459] Ring B is C 6-10 Arylene or 5-10 membered heteroarylene;
[0460] n is 0, 1, or 2;
[0461] L is -N(R L )C(O)-;
[0462] R L is hydrogen or C 1-6 alkyl;
[0463] R 7 for
[0464] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0465] R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0466] R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0467] Each R 7-e are independently halogen, hydroxy or C 1-6 alkyl;
[0468] R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 alkyl;
[0469] Each R 4a are independently halogen or cyano;
[0470] R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0471] Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0472] Each R 5-b are independently halogen, hydroxy or -OC 1-6alkyl;
[0473] Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl;
[0474] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0475] Each R 5-a-1 are independently halogen or hydroxy;
[0476] Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0477] Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0478] Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl;
[0479] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0480] Each R 9a are independently halogen or hydroxy;
[0481] Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl;
[0482] Each R 9-a are independently hydroxy, halogen or -NH2;
[0483] Each R 11 Independently C 1-6 alkyl;
[0484] Each R 12 are independently hydrogen;
[0485] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0486] Each R 14 are independently hydrogen. (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0487] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0488] In one solution, X is CR X ;
[0489] R X is hydrogen;
[0490] R 1 -N(R 6 )2;
[0491] Each R 6 are independently hydrogen;
[0492] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0493] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0494] m is 1, 2, or 3;
[0495] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0496] Each R 8a are independently halogen or hydroxy;
[0497] Each R 2a are independently deuterium, halogen or hydroxyl;
[0498] Ring B is C 6-10 Arylene or 5-10 membered heteroarylene;
[0499] n is 0, 1, or 2;
[0500] L is -N(R L )C(O)-;
[0501] R L is hydrogen or C 1-6 alkyl;
[0502] R 7 for
[0503] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0504] R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0505] R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0506] Each R 7-e are independently halogen, hydroxy or C 1-6 alkyl;
[0507] R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 alkyl;
[0508] Each R 4a are independently halogen or cyano;
[0509] R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0510] Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0511] Each R 5-b are independently halogen, hydroxy or -OC 1-6 alkyl;
[0512] Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl;
[0513] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0514] Each R 5-a-1 are independently halogen or hydroxy;
[0515] Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6Alkyl or -NR 9 R 10 ;
[0516] Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0517] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0518] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0519] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0520] Each R 9a are independently halogen, hydroxy, 3-12 membered heterocyclic hydrocarbon or -N(R 14 )2;
[0521] Each R 9c Independently C 1-6 alkyl;
[0522] Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -S(O)2(R 19 ),-OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl;
[0523] Each R 9-a Independently C 1-6Alkyl, hydroxy, -S(O)2(R 17 ), halogen, -NHR 16 、-N(R 16 )2 or -NH2;
[0524] Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0525] Each R 11c are independently -NH2, hydroxyl or C 1-6 alkyl;
[0526] Each R 12 are independently hydrogen;
[0527] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0528] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0529] Each R 16 Independently C 1-6 alkyl;
[0530] Each R 17 Independently C 1-6 alkyl;
[0531] Each R 19 Independently C 1-6 alkyl;
[0532] Each R 18 Independently C 1-6 (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0533] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0534] In one solution, X is CR X ;
[0535] R X is hydrogen;
[0536] R 1 -N(R 6 )2;
[0537] Each R 6 are independently hydrogen;
[0538] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0539] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0540] m is 2 or 3;
[0541] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0542] Each R 8a are independently halogen;
[0543] Each R 2a are independently deuterium or halogen;
[0544] Ring B is C 6-10 arylene;
[0545] n is 0;
[0546] L is -N(R L )C(O)-;
[0547] R L is hydrogen;
[0548] R 7 for
[0549] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0550] R 7b is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0551] R 7c is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0552] Each R7-e Independently C 1-6 alkyl;
[0553] R 4 C 1-6 alkyl;
[0554] R 5 For one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0555] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0556] Each R 5-b are independently hydroxy or -OC 1-6 alkyl;
[0557] Each R 15 are independently 3-12 membered heterocyclic hydrocarbon groups;
[0558] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0559] Each R 5-a-1 are independently hydroxyl groups;
[0560] Each R 5e are independently halogen or -NR 9 R 10 ;
[0561] Each R 5f are independently hydroxy or -NR 9 R 10 ;
[0562] Each R9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl;
[0563] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0564] Each R 9a are independently hydroxyl groups;
[0565] Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group;
[0566] Each R 9-a are independently hydroxyl groups;
[0567] Each R 11 Independently C 1-6 alkyl;
[0568] Each R 12 are independently hydrogen;
[0569] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0570] Each R 14 are independently hydrogen. (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0571] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0572] In one solution, X is CR X ;
[0573] R X is hydrogen;
[0574] R 1 -N(R 6 )2;
[0575] Each R 6 are independently hydrogen;
[0576] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0577] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0578] m is 2 or 3;
[0579] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0580] Each R 8a are independently halogen;
[0581] Each R 2a are independently deuterium or halogen;
[0582] Ring B is C 6-10 arylene;
[0583] n is 0;
[0584] L is -N(R L )C(O)-;
[0585] R L is hydrogen;
[0586] R 7 for
[0587] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0588] R 7b is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0589] R 7cis hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0590] Each R 7-e Independently C 1-6 alkyl;
[0591] R 4 C 1-6 alkyl;
[0592] R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0593] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0594] Each R 5-b are independently hydroxy or -OC 1-6 alkyl;
[0595] Each R 15 are independently 3-12 membered heterocyclic hydrocarbon groups;
[0596] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0597] Each R 5-a-1 are independently hydroxyl groups;
[0598] Each R 5e are independently halogen or -NR 9 R10 ;
[0599] Each R 5f are independently hydroxy or -NR 9 R 10 ;
[0600] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0601] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0602] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0603] Each R 9a are independently halogen, hydroxy, 3-12 membered heterocyclic hydrocarbon or -N(R 14 )2;
[0604] Each R 9c Independently C 1-6 alkyl;
[0605] Each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 1-6 Alkyl, -S(O)2(R 19 ), C 3-8 Cycloalkyl, oxo (=O), -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group;
[0606] Each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ) or -N(R 16 )2;
[0607] Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0608] Each R 11c are independently -NH2, hydroxyl or C 1-6 alkyl;
[0609] Each R 12 are independently hydrogen;
[0610] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0611] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0612] Each R 16 Independently C 1-6 alkyl;
[0613] Each R 17 Independently C 1-6 alkyl;
[0614] Each R 19 Independently C 1-6 alkyl;
[0615] Each R 18 Independently C 1-6 (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0616] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0617] In one solution, X is CR X ;
[0618] R X is hydrogen;
[0619] R 1 -N(R 6 )2;
[0620] Each R 6 are independently hydrogen;
[0621] Ring A is C 6-10 aryl;
[0622] Each R 2 Independently -OC 1-6 Alkyl or -C(O)N(R 8 )2;
[0623] m is 2;
[0624] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0625] Each R 8a are independently halogen (e.g., fluorine);
[0626] Ring B is C 6-10 arylene;
[0627] n is 0;
[0628] L is -N(R L )C(O)-;
[0629] R L is hydrogen;
[0630] R 7 for
[0631] R 7a is a halogen (e.g., fluorine);
[0632] R 7b is hydrogen;
[0633] R 7c is hydrogen;
[0634] R 4 C 1-6 Alkyl groups (e.g., methyl);
[0635] R 5 For one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group;
[0636] Each R 5a are independently hydroxyl, -NR 9 R 10 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0637] Each R 5e are independently -NR9 R 10 ;
[0638] Each R 5f are independently -NR 9 R 10 ;
[0639] Each R 5-f are independently halogen, hydroxy or C 1-6 alkyl;
[0640] Each R 9 and R 10 are each independently hydrogen or C 1-6 alkyl;
[0641] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0642] Each R 9f are independently halogen, hydroxy or C 1-6 (Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0643] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0644] In one solution, X is CR X ;
[0645] R X is hydrogen;
[0646] R 1 -N(R 6 )2;
[0647] Each R 6 are independently hydrogen;
[0648] Ring A is C 6-10 aryl;
[0649] Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2;
[0650] m is 2;
[0651] Each R 8are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0652] Each R 8a are independently halogen (e.g., fluorine);
[0653] Ring B is C 6-10 arylene;
[0654] n is 0;
[0655] L is -N(R L )C(O)-;
[0656] R L is hydrogen;
[0657] R 7 for
[0658] R 7a is a halogen (e.g., fluorine);
[0659] R 7b is hydrogen;
[0660] R 7c is hydrogen;
[0661] R 4 C 1-6 Alkyl groups (e.g., methyl);
[0662] R 5 -C(O)(R 11 )、-C(O)N(R 9 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group;
[0663] Each R 5a are independently hydroxyl, -NR 9 R 10 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0664] Each R 5e are independently -NR 9 R 10 ;
[0665] Each R 5f are independently -NR 9 R 10;
[0666] Each R 5-f are independently halogen, hydroxy or C 1-6 alkyl;
[0667] Each R 9 and R 10 Each independently represents hydrogen, hydroxy, 3-12 membered heterocyclic hydrocarbon, one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group or C 1-6 alkyl;
[0668] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0669] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0670] Each R 9c Independently C 1-6 alkyl;
[0671] Each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 3-8 Cycloalkyl, oxo (=O), C 1-6 Alkyl, one or more R 9- a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group;
[0672] Each R 9-a Each independently is C 1-6 Alkyl or hydroxyl;
[0673] Each R 11 is independently a 3-10 membered heterocyclic hydrocarbon group or is replaced by one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0674] Each R 11c Independently C 1-6 alkyl;
[0675] Each R 14 are independently hydrogen or C 1-6(Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0676] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0677] In one embodiment, X is CH;
[0678] R 1 is -NH2;
[0679] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0680] Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0681] m is 2 or 3;
[0682] Each R 8 are independently hydrogen, C 1-6 Alkyl, one or more R 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3- 8-cyclic hydrocarbon group;
[0683] Each R 8a and R 8b Each independently represents deuterium, halogen, hydroxyl, one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cycloalkyl;
[0684] Each R 8-a and R 8-b are each independently halogen;
[0685] Each R 2a are independently deuterium or halogen;
[0686] Ring B is C 6-10 arylene;
[0687] R 3 Halogen or C 1-6 alkyl;
[0688] n is 0 or 1;
[0689] L is -NHC(O)-;
[0690] R 7 for
[0691] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0692] R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0693] R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0694] Each R 7-a and R 7-e are independently halogen, hydroxy, C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group;
[0695] R 4 C 1-6 alkyl;
[0696] R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5fSubstituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0697] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0698] Each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group;
[0699] Each R 5-a-4 C 1-6 alkyl;
[0700] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0701] Each R 15b are independently halogen or C 1-6 alkyl;
[0702] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0703] Each R 5-a-1 is halogen or hydroxy;
[0704] Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0705] Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0706] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0707] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0708] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0709] Each R 9a are independently halogen, hydroxy, -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group;
[0710] Each R 9-c Independently C 1-6 alkyl;
[0711] Each R 9b are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl or C 1-6 alkyl;
[0712] Each R 9c Independently C 1-6 alkyl;
[0713] Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6Alkyl, -S(O)2(R 19 ), by one or more R 9- a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, -OC 1-6 Alkyl or C 3-8 Cycloalkyl;
[0714] Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2;
[0715] Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0716] Each R 11c are independently hydroxy or C 1-6 alkyl;
[0717] Each R 12 are independently hydrogen or C 1-6 alkyl;
[0718] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0719] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0720] Each R 16 Independently C 1-6 alkyl;
[0721] Each R 17 Independently C 1-6 alkyl;
[0722] Each R 18 Independently C 1-6 alkyl;
[0723] Each R 19 Independently C 1-6 alkyl;
[0724] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2, 3 or 4;
[0725] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0726] In one embodiment, X is CH;
[0727] R 1 is -NH2;
[0728] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0729] Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, wherein said -OC 1-6 Each alkyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0730] m is 2 or 3;
[0731] Each R 8 are independently hydrogen, 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl;
[0732] Each R 8a are independently deuterium, halogen, or one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cyclic hydrocarbon group, each R 8b are independently halogen or are replaced by one or more R 8-a Substituted C 1-6 alkyl;
[0733] Each R 8-a and R 8-b are each independently halogen;
[0734] Each R 2a for deuterium;
[0735] Ring B is C 6-10 arylene;
[0736] R 3 Halogen or C 1-6 alkyl;
[0737] n is 0 or 1;
[0738] L is -NHC(O)-;
[0739] R 7 for
[0740] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0741] R 7b is hydrogen, is replaced by one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0742] R 7c is hydrogen, is replaced by one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0743] Each R 7-a and R 7-e Each independently is C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group;
[0744] R 4 C 1-6 alkyl;
[0745] R 5 -C(O)(R 11 ), by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0746] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0747] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15bsubstituted 3-12 membered heterocyclic hydrocarbon group;
[0748] Each R 15b are independently halogen or C 1-6 alkyl;
[0749] Each R 5-f are independently halogen, hydroxy, -N(R 12 )2 or C 1-6 alkyl;
[0750] Each R 5e are independently halogen or -NR 9 R 10 ;
[0751] Each R 5f are independently hydroxy or -NR 9 R 10 ;
[0752] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9a Substituted C 1- 6 alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0753] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0754] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0755] Each R 9a are independently -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group;
[0756] Each R 9-c Independently C 1-6 alkyl;
[0757] Each R 9c Independently C 1-6 alkyl;
[0758] Each R 9f are independently halogen, -N(R14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, one or more R 9-a Substituted C 1- 6-membered alkyl, 3-12-membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl;
[0759] Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2;
[0760] Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0761] Each R 11c Independently C 1-6 alkyl;
[0762] Each R 12 are independently hydrogen or C 1-6 alkyl;
[0763] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0764] Each R 16 Independently C 1-6 alkyl;
[0765] Each R 17 Independently C 1-6 alkyl;
[0766] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2, 3 or 4;
[0767] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0768] In one embodiment, X is CH;
[0769] R 1 is -NH2;
[0770] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0771] Each R 2are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0772] m is 2 or 3;
[0773] Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl;
[0774] Each R 8a are independently deuterium, halogen or hydroxyl;
[0775] Each R 2a are independently deuterium or halogen;
[0776] Ring B is C 6-10 arylene;
[0777] R 3 Halogen or C 1-6 alkyl;
[0778] n is 0 or 1;
[0779] L is -NHC(O)-;
[0780] R 7 for
[0781] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0782] R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0783] R 7c For hydrogen, halogen, C 1-6Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0784] Each R 7-a and R 7-e are each independently halogen, hydroxyl or C 1-6 alkyl;
[0785] R 4 C 1-6 alkyl;
[0786] R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0787] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0788] Each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group;
[0789] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0790] Each R 15b are independently halogen or C 1-6 alkyl;
[0791] Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl;
[0792] Each R 5-a-1 is halogen or hydroxy;
[0793] Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0794] Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ;
[0795] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0796] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0797] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0798] Each R 9a are independently halogen, hydroxy, -N(R 14) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group;
[0799] Each R 9-c Independently C 1-6 alkyl;
[0800] Each R 9b are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl or C 1-6 alkyl;
[0801] Each R 9c Independently C 1-6 alkyl;
[0802] Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -S(O)2(R 19 ), by one or more R 9- a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, -OC 1-6 Alkyl or C 3-8 Cycloalkyl;
[0803] Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2;
[0804] Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0805] Each R 11c are independently hydroxy or C 1-6 alkyl;
[0806] Each R 12 are independently hydrogen or C 1-6 alkyl;
[0807] Each R 13 are independently hydrogen or C 1-6 alkyl;
[0808] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0809] Each R 16 Independently C 1-6 alkyl;
[0810] Each R 17 Independently C 1-6 alkyl;
[0811] Each R 18 Independently C 1-6 alkyl;
[0812] Each R 19 Independently C 1-6 alkyl;
[0813] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0814] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0815] In one embodiment, X is CH;
[0816] R 1 is -NH2;
[0817] Ring A is C 6-10 Aryl or 5-10 membered heteroaryl;
[0818] Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, wherein said -OC 1-6 Each alkyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0819] m is 2 or 3;
[0820] Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl;
[0821] Each R 8a are independently deuterium or halogen;
[0822] Each R 2a for deuterium;
[0823] Ring B is C 6-10 arylene;
[0824] R3 Halogen or C 1-6 alkyl;
[0825] n is 0 or 1;
[0826] L is -NHC(O)-;
[0827] R 7 for
[0828] R 7a is hydrogen, halogen or C 1-6 alkyl;
[0829] R 7b is hydrogen, is replaced by one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0830] R 7c is hydrogen, is replaced by one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group;
[0831] Each R 7-a and R 7-e Each independently is C 1-6 alkyl;
[0832] R 4 C 1-6 alkyl;
[0833] R 5 -C(O)(R 11 ), by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2;
[0834] Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group;
[0835] Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group;
[0836] Each R 15b are independently halogen or C 1-6 alkyl;
[0837] Each R 5-f are independently halogen, hydroxy, -N(R 12 )2 or C 1-6 alkyl;
[0838] Each R 5e are independently halogen or -NR 9 R 10 ;
[0839] Each R 5f are independently hydroxy or -NR 9 R 10 ;
[0840] Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9a Substituted C 1- 6 alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group;
[0841] or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0842] or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group;
[0843] Each R 9a are independently -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group;
[0844] Each R 9-c Independently C 1-6 alkyl;
[0845] Each R 9c Independently C 1-6 alkyl;
[0846] Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, one or more R 9-a Substituted C 1- 6-membered alkyl, 3-12-membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl;
[0847] Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2;
[0848] Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group;
[0849] Each R 11c Independently C 1-6 alkyl;
[0850] Each R 12 are independently hydrogen or C 1-6 alkyl;
[0851] Each R 14 are independently hydrogen or C 1-6 alkyl;
[0852] Each R 16 Independently C 1-6 alkyl;
[0853] Each R 17 Independently C 1-6 alkyl;
[0854] In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3;
[0855] In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
[0856] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-1):
[0857] Among them, X, R 1 、R 2 、R 4 、R 5 、R 7a 、R 7b 、R 7c , m and ring A are as defined in any embodiment of the present invention.
[0858] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-2):
[0859] Among them, R 2 、R 5 、R 7a 、R 7b 、R 7c , m and ring A are as defined in any embodiment of the present invention.
[0860] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-3):
[0861] Wherein, m' is 0, 1, 2, 3 or 4;
[0862] X, R 1 、R 2 、R 3 、R 4 、R 5 、R 7 , n, ring B and L are as defined in any embodiment of the present invention.
[0863] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-4):
[0864] Among them, X 1 、X 2 、X 3 and X 4 are each independently N, -CH or -CR 2’ ;
[0865] Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0866] X, R 1 、R 2a 、R 3 、R 4 、R 5 、R 7 、R 8 , n, ring B and L are as defined in any embodiment of the present invention.
[0867] In one scheme, each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1- 6-alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; preferably, each R 2’ Independently -OC 1-6 alkyl.
[0868] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-5):
[0869] Among them, R 2-1 For halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0870] R 2-2 is hydrogen or halogen;
[0871] X, R 1 、R 2a 、R 3 、R 4 、R 5 、R 7 、R 8, n, ring B and L are as defined in any embodiment of the present invention.
[0872] In one scenario, R 2-1 For halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a substituted; preferably, R 2-1 For-OC 1-6 alkyl.
[0873] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-6):
[0874] Among them, X, R 1 、R 2 、R 3 、R 7 、R 4 、R 9 , L, ring A, ring B, m and n are as defined in any embodiment of the present invention.
[0875] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-7) or formula (I-8):
[0876] Wherein, m' is 0, 1, 2, 3 or 4;
[0877] X, R 1 、R 2 、R 3 、R 7a 、R 7b 、R 7c 、R 4 、R 9 , L, R 7 , Ring A, Ring B, m and n are as defined in any embodiment of the present invention.
[0878] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-9), formula (I-10) or formula (I-11):
[0879] Wherein, m' is 0, 1, 2, 3 or 4;
[0880] X, R 1 、R 2 、R 7a、R 7b 、R 7c 、R 4 、R 9 、R 18 and R 11 The definition of is as described in any embodiment of the present invention.
[0881] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-12):
[0882] Among them, X 1 、X 2 、X 3 and X 4 are each independently N, CH or CR 2’ ;
[0883] Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0884] X, R 1 、R 2a 、R 3 、R 4 、R 5 、R 7 、R 8 and n are defined as described in any embodiment of the present invention.
[0885] In one scheme, each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1- 6-alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace.
[0886] In one scenario, X 1 、X 2 and X 4are each independently N or CH, X 3 CR 2’ ; or, X 1 and X 4 are each independently N or CH, X 3 and X 2 CR 2’ ; Preferably, X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ .
[0887] In one embodiment, the compound represented by formula (I) is a compound represented by formula (I-13), formula (I-14), formula (I-15), formula (I-16), formula (I-17) or formula (I-18):
[0888] Among them, X 1 、X 2 、X 3 and X 4 are each independently N, CH or CR 2’ ;
[0889] Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace;
[0890] R 5-1 For one or more R 5-1-a Substituted C 1-6 Alkyl; each R 5-1-a are independently hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group, NR 9 R 10 or -S(O)2(R 11 );
[0891] R 5-2 For one or more R 5e Substituted C 3-8 Cycloalkyl, 3-12 membered heterocyclic hydrocarbon, -P(O)(R 18 )2 or by one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group;
[0892] X, R 1 、R 2a 、R 3 、R 4 、R 5e 、R 5f 、R 7a 、R 7b 、R 7c 、R 8 、R 9 、R 10 、R 11 、R 15 、R 18 、R 5-f and n are defined as described in any embodiment of the present invention.
[0893] In one scenario, X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ ; or, X 1 and X 4 are each independently N or CH, X 3 and X 2 CR 2’ ; Preferably, X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ .
[0894] In one scheme, each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1- 6-alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace.
[0895] In one scenario, R 5-1-a For hydroxyl, C 1-6 Alkyl, -OC1-6 Alkyl or -S(O)2(R 11 ).
[0896] In one scenario, R 5-2 For one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5f In one embodiment, X is CH.
[0897] In one scenario, R 1 is -NH2.
[0898] In one embodiment, R2 is fluoro, -O-methyl or For example -O-methyl or
[0899] In one embodiment, R2 is fluoro, -O-methyl, -O-CD3, -O-CHF2, -O-CF2Cl, cyano, -O-ethyl, chlorine, -CF3, -CHF2, -O-CF3, methyl or For example, fluorine, chlorine, -O-methyl or For example -O-methyl or
[0900] In one embodiment, R2 is fluoro, -O-methyl, -O-CD3, -O-CHF2, -O-CF2Cl, cyano, -O-ethyl, chlorine, -CF3, -CHF2, -O-CF3, methyl, Such as fluorine, chlorine, -O-methyl, -O-CD3,
[0901] In one embodiment, Ring A is phenyl.
[0902] In one embodiment, ring A is phenyl or pyridyl, preferably For example
[0903] In one plan, for For example
[0904] In one plan, for For example For example
[0905] In one plan, for For example
[0906] In one embodiment, ring B is phenylene, for example
[0907] In one embodiment, L is -N(H)C(O)-.
[0908] In one scenario, R 3 is fluorine, chlorine or methyl.
[0909] In one plan, for Preferably, the end marked with * is connected to L.
[0910] In one scenario, R 7 for Preferred For example
[0911] In one scenario, R 7 for Preferred For example
[0912] In one scenario, R 7 for Preferred More preferred
[0913] In one plan, for Preferred For example
[0914] In one plan, for Preferred For example
[0915] In one plan, for For example For example
[0916] In one scenario, R 4 It is a methyl group.
[0917] In one scenario, R 5 for For example
[0918] In one scenario, R 5 for For example
[0919] In one scenario, R 5 for For example
[0920] In one scenario, R 5 for For example
[0921] In one embodiment, the compound represented by formula (I) is any one of the following compounds:
[0922] In one embodiment, the pharmaceutically acceptable salt of the compound represented by formula (I) is any of the following compounds:
[0923] The present invention also provides a pharmaceutical composition comprising (a therapeutically effective amount of) substance A and a pharmaceutically acceptable excipient, wherein the substance A is a compound as shown in formula (I) according to any embodiment of the present invention, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
[0924] The present invention also provides the use of a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, according to any embodiment of the present invention, in the preparation of an FGFR2 inhibitor. In such use, the FGFR2 inhibitor can be used in mammalian organisms; it can also be used in vitro, primarily for experimental purposes, for example, as a standard or control sample for comparison, or prepared into a kit according to conventional methods in the art to provide rapid detection of FGFR2 inhibitory effects.
[0925] The present invention also provides a use of a compound of formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described in any embodiment of the present invention in the preparation of a medicament for treating and / or preventing a disease associated with FGFR2; preferably, the compound of formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described above is in a therapeutically effective amount, and / or the disease associated with FGFR2 is a disease associated with abnormal activation of FGFR2. The disease may be cancer, preferably bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, bladder cancer, ovarian cancer, colorectal cancer, endometrial cancer, or urothelial cancer, more preferably bile duct cancer, gastric cancer, or endometrial cancer, such as gastric cancer, and more preferably small cell lung cancer.
[0926] The present invention also provides a use of a compound as represented by formula (I) according to any embodiment of the present invention, its stereoisomer or pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition in the preparation of a drug for treating and / or preventing cancer; preferably, the compound as represented by formula (I), its stereoisomer or pharmaceutically acceptable salt or the above-mentioned pharmaceutical composition is in a therapeutically effective amount, and / or the cancer is preferably bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, bladder cancer, ovarian cancer, colorectal cancer, endometrial cancer or urothelial cancer, the cancer is more preferably bile duct cancer, gastric cancer or endometrial cancer, such as gastric cancer, and the lung cancer is more preferably small cell lung cancer.
[0927] The present invention provides a method for inhibiting FGFR2, comprising administering to a patient a compound as represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition according to any embodiment of the present invention; preferably, the compound as represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or the above-mentioned pharmaceutical composition is in a therapeutically effective amount.
[0928] The present invention provides a method for treating and / or preventing a disease associated with FGFR2, comprising administering to a patient a compound as represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described in any embodiment of the present invention; preferably, the compound as represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described above is in a therapeutically effective amount, and / or the disease associated with FGFR2 is a disease associated with abnormal activation of FGFR2. The disease may be cancer, preferably bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, bladder cancer, ovarian cancer, colorectal cancer, endometrial cancer, or urothelial cancer, more preferably bile duct cancer, gastric cancer, or endometrial cancer, such as gastric cancer, and more preferably small cell lung cancer.
[0929] The present invention provides a method for treating and / or preventing cancer, comprising administering to a patient a compound as represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described in any embodiment of the present invention; preferably, the compound as represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described above is in a therapeutically effective amount, and / or, the cancer is preferably bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, bladder cancer, ovarian cancer, colorectal cancer, endometrial cancer, or urothelial cancer; the cancer is more preferably bile duct cancer, gastric cancer, or endometrial cancer, such as gastric cancer; the lung cancer is more preferably small cell lung cancer.
[0930] The present invention also provides a method for preparing the compound represented by formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, which is any one of the following methods:
[0931] Method 1: It comprises the following steps: in a solvent, a compound represented by formula (Ia) and a compound represented by formula (Ib) undergo a Sonogashira reaction to obtain a compound represented by formula (I);
[0932] Among them, X 1 is a halogen;
[0933] X, R 1 、R 2 、R 3 、R 4 、R 5 、R 7 , m, n, ring A, ring B and L are as defined in any embodiment of the present invention;
[0934] The Sonogashira reaction operation and conditions are conventional reaction operations and conditions for such reactions in the art. The present invention particularly prefers the following conditions:
[0935] Preferably, the X 1 For Br;
[0936] And / or, the solvent is a nitrogen-containing compound solvent, such as N,N-dimethylformamide and / or triethylamine, and another example is a mixed solvent of N,N-dimethylformamide and triethylamine;
[0937] And / or, the Sonogashira reaction is carried out under the action of a palladium catalyst; the palladium catalyst is preferably a divalent palladium catalyst and / or a zerovalent palladium catalyst, more preferably dichloro[bis(diphenylphosphinophenyl)ether]palladium and / or tetrakis(triphenylphosphine)palladium, for example, a mixture of dichloro[bis(diphenylphosphinophenyl)ether]palladium and tetrakis(triphenylphosphine)palladium;
[0938] And / or, the Sonogashira reaction is carried out under the action of a base; the base is preferably an organic amine, such as triethylamine;
[0939] Method 2: comprising the following steps: performing a deprotection reaction on a compound represented by formula (Ic) in a solvent to prepare a compound represented by formula (I);
[0940] Among them, R 5’ -C(O)-R 11’ 、 By one or more R 5a’ Substituted C1-6 Alkyl, with one or more -NYR 9 Substituted C 3-8 Cyclic hydrocarbon or one or more -NYR 9 Substituted 3-12 membered heterocyclic hydrocarbon group, each R 5a’ Independently for-NYR 9 or a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys, each Y being independently an amino protecting group;
[0941] R 9’ is a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys;
[0942] or R 9 and R 9’ Together with the nitrogen atoms to which they are attached, they form a group consisting of one or more -NYR 14 a substituted 3- to 12-membered heterocyclic hydrocarbon group or a 3- to 12-membered heterocyclic hydrocarbon group substituted by one or more Ys;
[0943] R 11’ is a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys;
[0944] R 5 -C(O)R 11 、-C(O)N(R 9 ) 2、 By one or more R 5a Substituted C 1-6 Alkyl, separated by one or more -NHR 9 Substituted C 3- 8-cyclic hydrocarbon group or one or more -NHR 9 Substituted 3-12 membered heterocyclic hydrocarbon group; each R 5a Independently -NHR 9 or a 3-12 membered heterocyclic hydrocarbon group;
[0945] X, R 1 、R 2 、R 3 、R 4 、R 7 、R 9 、R 14 , m, n, ring A, ring B and L are as defined in any embodiment of the present invention;
[0946] Preferably, R 5’ For one or more R 5a’ Substituted C 1-6 Alkyl, with one or more -NYR 9 Substituted C 3-8 Cyclic hydrocarbon or one or more -NYR 9Substituted 3-12 membered heterocyclic hydrocarbon group, each R 5a’ Independently for-NYR 9 or a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys, each Y being independently an amino protecting group;
[0947] R 5 For one or more R 5a Substituted C 1-6 Alkyl, separated by one or more -NHR 9 Substituted C 3-8 Cycloalkyl or one or more -NHR 9 Substituted 3-12 membered heterocyclic hydrocarbon group; each R 5a Independently -NHR 9 or a 3-12 membered heterocyclic hydrocarbon group;
[0948] X, R 1 、R 2 、R 3 、R 4 、R 7 、R 9 , m, n, ring A, ring B and L are as defined in any embodiment of the present invention;
[0949] More preferably, the solvent is a halogenated hydrocarbon solvent, such as dichloromethane;
[0950] And / or, said Y is tert-butyloxycarbonyl;
[0951] And / or, the deprotection reaction is carried out under the action of an acid, and the acid is preferably an organic acid, such as trifluoroacetic acid.
[0952] The present invention also provides a method for preparing a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, comprising the following steps: condensing a compound represented by formula (Id) with ammonia or an ammonia salt in a solvent to obtain a compound represented by formula (I);
[0953] Among them, R 5” is hydroxy or halogen;
[0954] X, R 1 、R 2 、R 3 、R 4 、R 5 、R 7 、R 9 , m, n, ring A, ring B and L are as defined in any embodiment of the present invention.
[0955] Preferably, the solvent is a nitrogen-containing compound solvent or a halogenated hydrocarbon solvent, such as N,N-diisopropylethylamine or dichloromethane;
[0956] and / or, the R 5” is hydroxyl group;
[0957] And / or, the condensation reaction is carried out under the action of a condensation reagent, and the condensation reagent is preferably 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; further preferably, the condensation reaction is carried out under the action of a condensation reagent and a base, and the base is preferably N,N-diisopropylethylamine;
[0958] And / or, the ammonia salt is ammonia hydrochloride.
[0959] The present invention also provides a compound of formula (Ia) or formula (Ic) as shown below:
[0960] Among them, X 1 , X, R 1 、R 2 、R 3 、R 4 、R 5’ 、R 7 , m, n, ring A, ring B and L are as defined in any embodiment of the present invention;
[0961] Preferably, the compound of formula (Ia) or formula (Ic) is any one of the following compounds,
[0962] The present invention also provides a compound of formula (Id) as shown below:
[0963] Among them, X, R 1 、R 2 、R 3 、R 4 、R 5” 、R 7 , m, n, ring A, ring B and L are as defined in any embodiment of the present invention;
[0964] Preferably, the compound of formula (Id) is any one of the following compounds:
[0965] In addition to the foregoing, when used in the specification and claims of this application, unless otherwise specifically indicated, the following terms have the following meanings:
[0966] The term "pharmaceutically acceptable salt" refers to salts prepared from compounds of the present invention with relatively nontoxic, pharmaceutically acceptable acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of a pharmaceutically acceptable base in neat solution or in a suitable inert solvent. When the compounds of the present invention contain relatively basic functional groups, acid addition salts, such as methanesulfonate salts, can be obtained by contacting the neutral form of such compounds with a sufficient amount of a pharmaceutically acceptable acid in neat solution or in a suitable inert solvent.
[0967] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0968] The term "alkyl" refers to a group having the specified number of carbon atoms (e.g., C 1-6 or C1-C6, C 1-4 or C1-C4), linear or branched, saturated, monovalent hydrocarbon group. Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like.
[0969] The term "alkylene" refers to a divalent alkyl group, i.e., one hydrogen atom of an alkyl group is replaced, wherein the definition of alkyl is as described above, for example, C 1-6 Alkylene.
[0970] The term "alkenyl" refers to a group having the specified number of carbon atoms (e.g., C 2-6 or C2-C6), linear or branched, unsaturated monovalent hydrocarbon group having a carbon-carbon sp 2 Double bond.
[0971] The term "alkynyl" refers to a group having the specified number of carbon atoms (e.g., C 2-6 or C2-C6), linear or branched, unsaturated monovalent hydrocarbon group having a carbon-carbon sp 3 Triple bond. Alkynyl groups include but are not limited to: wait.
[0972] The term "-OC 1-6 In the "alkyl group", the definition of alkyl group is as described above.
[0973] The term "-SC 1-6 In the "alkyl group", the definition of alkyl group is as described above.
[0974] The term "cycloalkyl" refers to a group having the specified number of ring carbon atoms (e.g., C 3-8 or C3-C8) non-aromatic saturated or partially unsaturated cyclic hydrocarbon groups, including cycloalkyl and cycloalkenyl groups. The cyclic hydrocarbon groups may be monocyclic or polycyclic, and may be cyclic, spirocyclic or bridged. The cyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0975] The term "cycloalkyl" refers to a group having the specified number of ring carbon atoms (e.g., C 3-8 or C3-C8, C 6-8 or C6-C8), saturated monocyclic, spirocyclic, bridged, or paracyclic cyclic groups whose ring atoms consist solely of carbon atoms. Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0976] The term "cycloalkenyl" refers to a group having the specified number of carbon atoms (e.g., C 3-8 or C3-C8, C 6-8 or C6-C8), an unsaturated monocyclic, spirocyclic, bridged or paracyclic cyclic group whose ring atoms consist only of carbon atoms, and which does not have aromaticity.
[0977] The term "cycloalkylene" refers to a divalent cycloalkyl group, wherein cycloalkyl is as defined above.
[0978] The term "heterocyclic hydrocarbon group" refers to a non-aromatic saturated or partially unsaturated cyclic group having a specified number of ring atoms (e.g., 3-10 members, 3-12 members), a specified number of heteroatoms (e.g., 1, 2, 3, or 4), and a specified type of heteroatoms (1, 2, or 3 of N, O, and S), including heterocyclic alkyl or heterocyclic alkenyl. The heterocyclic hydrocarbon group may be monocyclic or polycyclic, and may be a cyclic, spirocyclic, or bridged ring structure. Heterocyclic hydrocarbon groups include, but are not limited to, oxetane (e.g., ), azetidinyl (e.g., ), tetrahydropyrrolyl, piperazinyl, piperidinyl, morpholinyl, etc., for example For example
[0979] The term "heterocycloalkyl" refers to a saturated monocyclic, spirocyclic, bridged, or paracyclic cyclic group having a specified number of ring atoms (e.g., 3-6, 3-10, 3-12, 6-10, 6-12), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatoms (1, 2, or 3 of N, O, and S). When polycyclic, each ring is saturated. Heterocycloalkyl includes, but is not limited to, oxetane (e.g., ), azetidinyl (e.g., ), tetrahydropyrrolyl, piperazinyl, piperidinyl, morpholinyl, etc., for example For example
[0980] The term "heterocycloalkenyl" refers to an unsaturated monocyclic, spirocyclic, bridged, or paracyclic cyclic group having a specified number of ring atoms (e.g., 3-6, 3-10, 3-12, 6-10, 6-12), a specified number of heteroatoms (e.g., 1, 2, 3, or 4), and a specified type of heteroatom (one or more of N, O, and S), which is not aromatic. When the heterocycloalkenyl group is polycyclic, at least one ring is not aromatic. Heterocycloalkenyl groups include, but are not limited to Further example
[0981] The term "heterocycloalkylene" refers to a divalent heterocycloalkyl group, wherein heterocycloalkyl is as defined above.
[0982] The term "aryl" refers to a radical having the specified number of ring carbon atoms (e.g., C 6-10 or C6-C 10 ). Examples of aryl groups include, but are not limited to, phenyl or naphthyl.
[0983] The term "arylene" refers to a divalent aromatic group, wherein aryl is as defined above.
[0984] The term "heteroaryl" refers to a cyclic group having a specified number of ring atoms (e.g., 5-10 members, 5-6 members, 8-10 members), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatom (e.g., one, two, or more of N, O, and S), which can be monocyclic or polycyclic (e.g., cyclic, spirocyclic, and bridged), and at least one ring is aromatic (in accordance with Huckel's rule). The heteroaryl group is connected to other fragments in the molecule through an aromatic ring or a non-aromatic ring. Heteroaryl includes, but is not limited to, furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, or 1,2,3,4-tetrahydroisoquinolinyl, for example
[0985] The term "heteroarylene" refers to a divalent heteroaryl group, wherein heteroaryl is as defined above.
[0986] The term "one or more" means 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.
[0987] It will be understood by those skilled in the art that the structural formulas used in the present invention to describe groups are based on the conventions used in the art. It means that the corresponding group R is connected to other fragments and groups in the compound through this site.
[0988] In the present invention, for any group, when its connection site is not specified, the group can be connected to other parts of the molecule through any permissible connection site; for example It means that it can be attached to other parts of the molecule through any permissible ring atom on any ring, for example, the attachment site can be on a four-membered heterocyclic ring (e.g. ), or on a six-membered heterocyclic ring (e.g. ).
[0989] When the linking groups listed in the present invention do not specify their connection direction, their connection direction is the same as the reading order from left to right, as shown below: The connecting group L1 is -CD-, in which case -CD- connects ring A and ring B in the same direction as the reading order from left to right to form Rather than constituting Specifically in the present invention, L is -N(H)C(O)-, which means that N is connected to ring B via a single bond, rather than C being connected to ring B.
[0990] As used herein, the compound shown in formula (I) of the present invention may contain one or more chiral centers and exist in different optically active forms. When the compound contains one chiral center, the compound comprises enantiomers. The present invention includes both isomers and mixtures of isomers, such as racemic mixtures. Enantiomers can be resolved by methods known in the art, such as crystallization and chiral chromatography. When the compound shown in formula (I) contains more than one chiral center, diastereomers may exist. The present invention includes resolved optically pure specific isomers and mixtures of diastereomers. Diastereomers can be resolved by methods known in the art, such as crystallization and preparative chromatography. The term "stereoisomer" includes conformational isomers and configurational isomers, wherein configurational isomers mainly include cis-trans isomers and optical isomers. The compounds of the present invention may exist in the form of stereoisomers, and therefore encompass all possible stereoisomeric forms, including but not limited to cis-trans isomers, enantiomers, diastereomers, atropisomers, etc. The compounds of the present invention may also exist in the form of any combination or any mixture of the aforementioned stereoisomers, such as mesomorphs, racemates, equal mixtures of atropisomers, etc. For example, a single enantiomer, a single diastereomer or a mixture thereof, or a single atropisomer or a mixture thereof. When the compound of the present invention contains an olefin double bond, unless otherwise specified, it includes cis-isomers and trans-isomers, and any combination thereof. The atropisomers of the present invention are stereoisomers with axial or planar chirality based on restricted intramolecular rotation.
[0991] As mentioned above, the present invention provides compounds represented by the above-mentioned various structures, or their cis-trans isomers, meso-isomers, racemates, enantiomers, diastereomers, atropisomers, tautomers or mixtures thereof, wherein "their mixtures" include any mixtures of any of the aforementioned stereoisomers (e.g., cis-trans isomers, enantiomers, diastereomers, atropisomers), tautomers and / or mixtures (meso-isomers, racemates), such as mixtures of cis-trans isomers, mixtures of enantiomers and diastereomers, mixtures of diastereomers, mixtures of atropisomers, or mixtures of cis-trans isomers and racemates, mixtures of enantiomers and diastereomer mixtures, mixtures of cis-trans isomers and tautomers, mixtures of atropisomers and diastereomer mixtures, etc.
[0992] The term "pharmaceutically acceptable excipients" refers to excipients and additives used in the production of pharmaceuticals and the preparation of prescriptions. These excipients are all substances contained in pharmaceutical preparations, other than the active ingredient. For more information, see Part IV of the Pharmacopoeia of the People's Republic of China (2020 Edition) or the Handbook of Pharmaceutical Excipients (Raymond C. Rowe, 2009, Sixth Edition).
[0993] The term "treat" refers to therapeutic treatment. When referring to a specific condition, treatment means: (1) alleviating the disease or one or more biological manifestations of the condition, (2) interfering with (a) one or more points in the biological cascade that leads to or causes the condition or (b) one or more biological manifestations of the condition, (3) ameliorating one or more symptoms, effects, or side effects associated with the condition or one or more symptoms, effects, or side effects associated with the condition or its treatment, or (4) slowing the progression of the condition or one or more biological manifestations of the condition.
[0994] The term "prevent" refers to the reduction of the risk of acquiring or developing a disease or disorder.
[0995] The term "FGFR2 abnormality" refers to "abnormal activation of FGFR2", and its molecular mechanisms mainly include (1) gene amplification; (2) gene mutation; (3) gene fusion caused by gene translocation, etc.
[0996] The term "therapeutically effective amount" refers to an amount administered to a patient that is sufficient to effectively treat a disease. The therapeutically effective amount will vary depending on the type of compound, the type of disease, the severity of the disease, the age of the patient, etc., but can be adjusted by those skilled in the art as appropriate.
[0997] Without violating the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain preferred embodiments of the present invention.
[0998] The reagents and raw materials used in the present invention are commercially available.
[0999] The positive advances of this invention include: the compounds exhibit excellent inhibitory activity and selectivity against FGFR2 abnormalities, demonstrating superior proliferation inhibition against human gastric cancer cells SNU-16, compared to human small cell lung cancer cells DMS114 and human bladder cancer cells RT112 / 84. The compounds are well absorbed after oral administration and exhibit good drug exposure in rats. DETAILED DESCRIPTION
[1000] The present invention is further illustrated by way of examples below, but the present invention is not limited to the scope of the examples. Experimental methods in the following examples where specific conditions are not specified were performed according to conventional methods and conditions, or selected according to the product specifications.
[1001] One of the synthetic routes in the following examples is:
[1002] When X is CH, R 1 -NH2, R 4 When it is -CH3, its preparation method is as follows:
[1003] 1: Cyclization reaction is carried out in the presence of vinylmagnesium bromide.
[1004] 2: Under alkaline conditions, alkylation reaction occurs with CH3I.
[1005] 3: Buchwald coupling reaction.
[1006] 4: Under acidic conditions, amino deprotection reaction is carried out.
[1007] 5: Under acidic conditions, iodination reaction (NIS: N-iodosuccinimide) is carried out.
[1008] 6: Suzuki reaction.
[1009] 7: Under acidic conditions, iodination reaction is carried out.
[1010] 8: Suzuki reaction.
[1011] 9: Sonogashira reaction.
[1012] Synthesis of Intermediate 1 (4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide)
[1013] Step 1: 4,7-Dibromo-1H-pyrrolo[3,2-c]pyridine
[1014] Dissolve vinylmagnesium bromide (1M, 434 mL, 434 mmol, 3.5 eq) in tetrahydrofuran (200 mL). Cool to 0°C in an ice bath under nitrogen. Add a solution of 2,5-dibromo-4-nitropyridine (35 g, 124 mmol, 1.0 eq) in tetrahydrofuran (300 mL) dropwise over 1.5 hours. Warm to room temperature and react for 1 hour. LCMS indicates the reaction is complete. The reaction solution was quenched into a saturated aqueous ammonium chloride solution at 0°C and extracted twice with ethyl acetate (500 mL × 2). The organic phase was concentrated under reduced pressure, and the residue was dissolved with methanol (120 mL) and concentrated hydrochloric acid (3 mL), stirred at room temperature for 1 hour, and concentrated under reduced pressure. The residue was added with ethyl acetate (500 mL) and a saturated aqueous sodium hydroxide solution (500 mL) and dissolved, extracted twice with ethyl acetate (500 mL × 2). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was added with diethyl ether (20 mL) and stirred at room temperature for 1 hour, filtered under reduced pressure, and the filtrate was concentrated under reduced pressure. The residue was added with diethyl ether (20 mL) and stirred at room temperature for 1 hour, filtered under reduced pressure, and the combined residues were concentrated under reduced pressure to give 4,7-dibromo-1H-pyrrolo[3,2-c]pyridine (12.2 g, yield: 35.6%) as a white solid.
[1015] MS m / z:277[M+H] +
[1016] 1 H NMR (400MHz, DMSO-d6) δ12.40(s,1H),8.13(s,1H),7.68-7.64(m,1H),6.62-6.42(m,1H).
[1017] Step 2: 4,7-Dibromo-1-methyl-1H-pyrrolo[3,2-c]pyridine
[1018] 4,7-Dibromo-1H-pyrrolo[2,3-c]pyridine (12.2 g, 44 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (150 mL) and cooled to 0°C in an ice bath. Methyl iodide (6.9 g, 48 mmol, 1.1 eq) was added, and sodium hydride (3.2 g, 132 mmol, 3.0 eq) was added portionwise at 0°C. The mixture was allowed to warm to room temperature and stirred for 1 hour. LCMS confirmed the reaction was complete. The reaction solution was quenched into ice water (100 mL) and extracted twice with dichloromethane (200 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 40-60%) to afford 4,7-dibromo-1-methyl-1H-pyrrolo[3,2-c]pyridine (10.0 g, 78% yield) as a white solid.
[1019] MS m / z:291[M+H] +
[1020] Step 3: tert-Butyl (7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-yl)carbamate
[1021] Dissolve 4,7-dibromo-1-methyl-1H-pyrrolo[3,2-c]pyridine (10.0 g, 34 mmol, 1.0 eq), tert-butyl carbamate (12.1 g, 103.1 mmol, 3.0 eq), cesium carbonate (16.8 g, 52.7 mmol, 1.5 eq), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (1.99 g, 3.4 mmol, 0.1 eq), and tris(dibenzylideneacetone)dipalladium (1.57 g, 1.7 mmol, 0.05 eq) in 1,4-dioxane (200 mL). Under nitrogen, heat the mixture to 66°C in an oil bath and react for 2 hours. LCMS analysis confirmed the reaction was complete. The reaction solution was quenched into water (100 mL), extracted twice with ethyl acetate (200 mL × 2), the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column (ethyl acetate / petroleum ether: 30-45%) to give tert-butyl (7-bromo-1-methyl-1H-pyrrolo [3, 2-c] pyridin-4-yl) carbamate (5.8 g, yield: 52%) as a yellow solid.
[1022] MS m / z:327[M+H] +
[1023] Step 4: 7-Bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine
[1024] Tert-butyl (7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-yl) carbamate (5.8 g, 17.8 mmol, 1.0 eq) was dissolved in dichloromethane (45 mL) and trifluoroacetic acid (15 mL) and allowed to react at room temperature for 4 hours. LCMS confirmed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in dichloromethane. The pH was adjusted to 7 with aqueous sodium bicarbonate solution, and the mixture was extracted twice with dichloromethane (100 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford 7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine (660 mg, 16% yield) as a yellow solid.
[1025] MS m / z:227[M+H] +
[1026] 1 H NMR (400MHz, DMSO-d6) δ7.62(s,1H),7.20(d,J=3.2Hz,1H),6.71(d,J=3.2Hz,1H),6.64(s,2H),4.02(s,3H).
[1027] Step 5: 7-Bromo-3-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine
[1028] 7-Bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine (400 mg, 1.8 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (40 mL), cooled to 0°C in an ice bath, trifluoroacetic acid (262 mg, 2.3 mmol, 1.3 eq) was added and stirred for 30 minutes, N-iodosuccinimide (597 mg, 2.6 mmol, 1.5 eq) was added in batches and stirred for 30 minutes, then warmed to room temperature and stirred for 2 hours. The reaction was complete when LCMS was detected. The reaction was also quenched into aqueous sodium sulfite solution, and the solution was adjusted to pH 7 with sodium bicarbonate. The product was extracted twice with dichloromethane (100 mL × 2), and the organic phase was washed twice with water (500 mL × 2). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 20-30%) to give 7-bromo-3-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine (370 mg, yield: 59.35%) as a yellow solid.
[1029] MS m / z:352[M+H] +
[1030] Step 6: 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1031] 7-Bromo-3-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine (1.5 g, 4.2 mmol, 1.0 eq) and 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide (1.68 g, 4.6 mmol, 1.1 eq) (synthesis method reference patent WO2023046117A1), potassium phosphate (2.26 g, 10.6 mmol, 2.5 eq), tetrakis(triphenylphosphine)palladium (490 mg, 0.42 mmol, 0.1 eq) were dissolved in N,N-dimethylformamide (120 mL) and water (15 mL). The mixture was protected by nitrogen and the oil bath was heated to 70 ° C for 2.5 hours. The reaction was complete when LCMS was detected. The reaction mixture was cooled to room temperature, quenched into water (200 mL), extracted twice with dichloromethane (100 mL × 2), and the combined organic phases were washed three times with water (500 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (methanol / dichloromethane: 3-5%) to give 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (1.5 g, yield: 77%) as a yellow solid.
[1032] MS m / z:457[M+H] +
[1033] 1 H NMR (400MHz, DMSO-d6) δ8.70(t,J=6.4Hz,1H),7.86(d,J=7.8Hz,1H),7.73(s,1H),7.44(s,1H),7.19(s ,1H),7.12(dd,J=7.8,1.5Hz,1H),5.49(s,2H),4.14(dd,J=9.8,6.5Hz,2H),4.09(s,3H),3.96(s,3H).
[1034] Step 7: 4-(4-amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1035] Dissolve 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (1.5 g, 3.28 mmol, 1.0 eq) in anhydrous ethanol (224 g). Cool to 0°C in an ice bath. Slowly add concentrated sulfuric acid (112 g). Add 1,3-diiodo-5,5-dimethylhydantoin (1.24 g, 3.28 mmol, 1.0 eq) in portions while maintaining the temperature at 0°C. Maintain stirring at 0°C for 4 hours. The reaction is complete as determined by LCMS. The reaction solution was quenched into aqueous sodium sulfite solution (300 mL), adjusted to pH 7 with aqueous sodium bicarbonate solution, extracted twice with dichloromethane (100 mL × 2), the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column (tetrahydrofuran / petroleum ether: 50-60%) to give 4- (4-amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl) -2-methoxy-N- (2,2,2-trifluoroethyl) benzamide (1.52 g, yield: 68.6%) as a yellow solid.
[1036] MS m / z:583[M+H] +
[1037] 1 H NMR(400MHz,DMSO-d6)δ8.80(t,J=6.4Hz,1H),7.83(d,J=7.8Hz,1H),7.70(s,1H) ,7.13(s,1H),7.04(dd,J=7.8,1.4Hz,1H),5.27(s,2H),4.13(m,5H),3.91(s,3H).
[1038] Step 8: 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1039] 4-(4-Amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (1.53 g, 2.62 mmol, 1 eq) was dissolved in N,N-dimethylformamide (80 mL) and water (10 mL). 2-Fluoro-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (918 mg, 3.14 mmol, 1.2 eq) (synthesis method referenced in patent WO2023046117A1), potassium phosphate (1.67 g, 7.86 mmol, 3 eq), and tetrakis(triphenylphosphine)palladium (302.6 mg, 0.262 mmol, 0.1 eq) were added. The mixture was reacted at 65°C under nitrogen for 2 hours. The reaction was complete as monitored by LCMS. The reaction solution was concentrated and the residue was purified by column chromatography (methanol / dichloromethane: 7%) to give 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (1.42 g, yield: 87.4%) as a gray solid.
[1040] MS m / z:620[M+H] +
[1041] Intermediate 2:
[1042] (Intermediate 2)
[1043] Step 1: 4-Bromo-2-chloro-N-(2,2,2-trifluoroethyl)benzamide
[1044] 4-Bromo-2-chlorobenzoic acid (48 g, 203.86 mmol, 1.0 eq) and 2,2,2-trifluoroethylamine (26.25 g, 265.01 mmol, 1.3 eq), N,N-diisopropylethylamine (39.52 g, 305.78 mmol, 1.5 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (116.27 g, 305.78 mmol, 1.5 eq) were dissolved in dichloromethane (500 mL) and reacted at room temperature for 16 hours. The reaction was complete when detected by LCMS. The reaction solution was quenched into water (1000 mL), extracted twice with dichloromethane (500 mL × 2), and the combined organic phases were washed once with saturated brine (2000 mL × 1). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 35-40%) to give 4-bromo-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (48 g, yield: 74.39%) as a white solid.
[1045] MS m / z:317[M+H] +
[1046] 1 H NMR (400MHz, DMSO-d6) δ9.22(s,1H),7.85(d,J=1.8Hz,1H),7.66(dd,J=8.2,1.8Hz,1H),7.40(d,J=8.2Hz,1H),4.08(dd,J=9.8,6.4Hz,2H).
[1047] Step 2: 2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide
[1048] 4-Bromo-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (45 g, 142.18 mmol, 1.0 eq) and pinacol diboron (43.33 g, 170.62 mmol, 1.2 eq), potassium acetate (20.93 g, 213.27 mmol, 1.5 eq), and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (5.20 g, 7.11 mmol, 0.05 eq) were dissolved in 1,4-dioxane (500 mL) under nitrogen protection. The oil bath was heated to 90 ° C for 16 hours. The reaction was complete when LCMS was performed. The reaction solution was quenched into water (1000 mL), extracted twice with dichloromethane (500 mL × 2), and the combined organic phases were washed once with saturated brine (2000 mL × 1). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 25-30%) to give 2-chloro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -N- (2,2,2-trifluoroethyl) benzamide (51 g, yield: 98.66%) as a white solid.
[1049] MS m / z:364[M+H] +
[1050] 1 H NMR (400MHz, DMSO-d6) δ9.21 (s, 1H), 7.71–7.65 (m, 2H), 7.46 (d, J = 7.8Hz, 1H), 4.14–4.06 (m, 2H), 1.32 (s, 12H).
[1051] Step 3: 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide
[1052] 7-Bromo-3-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine (8.0 g, 22.7 mmol, 1.0 eq) and 2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide (9.09 g, 25.0 mmol, 1.1 eq), potassium phosphate (14.47 g, 68.19 mmol, 3.0 eq), tetrakis(triphenylphosphine)palladium (2.63 g, 2.27 mmol, 0.1 eq) were dissolved in N,N-dimethylformamide (60 mL) and water (6 mL). Under nitrogen protection, the oil bath was heated to 65°C and reacted for 5 hours. The reaction was complete when LCMS was performed. The reaction mixture was cooled to room temperature, and the DMF was removed by rotary evaporation. The mixture was diluted with ethanol (40 mL), added to water (500 mL), filtered and dried to give a crude product, which was slurried with ethyl acetate (40 mL) to give 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (7.8 g, yield: 74%) as a yellow solid.
[1053] MS m / z:461[M+H] +
[1054] 1 H NMR (400MHz, DMSO-d6) δ9.19(t,J=6.4Hz,1H),7.74(s,1H),7.60–7.50(m,2H),7.49–7.43(m,2H),5.46(s,2H),4.17–4.01(m,5H).
[1055] Step 4: 4-(4-amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide
[1056] Dissolve 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (6.5 g, 14.08 mmol, 1.0 eq) in anhydrous ethanol (70 mL). Cool to 0°C in an ice bath. Slowly add concentrated sulfuric acid (35 mL). Add 1,3-diiodo-5,5-dimethylhydantoin (5.35 g, 14.08 mmol, 1.0 eq) in portions while maintaining the temperature at 0°C. Stir at 0°C for 0.5 hour. LCMS analysis indicates the reaction is complete. Slowly pour the reaction mixture into aqueous sodium carbonate solution (500 mL), stir for 0.5 hour, and filter to obtain the crude product. The crude product was slurried with ethanol (100 mL) to give 4-(4-amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (7.5 g, yield: 90%) as a yellow solid.
[1057] MS m / z:587[M+H] +
[1058] Step 5: 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide
[1059] 4-(4-Amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (10 g, 17.02 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (200 mL) and water (20 mL). 2-Fluoro-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (5.45 g, 18.72 mmol, 1.1 eq), potassium phosphate (9.03 g, 42.55 mmol, 2.5 eq), and tetrakis(triphenylphosphine)palladium (1.97 g, 1.70 mmol, 0.1 eq) were added. The mixture was reacted at 65°C under nitrogen for 4 hours. The reaction was monitored by LCMS for completion. The reaction solution was concentrated to remove DMF, diluted with ethanol (50 mL), poured into water (700 mL), stirred for 0.5 h and filtered. The solid was dried and slurried with ethyl acetate (100 mL) to give 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-chloro-N-(2,2,2-trifluoroethyl)benzamide (8.6 g, yield: 81%) as a yellow solid.
[1060] MS m / z:624[M+H] +
[1061] Intermediate 3:
[1062] (Intermediate 3)
[1063] Step 1: 4-Bromo-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide
[1064] 4-Bromo-2-fluorobenzoic acid (10 g, 45.66 mmol, 1.0 eq) and 2,2,2-trifluoroethylamine (5.88 g, 59.36 mmol, 1.3 eq), N,N-diisopropylethylamine (8.85 g, 68.49 mmol, 1.5 eq), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (26.14 g, 68.49 mmol, 1.5 eq) were dissolved in dichloromethane (100 mL) and reacted at room temperature for 16 hours. The reaction was complete when detected by LCMS. The reaction solution was quenched into water (200 mL), extracted twice with dichloromethane (100 mL × 2), and the combined organic phases were washed once with saturated brine (500 mL × 1). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 35-40%) to give 4-bromo-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (11.2 g, yield: 81.75%) as a white solid.
[1065] MS m / z:301[M+H] +
[1066] 1 H NMR (400MHz, DMSO-d6) δ9.07(s,1H),7.72(dd,J=10.2,1.6Hz,1H),7.61–7.52(m,2H),4.09(dd,J=9.8,6.4Hz,2H).
[1067] Step 2: 2-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide
[1068] 4-Bromo-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (11.2 g, 37.33 mmol, 1.0 eq) and pinacol diboron (11.37 g, 44.79 mmol, 1.2 eq), potassium acetate (5.49 g, 55.99 mmol, 1.5 eq), and 1,1-bis(diphenylphosphino)ferrocenepalladium dichloride (2.73 g, 3.73 mmol, 0.1 eq) were dissolved in 1,4-dioxane (120 mL) under nitrogen protection. The oil bath was heated to 90 ° C and reacted for 16 hours. The reaction was complete when LCMS was detected. The reaction solution was quenched into water (200 mL), extracted twice with dichloromethane (100 mL × 2), and the combined organic phases were washed once with saturated brine (500 mL × 1). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate / petroleum ether: 25-30%) to give 2-fluoro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -N- (2,2,2-trifluoroethyl) benzamide (12 g, yield: 92.61%) as a white solid.
[1069] MS m / z:348[M+H] +
[1070] 1 H NMR (400MHz, DMSO-d6) δ9.10–9.03(m,1H),7.64(t,J=7.2Hz,1H),7.57(dd,J=7.6,1 .0Hz,1H),7.44(dd,J=10.6,1.0Hz,1H),4.09(dd,J=9.8,6.4Hz,2H),1.32(s,12H).
[1071] Step 3: 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide
[1072] 7-Bromo-3-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-4-amine (2.0 g, 5.68 mmol, 1.0 eq) and 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)benzamide (2.17 g, 6.25 mmol, 1.1 eq), potassium phosphate (3.62 g, 17.05 mmol, 3.0 eq), tetrakis(triphenylphosphine)palladium (0.66 g, 0.57 mmol, 0.1 eq) were dissolved in N,N-dimethylformamide (20 mL) and water (6 mL). Under nitrogen protection, the oil bath was heated to 65 ° C and reacted for 4 hours. The reaction was completed by LCMS. The reaction mixture was cooled to room temperature, and the reaction solution was evaporated to remove N,N-dimethylformamide, diluted with ethanol (30 mL), added to water (300 mL), filtered and dried to give a crude product, which was slurried with ethyl acetate (50 mL) to give 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (1.7 g, yield: 67.2%) as a yellow solid.
[1073] MS m / z:445[M+H] +
[1074] 1H NMR (400MHz, DMSO-d6) δ8.98(td,J=6.4,2.1Hz,1H),7.77–7.69(m,2H),7.46(s,1H),7.40–7.29(m,2H),5.50(s,2H),4.20–4.02(m,5H).
[1075] Step 4: 4-(4-amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide
[1076] Dissolve 4-(4-amino-7-bromo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (1.7 g, 3.8 mmol, 1.0 eq) in anhydrous ethanol (20 mL). Cool to 0°C in an ice bath. Slowly add concentrated sulfuric acid (5 mL). Add 1,3-diiodo-5,5-dimethylhydantoin (1.40 g, 3.8 mmol, 1.0 eq) in portions while maintaining the temperature at 0°C. Stir at 0°C for 0.5 hour. LCMS indicates the reaction is complete. Slowly pour the reaction mixture into aqueous sodium carbonate solution (200 mL), stir for 0.5 hour, and filter to obtain the crude product. The crude product was slurried with ethanol (20 mL) to give 4-(4-amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (2.1 g, yield: 95%) as a yellow solid.
[1077] MS m / z:571[M+H] +
[1078] Step 5: 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide
[1079] 4-(4-Amino-7-bromo-2-iodo-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (1.8 g, 3.15 mmol, 1.0 eq) was dissolved in N,N-dimethylformamide (40 mL) and water (4 mL). 2-Fluoro-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acrylamide (1.01 g, 3.47 mmol, 1.1 eq), potassium phosphate (1.67 g, 7.88 mmol, 2.5 eq), and tetrakis(triphenylphosphine)palladium (0.36 g, 0.32 mmol, 0.1 eq) were added. The mixture was reacted at 65°C under nitrogen for 6 hours. The reaction was complete as monitored by LCMS. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and spun down to afford the crude product. Column chromatography (eluent: dichloromethane:ethyl acetate = 1:1) afforded 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-fluoro-N-(2,2,2-trifluoroethyl)benzamide (1.6 g, 83% yield) as a yellow solid.
[1080] MS m / z:608[M+H] +
[1081] Intermediate 4:
[1082] Step 1: Methyl 4-bromo-2-[(trideuterylmethyl)oxy]benzoate
[1083] Methyl 4-bromo-2-hydroxybenzoate (25 g, 108.21 mmol, 1.0 eq) and potassium carbonate (44.86 g, 324.62 mmol, 3.0 eq) were dissolved in N,N-dimethylformamide (500 mL). Deuterated iodomethane (54.9 g, 378.72 mmol, 3.5 eq) was added and the reaction mixture was stirred at room temperature for 4 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (1000 mL) and extracted with dichloromethane (500 mL x 2). The organic phases were washed with water (1000 mL), combined, dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to afford methyl 4-bromo-2-[(trideuteriomethyl)oxy]benzoate (26 g, yield: 96.8%) as a white solid.
[1084] MS m / z:248[M+H] + .
[1085] Step 2: 4-Bromo-2-[(trideuterylmethyl)oxy]benzoic acid
[1086] Methyl 4-bromo-2-[(trideuteriomethyl)oxy]benzoate (26 g, 104.8 mmol, 1.0 eq) and potassium hydroxide (17.64 g, 314.4 mmol, 3.0 eq) were dissolved in methanol (260 mL) and water (260 mL). The mixture was heated to 65°C in an oil bath for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was cooled to room temperature, then to 0°C in an ice-water bath. The pH of the solution was adjusted to approximately 2 with dilute hydrochloric acid. The precipitated solid was filtered under reduced pressure. The filter cake was concentrated under reduced pressure and dried. The crude product was used directly in the next step to yield 4-bromo-2-[(trideuteriomethyl)oxy]benzoic acid (23 g, 93.7% yield) as a white solid.
[1087] MS m / z:234[M+H] + .
[1088] Step 3: 4-Bromo-2-[(trideuterylmethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide
[1089] 4-Bromo-2-[(trideuterium methyl)oxy]benzoic acid (7.5 g, 32.04 mmol, 1.0 eq), diisopropylethylamine (10.35 g, 80.11 mmol, 2.5 eq) and 2,2,2-trifluoroethane-1-amine (4.76 g, 48.06 mmol, 1.5 eq) were dissolved in dichloromethane (150 mL) and added.
[1090] 1-Hydroxybenzotriazole (5.2 g, 38.45 mmol, 1.2 eq) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (7.37 g, 38.45 mmol, 1.2 eq). The reaction mixture was stirred at room temperature for 16 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (500 mL) and extracted with dichloromethane (500 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried by rotary evaporation. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 2:1) to yield 4-bromo-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (8.0 g, yield: 79.2%) as a white solid.
[1091] MS m / z:315[M+H] + .
[1092] Step 4: 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide
[1093] Under nitrogen, to a solution of 4-bromo-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (8.0 g, 25.38 mmol, 1.0 eq.) and bis(chlorobenzoyl)boron (7.73 g, 30.45 mmol, 1.2 eq.) in dioxane (160 mL) were added [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (1.85 g, 2.53 mmol, 0.1 eq.) and potassium acetate (3.73 g, 38.08 mmol, 1.5 eq.). The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After completion of the reaction, monitored by LCMS, the solvent was removed by distillation under reduced pressure, diluted with water (500 mL), and extracted with dichloromethane (500 mL). The combined organic phases were washed with saturated brine (1000 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used to purify the product to yield 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (7.24 g, yield: 78.8%) as a yellow solid.
[1094] MS m / z:363[M+H] + .
[1095] Step 5: 4-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide
[1096] To a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (5.0 g, 14.21 mmol, 1.0 eq) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (5.14 g, 14.21 mmol, 1.0 eq) in N,N-dimethylformamide (100 mL) and water (16 mL) was added tetrakis(triphenylphosphine)palladium (820 mg, 0.71 mmol, 0.05 eq) and potassium phosphate (7.54 g, 35.51 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, monitored by LCMS, the solvent was removed by distillation under reduced pressure, diluted with water (500 mL), and extracted with dichloromethane (100 mL). The organic phase was collected, washed with water (1000 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) afforded 4-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (4.11 g, yield: 62.8%) as a yellow solid.
[1097] MS m / z:460[M+H] + .
[1098] Step 6: 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide
[1099] To a solution of 4-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (4.1 g, 8.91 mmol, 1.0 eq) in ethanol (100 mL) was slowly added concentrated sulfuric acid (30 mL) followed by diiodohydantoin (3.32 g, 8.73 mmol, 0.98 eq) at 0°C. The reaction mixture was stirred at 0°C for 1 hour. Completion of the reaction was monitored by LCMS. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (200 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was vacuum dried and slurried with ethanol (40 mL) to give 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (3.8 g, yield: 72.7%) as a yellow solid.
[1100] MS m / z:586[M+H] + .
[1101] Step 7: 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide
[1102] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (3.8 g, 6.48 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (2.18 g, 7.14 mmol, 1.1 eq) in N,N-dimethylformamide (80 mL) and water (8 mL) was added tetrakis(triphenylphosphine)palladium (369 mg, 0.32 mmol, 0.05 eq) and sodium carbonate (1.72 g, 16.2 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 65°C under nitrogen for 16 hours. After completion of the reaction, monitored by LCMS, the solvent was removed by distillation under reduced pressure, diluted with water (200 mL), and extracted with ethyl acetate (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-[(trideuteriomethyl)oxy]-N-(2,2,2-trifluoroethyl)benzamide (2.76 g, yield: 66.8%) as a yellow solid.
[1103] MS m / z:637[M+H] + .
[1104] Intermediate 5:
[1105] Step 1: 6-Chloro-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide
[1106] 6-Chloro-2-methoxypyridine-3-carboxylic acid (2.7 g, 14.39 mmol, 1.0 eq), diisopropylethylamine (2.79 g, 21.59 mmol, 1.5 eq), and 2,2,2-trifluoroethane-1-amine (1.85 g, 18.71 mmol, 1.3 eq) were dissolved in dichloromethane (60 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (8.21 g, 21.59 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 6-chloro-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.12 g, yield: 80.6%) as a white solid.
[1107] MS m / z:269[M+H] + .
[1108] Step 2: 6-(dihydroxyboryl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide
[1109] Under nitrogen, to a solution of 6-chloro-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.12 g, 11.64 mmol, 1.0 eq.) and bis(chloro-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.12 g, 11.64 mmol, 1.0 eq.) and bis(chloro-2-methoxy-1-naphthalene)diboron (3.54 g, 13.97 mmol, 1.2 eq.) in dioxane (60 mL) were added [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.85 g, 1.16 mmol, 0.1 eq.) and potassium acetate (2.85 g, 29.1 mmol, 2.5 eq.). The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After completion of the reaction, as monitored by LCMS, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 2). The organic phase was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. 6-(Dihydroxyboryl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.13 g).
[1110] MS m / z:279[M+H] + .
[1111] Step 3: 6-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide
[1112] To a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (3.9 g, 11.07 mmol, 1.0 eq) and 6-(dihydroxyboryl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.08 g, 11.07 mmol, 1.0 eq) in N,N-dimethylformamide (100 mL) and water (15 mL) was added tetrakis(triphenylphosphine)palladium (0.63 g, 0.55 mmol, 0.05 eq) and potassium phosphate (5.87 g, 27.69 mmol, 2.5 eq). The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 3). The organic phase was collected, washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used to purify the product to afford 6-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.24 g, yield: 64%) as a yellow solid.
[1113] MS m / z:458[M+H] + .
[1114] Step 4: 6-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide
[1115] To a solution of 6-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (3.24 g, 7.08 mmol, 1.0 eq) in acetonitrile (120 mL) was slowly added concentrated sulfuric acid (12 mL) followed by diiodohydantoin (2.64 g, 6.94 mmol, 0.98 eq) at 0°C. The reaction mixture was stirred at 0°C for 1 hour. Completion of the reaction was monitored by LCMS. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (1000 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was dried under vacuum and slurried with ethanol (40 mL) to give 6-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (2.68 g, yield: 65%) as a yellow solid.
[1116] MS m / z:584[M+H] +.
[1117] Step 5: 6-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide
[1118] To a solution of 6-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (1.0 g, 1.71 mmol, 1.0 eq) and 2-fluoro-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (0.49 g, 1.71 mmol, 1.0 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium (0.19 g, 0.17 mmol, 0.1 eq) and sodium carbonate (0.45 g, 4.28 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 6-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)pyridine-3-carboxamide (627 mg, yield: 59%) as a yellow solid.
[1119] MS m / z:621[M+H] + .
[1120] Intermediate 6:
[1121] Step 1: 6-Chloro-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide
[1122] 6-Chloro-2-methoxypyridine-3-carboxylic acid (3.0 g, 15.99 mmol, 1.0 eq), diisopropylethylamine (7.23 g, 55.98 mmol, 3.5 eq), and (1-fluorocyclopropyl)methylamine hydrochloride (2.01 g, 15.99 mmol, 1.0 eq) were dissolved in dichloromethane (60 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (9.12 g, 23.99 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 6-chloro-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (2.5 g, yield: 60.3%) as a white solid.
[1123] MS m / z:259[M+H] + .
[1124] Step 2: 6-(dihydroxyboryl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide
[1125] Under nitrogen, to a solution of 6-chloro-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (2.5 g, 9.66 mmol, 1.0 eq.) and bis(chloro-1,1'-diphenylphosphino)ferrocene]palladium dichloride (0.71 g, 0.97 mmol, 0.1 eq.) and potassium acetate (2.37 g, 24.16 mmol, 2.5 eq.) in dioxane (50 mL) was added. The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After completion of the reaction, as monitored by LCMS, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 2). The organic phase was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. 6-(Dihydroxyboryl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (2.5 g, yield: 96.5%).
[1126] MS m / z:269[M+H] + .
[1127] Step 3: 6-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide
[1128] Under nitrogen, tetrakis(triphenylphosphine)palladium (0.98 g, 0.85 mmol, 0.1 eq) and potassium phosphate (4.52 g, 21.31 mmol, 2.5 eq) were added to a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (3.0 g, 8.52 mmol, 1.0 eq) and 6-(dihydroxyboryl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (2.28 g, 8.52 mmol, 1.0 eq) in N,N-dimethylformamide (100 mL) and water (15 mL). The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 3). The organic phase was collected, washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used to purify the product to afford 6-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (2.3 g, yield: 60.1%) as a yellow solid.
[1129] MS m / z:448[M+H] + .
[1130] Step 4: 6-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide
[1131] To a solution of 6-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (2.3 g, 5.14 mmol, 1.0 eq) in acetonitrile (80 mL) was slowly added concentrated sulfuric acid (8 mL) and diiodohydantoin (1.91 g, 5.04 mmol, 0.98 eq) at 0°C. The reaction mixture was stirred at 0°C for 1 hour. LCMS monitored the reaction completion. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (1000 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was vacuum dried and slurried with ethanol (20 mL) to give 6-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (1.97 g, yield: 67%) as a yellow solid.
[1132] MS m / z:574[M+H] + .
[1133] Step 5: 6-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide
[1134] To a solution of 6-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (1.9 g, 3.31 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (1.01 g, 3.31 mmol, 1.0 eq) in N,N-dimethylformamide (60 mL) and water (6 mL) was added tetrakis(triphenylphosphine)palladium (0.38 g, 0.31 mmol, 0.1 eq) and sodium carbonate (0.87 g, 8.28 mmol, 2.5 eq). The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After completion of the reaction, monitored by LCMS, the solvent was removed by distillation under reduced pressure, diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 6-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxypyridine-3-carboxamide (1.24 g, yield: 60%) as a yellow solid.
[1135] MS m / z:625[M+H] + .
[1136] Intermediate 7:
[1137] Step 1: 4-Bromo-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide
[1138] 4-Bromo-2-methoxybenzoic acid (2.5 g, 10.82 mmol, 1.0 eq), diisopropylethylamine (3.5 g, 27.05 mmol, 2.5 eq), and (1-fluorocyclopropyl)methylamine hydrochloride (1.36 g, 10.82 mmol, 1.0 eq) were dissolved in dichloromethane (50 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (6.17 g, 16.23 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spun down to dryness. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 4-bromo-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (2.18 g, yield: 66.6%) as a white solid.
[1139] MS m / z:302[M+H] + .
[1140] Step 2: N-[(Fluorocyclopropyl)methyl]-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
[1141] Under nitrogen, to a solution of 4-bromo-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (1.68 g, 5.56 mmol, 1.0 eq.) and bis(chlorobenzoyl)boron (1.69 g, 6.67 mmol, 1.2 eq.) in dioxane (30 mL) were added [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.41 g, 0.56 mmol, 0.1 eq.) and potassium acetate (0.82 g, 8.34 mmol, 1.5 eq.). The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After completion of the reaction, as monitored by LCMS, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 2). The organic phase was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Purification by column chromatography (petroleum ether:ethyl acetate = 3:1) gave N-[(fluorocyclopropyl)methyl]-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.9 g, yield: 97.8%).
[1142] MS m / z:350[M+H] + .
[1143] Step 3: 4-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide
[1144] Under nitrogen, tetrakis(triphenylphosphine)palladium (0.31 g, 0.26 mmol, 0.05 eq) and potassium phosphate (2.86 g, 13.49 mmol, 2.5 eq) were added to a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (1.9 g, 5.39 mmol, 1.0 eq) and N-[(fluorocyclopropyl)methyl]-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (1.88 g, 5.39 mmol, 1.0 eq) in N,N-dimethylformamide (50 mL) and water (10 mL). The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 3). The organic phase was collected, washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used to purify the product to yield 4-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (1.44 g, yield: 60%) as a yellow solid.
[1145] MS m / z:447[M+H] + .
[1146] Step 4: 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide
[1147] To a solution of 4-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (1.2 g, 2.68 mmol, 1.0 eq) in ethanol (20 mL) at 0°C, concentrated sulfuric acid (7 mL) and diiodide hydantoin (1.0 g, 2.63 mmol, 0.98 eq) were slowly added. The reaction mixture was stirred at 0°C for 1 hour. LCMS monitoring indicated the reaction was complete. The reaction mixture was then added dropwise to a saturated aqueous sodium carbonate solution (500 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was then dried under vacuum and slurried in ethanol (20 mL) to obtain 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (1.03 g, yield: 66.9%). Yellow solid.
[1148] MS m / z:573[M+H] + .
[1149] Step 5: 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide
[1150] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (1.0 g, 1.74 mmol, 1.0 eq) and 2-fluoro-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (0.51 g, 1.74 mmol, 1.0 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium (0.2 g, 0.17 mmol, 0.1 eq) and sodium carbonate (0.46 g, 4.36 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used for purification to afford 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (671 mg, yield: 63%) as a yellow solid.
[1151] MS m / z:610[M+H] + .
[1152] Intermediate 8:
[1153] Step 1: 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide
[1154] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (1.0 g, 1.74 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (586 mg, 1.92 mmol, 1.1 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium (100 mg, 0.08 mmol, 0.05 eq) and sodium carbonate (463 mg, 4.37 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, followed by dilution with water (50 mL) and extraction with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used for purification to afford 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-N-[(fluorocyclopropyl)methyl]-2-methoxybenzamide (795 mg, yield: 73.1%) as a yellow solid.
[1155] MS m / z:624[M+H] + .
[1156] Intermediate 9:
[1157] Step 1: 2-Fluoro-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide
[1158] 3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.0 g, 8.41 mmol, 1.0 eq), diisopropylethylamine (2.72 g, 21.08 mmol, 2.5 eq), and 2-fluoroprop-2-enoic acid (0.98 g, 10.96 mmol, 1.3 eq) were dissolved in dichloromethane (40 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (4.81 g, 12.65 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 4 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 2-fluoro-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (1.95 g, yield: 75.1%) as a white solid.
[1159] MS m / z:310[M+H] + .
[1160] Step 2: 4-(4-amino-7-bromo-2-{2-fluoro-4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1161] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (500 mg, 0.86 mmol, 1.0 eq) and 2-fluoro-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (292 mg, 0.94 mmol, 1.1 eq) in N,N-dimethylformamide (10 mL) and water (1 mL) was added tetrakis(triphenylphosphine)palladium (99 mg, 0.08 mmol, 0.1 eq) and sodium carbonate (227 mg, 2.14 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 4-(4-amino-7-bromo-2-{2-fluoro-4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (410 mg, yield: 75.1%) as a yellow solid.
[1162] MS m / z:638[M+H] + .
[1163] Intermediate 10:
[1164] Step 1: 2-Fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide
[1165] 3-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (10.0 g, 42.9 mmol, 1.0 eq), diisopropylethylamine (13.86 g, 107.24 mmol, 2.5 eq), and 2-fluoroprop-2-enoic acid (5.02 g, 55.77 mmol, 1.3 eq) were dissolved in dichloromethane (200 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (24.47 g, 107.24 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 1 hour. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (500 mL) and extracted with dichloromethane (100 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (10.2 g, yield: 77.9%) as a white solid.
[1166] MS m / z:306[M+H] + .
[1167] Step 2: 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1168] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (1.0 g, 1.72 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (576 mg, 1.89 mmol, 1.1 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium (99 mg, 0.08 mmol, 0.05 eq) and sodium carbonate (446 mg, 4.29 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, diluted with water (50 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used for purification to afford 4-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (830 mg, yield: 76.3%) as a yellow solid.
[1169] MS m / z:634[M+H] + .
[1170] Intermediate 11:
[1171] Step 1: N-[3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoroprop-2-enamide
[1172] 3-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.0 g, 3.94 mmol, 1.0 eq), diisopropylethylamine (1.27 g, 9.86 mmol, 2.5 eq), and 2-fluoroprop-2-enoic acid (0.46 g, 5.13 mmol, 1.3 eq) were dissolved in dichloromethane (20 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (2.25 g, 5.92 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 1 hour. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spun down to dryness. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give N-[3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoroprop-2-enamide (1.1 g, yield: 85.6%) as a white solid.
[1173] MS m / z:326[M+H] + .
[1174] Step 2: 4-(4-amino-7-bromo-2-{2-chloro-4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1175] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (500 mg, 0.86 mmol, 1.0 eq) and N-[3-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoroprop-2-enamide (307 mg, 0.94 mmol, 1.1 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium (99 mg, 0.08 mmol, 0.1 eq) and sodium carbonate (227 mg, 2.14 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, followed by dilution with water (50 mL) and extraction with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used for purification to afford 4-(4-amino-7-bromo-2-{2-chloro-4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (420 mg, yield: 75%) as a yellow solid.
[1176] MS m / z:654[M+H] + .
[1177] Intermediate 12:
[1178] Step 1: 4-(4-amino-7-bromo-2-{2-fluoro-4-[(2-methylacryloylamino)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide
[1179] To a solution of 4-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (500 mg, 0.86 mmol, 1.0 eq) and N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-methylprop-2-enamide (288 mg, 0.94 mmol, 1.1 eq) (synthesis method refers to patent WO2023011581A1) in N,N-dimethylformamide (20 mL) and water (2 mL) were added tetrakistriphenylphosphine palladium (99 mg, 0.08 mmol, 0.1 eq) and sodium carbonate (227 mg, 2.14 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, diluted with water (50 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 4-(4-amino-7-bromo-2-{2-fluoro-4-[(2-methylacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (413 mg, yield: 76.1%) as a yellow solid.
[1180] MS m / z:634[M+H] + .
[1181] Intermediate 13:
[1182] Step 1: 5-Bromo-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[1183] 5-Bromo-3-chloropyridine-2-carboxylic acid (5.5 g, 23.26 mmol, 1.0 eq), diisopropylethylamine (14.18 mL, 81.41 mmol, 3.5 eq), and 1-trifluoromethylcyclopropylamine hydrochloride (3.76 g, 23.26 mmol, 1.0 eq) were dissolved in dichloromethane (100 mL). O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (13.27 g, 34.89 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 1 hour. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (500 mL) and extracted with dichloromethane (100 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 5:1) to give 5-bromo-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (5.6 g, yield: 70%) as a white solid.
[1184] MS m / z:343[M+H] + .
[1185] 1 H NMR (400MHz, DMSO-d6) δ9.47(s,1H),8.73(d,J=2.0Hz,1H),8.49(d,J=1.9Hz,1H),1.37–1.32(m,2H),1.15–1.11(m,2H).
[1186] Step 2: 3-Chloro-5-(dihydroxyboryl)-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[1187] Under nitrogen, to a solution of 5-bromo-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (5.6 g, 16.30 mmol, 1.0 eq.) and bis(trifluoromethyl)cyclopropylboronate (4.97 g, 19.56 mmol, 1.2 eq) in dioxane (120 mL) were added [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (1.19 g, 1.63 mmol, 0.1 eq) and potassium acetate (4.0 g, 40.75 mmol, 2.5 eq). The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After the reaction was completed as monitored by LCMS, the solvent was distilled off under reduced pressure, and dichloromethane (100 mL) was added to dilute the mixture. After filtration, the filtrate was spin-dried to give the crude product 3-chloro-5-(dihydroxyboryl)-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (4.9 g). The crude product was used directly in the next step without purification.
[1188] MS m / z:309[M+H] + .
[1189] Step 3: 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[1190] To a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (5.6 g, 15.91 mmol, 1.0 eq) and 3-chloro-5-(dihydroxyboryl)-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (4.9 g, 15.91 mmol, 1.0 eq) in N,N-dimethylformamide (100 mL) and water (16.5 mL) was added tetrakis(triphenylphosphine)palladium (0.92 g, 0.8 mmol, 0.05 eq) and potassium phosphate (8.44 g, 39.78 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (200 mL), and extracted with dichloromethane (100 mL x 3). The organic phase was collected, washed with saturated brine (500 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used to purify the product to afford 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (4.1 g, yield: 52%) as a yellow solid.
[1191] MS m / z:488[M+H] + .
[1192] Step 4: 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[1193] To a solution of 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (4.1 g, 8.39 mmol, 1.0 eq) in acetonitrile (100 mL) was slowly added concentrated sulfuric acid (10 mL) and diiodohydantoin (3.12 g, 8.22 mmol, 0.98 eq) at 25°C. The reaction mixture was stirred at 25°C for 1 hour. LCMS monitoring indicated that the reaction was complete. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (1000 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was vacuum dried and slurried with ethanol (120 mL) to give 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (3.7 g, yield: 71%) as a yellow solid.
[1194] MS m / z:614[M+H] + .
[1195] Step 5: 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide
[1196] To a solution of 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (3.0 g, 4.88 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (1.49 g, 4.88 mmol, 1.0 eq) in N,N-dimethylformamide (60 mL) and water (8 mL) was added tetrakis(triphenylphosphine)palladium (0.28 g, 0.24 mmol, 0.05 eq) and sodium carbonate (1.29 g, 12.2 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 16 hours. After the reaction was completed, the solvent was removed by evaporation under reduced pressure, diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (1.8 g, yield: 55%) as a yellow solid.
[1197] MS m / z:665[M+H] + .
[1198] Intermediate 14:
[1199] Step 1: 5-Bromo-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide
[1200] 5-Bromo-3-methoxypyridine-2-carboxylic acid (5.0 g, 21.6 mmol, 1.0 eq), triethylamine (3.28 g, 32.47 mmol, 1.5 eq), and 2,2,2-trifluoroethane-1-amine (2.78 g, 28.14 mmol, 1.3 eq) were dissolved in tetrahydrofuran (100 mL). A solution of 1-propylphosphoric anhydride in ethyl acetate (10.33 g, 32.47 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and spin-dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 5-bromo-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (5.28 g, yield: 78.2%) as a white solid.
[1201] MS m / z:313[M+H] + .
[1202] Step 2: 3-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide
[1203] Under nitrogen, to a solution of 5-bromo-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (5.28 g, 16.92 mmol, 1.0 eq) and bis(2,2,2-trifluoroethyl)pyridine-2-carboxamide (5.15 g, 20.3 mmol, 1.2 eq) in dioxane (100 mL) were added [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.61 g, 0.84 mmol, 0.05 eq) and potassium acetate (4.15 g, 42.3 mmol, 2.5 eq). The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After completion of the reaction, as monitored by LCMS, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (100 mL x 2). The organic phase was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 3:1) to give 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (3.23 g, yield: 53.1%).
[1204] MS m / z:361[M+H] + .
[1205] Step 3: 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide
[1206] Under nitrogen, tetrakis(triphenylphosphine)palladium (0.16 g, 0.14 mmol, 0.05 eq) and potassium phosphate (1.5 g, 7.1 mmol, 2.5 eq) were added to a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (1.0 g, 2.84 mmol, 1.0 eq) and 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (1.02 g, 2.84 mmol, 1.0 eq) in N,N-dimethylformamide (20 mL) and water (3.5 mL). The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (50 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used to purify the product to afford 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (849 mg, yield: 65.4%) as a yellow solid.
[1207] MS m / z:458[M+H] + .
[1208] Step 4: 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide
[1209] To a solution of 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (849 mg, 1.85 mmol, 1.0 eq) in acetonitrile (10 mL) at 0°C were slowly added concentrated sulfuric acid (1 mL) and diiodohydantoin (691 mg, 1.82 mmol, 0.98 eq). The reaction mixture was stirred at 0°C for 1 hour. Completion of the reaction was monitored by LCMS. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (300 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was dried under vacuum and slurried with ethanol (10 mL) to give 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (700 mg, yield: 65%) as a yellow solid.
[1210] MS m / z:584[M+H] + .
[1211] Step 5: 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide
[1212] To a solution of 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (700 mg, 1.2 mmol, 1.0 eq) and 2-fluoro-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (349 mg, 1.2 mmol, 1.0 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium (138 mg, 0.12 mmol, 0.1 eq) and sodium carbonate (318 mg, 3.0 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After the reaction was completed, the solvent was removed by distillation under reduced pressure, diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido)]phenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-methoxy-N-(2,2,2-trifluoroethyl)pyridine-2-carboxamide (450 mg, yield: 60.5%) as a yellow solid.
[1213] MS m / z:621[M+H] + .
[1214] Intermediate 15:
[1215] Step 1: 5-Bromo-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1216] 5-Bromo-3-chloropyridine-2-carboxylic acid (1.9 g, 8.04 mmol, 1.0 eq), diisopropylethylamine (3.64 g, 28.12 mmol, 3.5 eq), and (2R)-1,1,1-trifluoropropan-2-amine (1.2 g, 8.04 mmol, 1.0 eq) were dissolved in dichloromethane (40 mL). 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (4.58 g, 12.05 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 5 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 5-bromo-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (1.99 g, yield: 74.8%) as a white solid.
[1217] MS m / z:331[M+H] + .
[1218] Step 2: 3-Chloro-5-(dihydroxyboryl)-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1219] Under nitrogen, to a solution of 5-bromo-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (1.4 g, 4.22 mmol, 1.0 eq) and bis(2-(2R)-1,1,1-trifluoropropan-2-yl)pyridine-2-carboxamide (1.4 g, 4.22 mmol, 1.0 eq) and bis(2-(2-phenylphosphino)ferrocenepalladium dichloride) (0.31 g, 0.42 mmol, 0.1 eq) and potassium acetate (1.04 g, 10.56 mmol, 2.5 eq) in dioxane (30 mL) was added. The reaction mixture was stirred at 90°C under nitrogen for 16 hours. After completion of the reaction, as monitored by LCMS, the reaction mixture was cooled to room temperature, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (50 mL), and extracted with dichloromethane (50 mL x 2). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. 3-Chloro-5-(dihydroxyboryl)-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (1.2 g) was obtained.
[1220] MS m / z:297[M+H] + .
[1221] Step 3: 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1222] To a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (1.3 g, 3.69 mmol, 1.0 eq) and 3-chloro-5-(dihydroxyboryl)-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (1.09 g, 3.69 mmol, 1.0 eq) in N,N-dimethylformamide (50 mL) and water (8 mL) was added tetrakis(triphenylphosphine)palladium (0.43 g, 0.37 mmol, 0.1 eq) and potassium phosphate (1.96 g, 9.23 mmol, 2.5 eq). The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, monitored by LCMS, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (200 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used for purification to afford 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (1.1 g, yield: 62.4%) as a yellow solid.
[1223] MS m / z:476[M+H] + .
[1224] Step 4: 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1225] To a solution of 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (1.1 g, 2.31 mmol, 1.0 eq) in acetonitrile (10 mL) at 0°C were slowly added concentrated sulfuric acid (1 mL) and diiodohydantoin (0.88 g, 2.31 mmol, 1.0 eq). The reaction mixture was stirred at 0°C for 1 hour. Completion of the reaction was monitored by LCMS. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (500 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was dried in vacuo and slurried with ethanol (10 mL) to give 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (946 mg, yield: 68%) as a yellow solid.
[1226] MS m / z:602[M+H] + .
[1227] Step 5: 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1228] To a solution of 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (900 mg, 1.49 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (501.36 mg, 1.64 mmol, 1.1 eq) in N,N-dimethylformamide (20 mL) and water (2 mL) were added tetrakistriphenylphosphine palladium (172.6 mg, 0.15 mmol, 0.1 eq) and sodium carbonate (395.76 mg, 3.73 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 24 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2R)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (811 mg, yield: 83%). The product was a yellow liquid.
[1229] MS m / z:653[M+H] + .
[1230] Intermediate 16:
[1231] Step 1: 5-Bromo-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1232] 5-Bromo-3-chloropyridine-2-carboxylic acid (800 mg, 3.38 mmol, 1.0 eq), diisopropylethylamine (1.53 g, 11.84 mmol, 3.5 eq), and (2S)-1,1,1-trifluoropropan-2-amine (607 mg, 4.06 mmol, 1.2 eq) were dissolved in dichloromethane (10 mL). 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.92 g, 5.08 mmol, 1.5 eq) was added. The reaction mixture was stirred at room temperature for 2 hours. LCMS confirmed the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and dried. The crude product was purified by column chromatography (petroleum ether / ethyl acetate = 4:1) to give 5-bromo-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (850 mg, yield: 75.7%) as a white solid.
[1233] MS m / z:331[M+H] + .
[1234] Step 2: 3-Chloro-5-(dihydroxyboryl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1235] Under nitrogen, 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (258.24 mg, 0.35 mmol, 0.18 eq) and potassium acetate (577.26 mg, 5.88 mmol, 3.0 eq) were added to a solution of 5-bromo-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (650 mg, 1.96 mmol, 1.0 eq.) and bis(2-chloro-1,1'-trifluoropropan-2-yl)pyridine-2-carboxamide (1.24 g, 4.90 mmol, 2.5 eq.) in dioxane (23 mL) and stirred at 105°C for 4 hours. After completion of the reaction, monitored by LCMS, the reaction mixture was cooled to room temperature, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and the mixture was extracted with dichloromethane (50 mL x 2). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to give the crude product 3-chloro-5-(dihydroxyboryl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (450 mg).
[1236] MS m / z:297[M+H] + .
[1237] Step 3: 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1238] Under nitrogen, tetrakis(triphenylphosphine)palladium (147.74 mg, 0.13 mmol, 0.1 eq) and potassium phosphate (678.45 mg, 3.2 mmol, 2.5 eq) were added to a solution of 7-bromo-3-iodo-1-methylpyrrolo[3,2-c]pyridin-4-amine (450 mg, 1.28 mmol, 1.0 eq) and 3-chloro-5-(dihydroxyboryl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (379 mg, 1.28 mmol, 1.0 eq) in N,N-dimethylformamide (6 mL) and water (1 mL). The reaction mixture was stirred at 70°C under nitrogen for 8 hours. After completion of the reaction, monitored by LCMS, the solvent was removed by distillation under reduced pressure, the mixture was diluted with water (100 mL), and extracted with dichloromethane (50 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 2:1) was used for purification to afford 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (410 mg, yield: 67.2%) as a yellow solid.
[1239] MS m / z:476[M+H] + .
[1240] Step 4: 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1241] To a solution of 5-(4-amino-7-bromo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (410 mg, 0.86 mmol, 1.0 eq) in acetonitrile (10 mL) at 0°C were slowly added concentrated sulfuric acid (1 mL) and diiodohydantoin (326.78 mg, 0.86 mmol, 1.0 eq). The reaction mixture was stirred at 0°C for 1 hour. Completion of the reaction was monitored by LCMS. The reaction mixture was added dropwise to a saturated aqueous sodium carbonate solution (200 mL), stirred for 0.5 hour, and filtered to obtain a solid. The solid was dried under vacuum and slurried with ethanol (10 mL) to give 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (314 mg, yield: 60%) as a yellow solid.
[1242] MS m / z:602[M+H] + .
[1243] Step 5: 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide
[1244] To a solution of 5-(4-amino-7-bromo-2-iodo-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (314 mg, 0.52 mmol, 1.0 eq) and 2-fluoro-N-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]prop-2-enamide (174.92 mg, 0.57 mmol, 1.1 eq) in N,N-dimethylformamide (10 mL) and water (1 mL) were added tetrakistriphenylphosphine palladium (60.1 mg, 0.05 mmol, 0.1 eq) and sodium carbonate (138.08 mg, 1.3 mmol, 2.5 eq) under nitrogen. The reaction mixture was stirred at 70°C under nitrogen for 20 hours. After completion of the reaction, the solvent was removed by distillation under reduced pressure, diluted with water (50 mL), and extracted with dichloromethane (20 mL x 3). The organic phase was collected, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure to obtain the crude product. Column chromatography (dichloromethane:ethyl acetate = 1:1) was used to purify the product to yield 5-(4-amino-7-bromo-2-{4-[(2-fluoroacrylamido]-2-methylphenyl}-1-methylpyrrolo[3,2-c]pyridin-3-yl)-3-chloro-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-2-carboxamide (176 mg, yield: 51.6%). The product was a yellow liquid.
[1245] MS m / z:653[M+H] + .
[1246] Example 1: Compound 1 Methanesulfonate
[1247] 4-(4-amino-7-(3-(dimethylamino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 1 methanesulfonate)
[1248] Step 1: 4-(4-amino-7-(3-(dimethylamino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 1)
[1249] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (38.5 mg, 0.062 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2 mL) and triethylamine (2 mL), and N,N-dimethylprop-2-yn-1-amine (154 mg, 1.86 mmol, 30 eq), cuprous iodide (5.9 mg, 0.031 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl) ether]palladium(II) (4.4 mg, 0.0062 mmol, 0.1 eq), and tetrakistriphenylphosphine palladium (7.2 mg, 0.0062 mmol, 0.1 eq) were added under nitrogen protection and microwave reaction at 115 ° C for 1 hour. The reaction was complete as monitored by LCMS. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by preparative column chromatography to obtain 4-(4-amino-7-(3-(dimethylamino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (3.5 mg, yield: 9.1%).
[1250] MS m / z:623[M+H] +
[1251] 1 H NMR(400MHz,DMSO-d6)δ10.41(s,1H),8.65(t,J=6.5Hz,1H),7.84(s,1H),7.73 (d,J=8.2Hz,2H),7.68(d,J=7.8Hz,1H),7.32(d,J=8.3Hz,2H),6.96(s,1H),6. 88(d,J=8.0Hz,1H),5.71(dd,J=47.6,3.8Hz,1H),5.46(s,2H),5.42(d,J=3.7H z,1H),4.11-4.05(m,2H),3.91(s,3H),3.73(s,3H),3.50(s,2H),2.25(s,6H).
[1252] HPLC separation conditions:
[1253] Column: Phenomenex C18 80*40mm*3μm;
[1254] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1255] Flow rate: 25mL / min.
[1256] Step 2: 4-(4-amino-7-(3-(dimethylamino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 1 methanesulfonate)
[1257] 4-(4-amino-7-(3-(dimethylamino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (11.2 mg, 0.018 mmol, 1 eq) was dissolved in acetonitrile (5 mL), and methanesulfonic acid (34.6 mg, 0.36 mmol, 20 eq) was dissolved in water (2 mL). 0.1 mL of the methanesulfonic acid aqueous solution was slowly added dropwise to the system under nitrogen protection and reacted at room temperature for 2 hours. Distilled water (20 mL) was added and the mixture was directly lyophilized to give 4-(4-amino-7-(3-(dimethylamino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (12.3 mg, yield: 95.3%) as a light yellow solid.
[1258] MS m / z:623[M+H] +
[1259] Example 2: Compound 2
[1260] 4-(4-amino-7-((3-aminooxetan-3-yl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 2)
[1261] Step 1: tert-Butyl-(3-((4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)ethynyl)oxetan-3-yl)carbamate
[1262] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (38.2 mg, 0.062 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2 mL) and triethylamine (2 mL), and tert-butyl-(3-ethynyloxetane-3-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide was added. The mixture was stirred at 400 ℃ for 1 h under a nitrogen atmosphere at 115°C for 1 h. The reaction was monitored by LCMS for completion. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by column chromatography (methanol / dichloromethane: 7%) to give tert-butyl-(3-((4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)ethynyl)oxetan-3-yl)carbamate (20 mg, yield: 44.1%).
[1263] MS m / z:737[M+H] +
[1264] Step 2: 4-(4-amino-7-((3-aminooxetan-3-yl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 2)
[1265] Dissolve tert-butyl-(3-((4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)ethynyl)oxetan-3-yl)carbamate (14 mg, 0.019 mmol, 1 eq) in dichloromethane (5 mL). Add trifluoroacetic acid (2.5 mL) and react at room temperature under nitrogen for 2 hours. LCMS monitoring indicates the reaction is complete. The reaction solution was concentrated, adjusted to weak alkalinity with saturated sodium bicarbonate, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and spin-dried. The residue was purified by preparative chromatography to give 4-(4-amino-7-((3-aminooxetan-3-yl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (3.8 mg, yield: 31.4%) as a gray solid.
[1266] MS m / z:637[M+H] +
[1267] 1 H NMR (400MHz, DMSO-d6) δ10.42(s,1H),8.66(t,J=6.5Hz,1H),7.86(d,J=6.2Hz,1H),7.7 5(d,J=8.3Hz,2H),7.69(d,J=7.9Hz,1H),7.32(d,J=8.3Hz,2H),6.97(s,1H),6.89(d,J= 8.0Hz,1H),5.73(dd,J=47.6,3.7Hz,1H),5.51(s,2H),5.45(dd,J=15.7,3.7Hz,1H),4. 75(d,J=5.7Hz,2H),4.52(d,J=5.6Hz,2H),4.11-4.07(m,2H),3.92(s,3H),3.74(s,3H).
[1268] The HPLC separation conditions were the same as in Example 1.
[1269] Example 3: Compound 3 Methanesulfonate
[1270] 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-morpholinoprop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 3 methanesulfonate)
[1271] Step 1: 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-morpholinoprop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 3)
[1272] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (45 mg, 0.073 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2.25 mL) and triethylamine (2.25 mL), and 4-(prop-2-yn-1 The mixture was stirred at 115°C for 1 hour under nitrogen protection in a microwave oven. The reaction was monitored by LCMS for completion. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by preparative chromatography to give 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-morpholinoprop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (5 mg, yield: 10.3%).
[1273] MS m / z:665[M+H] +
[1274] 1 H NMR (400MHz, DMSO-d6) δ10.41(s,1H),8.65(t,J=6.4Hz,1H),7.86(s,1H),7.74(d,J=8.6Hz,2H),7.69(d,J=7.9Hz,1H),7.33(d,J=8.6Hz, 2H),6.97(s,1H),6.89(d,J=7.7Hz,1H),5.73(dd,J=47.6,3.7Hz,1H),5.51(s,2H),5.45(dd,J=15.5,3.7Hz,1H),4.11-4.07(m,2H),3.91 (s,3H),3.74(s,3H),3.65-3.55(m,6H),2.58-2.52(m,4H).
[1275] HPLC separation conditions:
[1276] Column: Phenomenex C18 80*40mm*3μm;
[1277] Mobile phase: [A (formic acid / water, 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1278] Flow rate: 25mL / min.
[1279] Step 2: 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-morpholinoprop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 3 methanesulfonate)
[1280] 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-morpholinoprop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (12.3 mg, 0.0185 mmol, 1 eq) was dissolved in acetonitrile (5 mL), and methanesulfonic acid (35.6 mg, 0.37 mmol, 20 eq) was dissolved in water (2 mL). 0.1 mL of the methanesulfonic acid aqueous solution was slowly added dropwise to the system under nitrogen protection and reacted at room temperature for 2 hours. Distilled water (20 mL) was added and the mixture was directly freeze-dried to give 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-morpholinoprop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (13.7 mg, yield: 97.4%) as a light yellow solid.
[1281] MS m / z:665[M+H] +
[1282] Example 4: Compound 4
[1283] 4-(4-amino-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-7-(3-(methylamino)prop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 4)
[1284] Step 1: tert-Butyl-(3-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)prop-2-yn-1-yl)(methyl)carbamate
[1285] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (45 mg, 0.073 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2.25 mL) and triethylamine (2.25 mL), and tert-butyl-methyl(prop-2-yn- 1-yl) carbamate (370 mg, 2.19 mmol, 30 eq), cuprous iodide (6.9 mg, 0.037 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl)ether]palladium(II) (5.1 mg, 0.0073 mmol, 0.1 eq), tetrakis(triphenylphosphine)palladium (8.4 mg, 0.0073 mmol, 0.1 eq), under nitrogen protection, microwave reaction at 115°C for 1 hour. The reaction was complete by LCMS monitoring. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by column chromatography (methanol / dichloromethane: 7%) to give tert-butyl-(3-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)prop-2-yn-1-yl)(methyl)carbamate (15 mg, yield: 29%).
[1286] MS m / z:709[M+H] +
[1287] Step 2: 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-(methylamino)prop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 4)
[1288] Dissolve tert-butyl-(3-(4-amino-2-(4-(2-fluoroacryloylamino)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)prop-2-yn-1-yl)(methyl)carbamate (14.2 mg, 0.02 mmol, 1 eq) in dichloromethane (5 mL). Add trifluoroacetic acid (2.5 mL) and react at room temperature under nitrogen for 2 hours. LCMS monitoring indicates the reaction is complete. The reaction solution was concentrated, adjusted to weak alkalinity with saturated sodium bicarbonate, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and spin-dried. The residue was purified by preparative chromatography to give 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-(methylamino)prop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (3.5 mg, yield: 28.8%) as a gray solid.
[1289] MS m / z:609[M+H] +
[1290] 1 H NMR(400MHz,DMSO-d6)δ10.41(s,1H),8.65(t,J=6.4Hz,1H),8.28(s,1H),7.83(s,1 H),7.80-7.70(m,2H),7.68(d,J=7.9Hz,1H),7.37-7.27(m,2H),6.97(d,J=1.4Hz,1H ),6.89(dd,J=7.8,1.5Hz,1H),5.73(dd,J=47.7,3.7Hz,1H),5.47(s,2H),5.43(d,J =3.7Hz,1H),4.13-4.04(m,2H),3.91(s,3H),3.74(s,3H),3.59(s,2H),2.38(s,3H).
[1291] The HPLC separation conditions were the same as in Example 1.
[1292] Example 5: Compound 5 Methanesulfonate
[1293] 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 5 methanesulfonate)
[1294] Step 1: 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 5)
[1295] 4-(4-Amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (45 mg, 0.073 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2 mL) and triethylamine (2 mL), and 2-methylbut-3-yn-2-ol (123 mg, 1.46 mmol, 20 eq), cuprous iodide (6.9 mg, 0.0365 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl) ether]palladium(II) (5.1 mg, 0.0073 mmol, 0.1 eq), and tetrakistriphenylphosphine palladium (8.4 mg, 0.0073 mmol, 0.1 eq) were added. The mixture was protected by nitrogen and microwaved at 115 ° C for 1 hour. The reaction was complete as monitored by LCMS. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by preparative column chromatography to obtain 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (4.6 mg, yield: 10.1%).
[1296] MS m / z:624[M+H] +
[1297] 1 H NMR(400MHz,CH3OH-d4)δ7.86(d,J=7.9Hz,1H),7.78(s,1H),7.76-7.65(m,2H),7.34-7.23(m,2H),6.99(dd,J=8.0,1.5Hz,1H),6.96(d, J=1.5Hz,1H),5.72(dd,J=46.5,3.5Hz,1H),5.31(dd,J=15.1,3.5Hz,1H),4.11(q,J=9.3Hz,2H),4.01(s,3H),3.78(s,3H),1.59(s,6H).
[1298] HPLC separation conditions:
[1299] Column: Phenomenex C18 80*40mm*3μm;
[1300] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1301] Flow rate: 25mL / min.
[1302] Step 2: 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 5 methanesulfonate)
[1303] 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (12.5 mg, 0.02 mmol, 1 eq) was dissolved in acetonitrile (5 mL), and methylsulfonic acid (38.4 mg, 0.4 mmol, 20 eq) was dissolved in water (2 mL). 0.1 mL of the solution was slowly added dropwise to the system under nitrogen protection and reacted at room temperature for 2 hours. Distilled water (20 mL) was added and the mixture was directly freeze-dried to give 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (13.8 mg, yield: 96%) as a light yellow solid.
[1304] MS m / z:624[M+H] +
[1305] Example 6: Compound 6
[1306] 4-(4-amino-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-7-(3-(pyrrolidin-1-yl)prop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 6)
[1307] Step 1: 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-(pyrrolidin-1-yl)prop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 6)
[1308] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (65 mg, 0.105 mmol, 1 eq) was dissolved in N,N-dimethylformamide (3 mL) and triethylamine (3 mL), and 1-(prop-2-yn-1-yl)pyrrolidine (229 mg, 2.1 mmol, 20 eq), cuprous iodide (10 mg, 0.0525 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl) ether]palladium(II) (7.4 mg, 0.0105 mmol, 0.1 eq), and tetrakistriphenylphosphine palladium (12.1 mg, 0.0105 mmol, 0.1 eq) were added. The mixture was protected by nitrogen and microwaved at 115 ° C for 1 hour. The reaction was complete as monitored by LCMS. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by preparative column chromatography to obtain 4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-7-(3-(pyrrolidin-1-yl)prop-1-yn-1-yl)-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (5 mg, yield: 7.3%).
[1309] MS m / z:649[M+H] +
[1310] 1H NMR (400MHz, DMSO-d6) δ10.40(d,J=1.9Hz,1H),8.65(t,J=6.4Hz,1H),7.84(s,1H),7.74(d,J=8 .6Hz,2H),7.67(d,J=7.9Hz,1H),7.32(d,J=8.6Hz,2H),6.96(d,J=1.4Hz,1H),6.88(dd,J=7.9,1 .4Hz,1H),5.72(dd,J=47.6,3.7Hz,1H),5.62-5.45(m,2H),5.43(d,J=3.7Hz,1H),4.08(qd,J=9 .6,6.2Hz,2H),3.91(s,3H),3.73(s,3H),3.66(s,2H),2.70-2.56(m,4H),1.72(t,J=3.6Hz,4H).
[1311] HPLC separation conditions:
[1312] Column: Phenomenex C18 80*40mm*3μm;
[1313] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1314] Flow rate: 25mL / min.
[1315] Example 7: Compound 7
[1316] (S)-4-(4-amino-2-(4-(2-fluoroacryloylamino)phenyl)-7-(3-(3-hydroxypyrrolidin-1-yl)prop-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 7)
[1317] Step 1: (S)-4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-(3-hydroxypyrrolidin-1-yl)prop-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 7)
[1318] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (50 mg, 0.081 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2.5 mL) and triethylamine (2.5 mL), and (S)-1-(prop-2-yn-1-yl)-1-yl benzoate was added. )pyrrolidin-3-ol (203 mg, 1.62 mmol, 20 eq), cuprous iodide (7.7 mg, 0.0405 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl)ether]palladium(II) (5.7 mg, 0.0081 mmol, 0.1 eq), and tetrakis(triphenylphosphine)palladium (9.4 mg, 0.0081 mmol, 0.1 eq) were reacted under nitrogen protection in a microwave oven at 115°C for 1 hour. The reaction was monitored for completion by LCMS. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by preparative chromatography to give (S)-4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-(3-hydroxypyrrolidin-1-yl)prop-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (4.5 mg, yield: 8.4%).
[1319] MS m / z:665[M+H] +
[1320] 1 H NMR (400MHz, DMSO-d6) δ10.40(d,J=1.9Hz,1H),8.65(t,J=6.5Hz,1H),7.87(s,1H),7.80-7.72(m,2H),7.68(d,J=7.9Hz,1H),7.38-7.29 (m,2H),6.97(d,J=1.4Hz,1H),6.89(dd,J=7.9,1.5Hz,1H),5.73(dd,J=47.7,3.7Hz,1H),5.52(s,2H),5.45(dd,J=15.6,3.7Hz,1H),4.85 (s,1H),4.26(s,1H),4.10(td,J=9.8,6.5Hz,2H),3.91(s,3H),3.75(d,J=7.2Hz,5H), 2.94-2.82(m,2H),2.68-2.60(m,2H),2.04(dt,J=14.5,7.1Hz,1H),1.67-1.58(m,1H).
[1321] HPLC separation conditions:
[1322] Column: Phenomenex C18 80*40mm*3μm;
[1323] Mobile phase: [A (formic acid / water, 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1324] Flow rate: 25mL / min.
[1325] Example 8: Compound 8
[1326] (R)-4-(4-amino-2-(4-(2-fluoroacryloylamino)phenyl)-7-(3-(3-hydroxypyrrolidin-1-yl)prop-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 8)
[1327] Step 1: (R)-4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-(3-hydroxypyrrolidin-1-yl)prop-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 8)
[1328] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (60 mg, 0.097 mmol, 1 eq) was dissolved in N,N-dimethylformamide (2.5 mL) and triethylamine (2.5 mL), and (R)-1-(prop-2-yn-1-yl)-1-yl benzoate was added. )pyrrolidin-3-ol (242 mg, 1.94 mmol, 20 eq), cuprous iodide (9.2 mg, 0.0485 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl)ether]palladium(II) (6.8 mg, 0.0097 mmol, 0.1 eq), and tetrakis(triphenylphosphine)palladium (11.2 mg, 0.0097 mmol, 0.1 eq) were reacted under nitrogen protection in a microwave oven at 115°C for 1 hour. The reaction was complete as monitored by LCMS. The reaction solution was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by preparative chromatography to give (R)-4-(4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-7-(3-(3-hydroxypyrrolidin-1-yl)prop-1-yn-1-yl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (8 mg, yield: 12.4%).
[1329] MS m / z:665[M+H] +
[1330] 1 H NMR (400MHz, DMSO-d6) δ10.42(d,J=1.8Hz,1H),8.64(t,J=6.4Hz,1H),7.99(s,1H),7.88-7.75(m,2 H),7.71(d,J=7.9Hz,1H),7.42-7.29(m,2H),6.97(d,J=1.5Hz,1H),6.90(dd,J=7.9,1.5Hz,1H),5. 92(s,2H),5.73(dd,J=47.7,3.7Hz,1H),5.55-5.38(m,2H),4.47(s,1H),4.43(s,2H),4.10(qd,J=9 .6,6.3Hz,2H),3.91(s,3H),3.75(s,3H),3.56-3.44(m,4H),2.25-2.13(m,1H),1.95-1.87(m,1H).
[1331] HPLC separation conditions:
[1332] Column: Phenomenex C18 80*40mm*3μm;
[1333] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1334] Flow rate: 25mL / min.
[1335] Example 9: Compound 9 Methanesulfonate
[1336] 4-(4-amino-7-((1-aminocyclopropyl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 9 methanesulfonate)
[1337] Step 1: tert-Butyl-(1-((4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)ethynyl)cyclopropyl)carbamate
[1338] 4-(4-amino-7-bromo-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (78 mg, 0.126 mmol, 1 eq) was dissolved in N,N-dimethylformamide (3 mL) and triethylamine (3 mL), and tert-butyl-(1-ethynylcyclopropyl)carbamate (114 mg, 0.63 mmol, 5 eq), cuprous iodide (12 mg, 0.063 mmol, 0.5 eq), dichloro[bis(diphenylphosphinophenyl) ether]palladium(II) (8.8 mg, 0.0126 mmol, 0.1 eq), and tetrakistriphenylphosphine palladium (14.6 mg, 0.0126 mmol, 0.1 eq) were added. The mixture was protected by nitrogen and microwaved at 115 ° C for 1 hour. The reaction was complete as monitored by LCMS. The reaction mixture was cooled, water was added, and the mixture was extracted with dichloromethane. The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, spin-dried, and concentrated. The residue was purified by column chromatography (methanol / dichloromethane: 5%) to obtain tert-butyl-(1-((4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)ethynyl)cyclopropyl)carbamate (38 mg, yield: 41.9%).
[1339] MS m / z:721[M+H] +
[1340] Step 2: 4-(4-amino-7-((1-aminocyclopropyl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 9)
[1341] Dissolve tert-butyl-(1-((4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-3-(3-methoxy-4-((2,2,2-trifluoroethyl)carbamoyl)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl)ethynyl)cyclopropyl)carbamate (35 mg, 0.049 mmol, 1 eq) in dichloromethane (3 mL). Add trifluoroacetic acid (1 mL) and react at room temperature under nitrogen for 2 hours. LCMS monitoring indicates the reaction is complete. The reaction solution was concentrated, adjusted to weak alkalinity with saturated sodium bicarbonate, extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and spin-dried. The residue was purified by preparative chromatography to give 4-(4-amino-7-((1-aminocyclopropyl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (13 mg, yield: 42.8%) as a white solid.
[1342] MS m / z:621[M+H] +
[1343] 1 H NMR(400MHz,DMSO-d6)δ10.40(d,J=1.7Hz,1H),8.64(t,J=6.4Hz,1H),7.81-7.70(m,3H ),7.67(d,J=7.9Hz,1H),7.36-7.25(m,2H),6.95(d,J=1.6Hz,1H),6.87(dd,J=7.9,1.4H z,1H),5.72(dd,J=47.7,3.7Hz,1H),5.47(d,J=3.7Hz,1H),5.43(d,J=4.0Hz,2H),4.08 (qd,J=9.7,6.4Hz,2H),3.88(s,3H),3.73(s,3H),0.98-0.90(m,2H),0.87-0.80(m,2H).
[1344] HPLC separation conditions:
[1345] Column: Phenomenex C18 80*40mm*3μm;
[1346] Mobile phase: [A (ammonia / water 1 / 999)-B (acetonitrile)]; B%: 25%-65%, 9 min;
[1347] Flow rate: 25mL / min.
[1348] Step 3: 4-(4-amino-7-((1-aminocyclopropyl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (Compound 9 methanesulfonate)
[1349] 4-(4-amino-7-((1-aminocyclopropyl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (11.2 mg, 0.018 mmol, 1 eq) was dissolved in acetonitrile (5 mL), and methylsulfonic acid (34.6 mg, 0.36 mmol, 20 eq) was dissolved in water (2 mL). 0.1 mL of the solution was slowly added dropwise to the system under nitrogen protection and reacted at room temperature for 2 hours. Distilled water (20 mL) was added and the mixture was directly freeze-dried to give 4-(4-amino-7-((1-aminocyclopropyl)ethynyl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide methanesulfonate (12.3 mg, yield: 95.3%) as a light yellow solid.
[1350] MS m / z:621[M+H] +
[1351] Example 10: Compound 10
[1352] 4-(4-amino-7-(3-(cis-2,6-dimethylmorpholino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 10)
[1353] Step 1: cis-2,6-dimethyl-4-(prop-2-yn-1-yl)morpholine
[1354] Cis-2,6-dimethylmorpholine (1.01 g, 8.77 mmol, 1 eq) was added to acetone (10 mL), and cesium carbonate (2.86 g, 8.77 mmol, 1 eq) and 3-bromoprop-1-yne (1.04 g, 8.77 mmol, 1 eq) were added in batches. The mixture was then reacted at room temperature for 6 hours. After the reaction, it was concentrated and ice water was added. The mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (PE / EtOAc = 30-60%) to give cis-2,6-dimethyl-4-(prop-2-yn-1-yl)morpholine (1.13 g, yield: 75.7%) as a yellow oil.
[1355] MS m / z:154[M+H] +
[1356] 1 H NMR (400MHz, CHCl3-d) δ3.71 (ddd, J=10.2, 6.2, 2.1Hz, 2H), 3.29 (d, J=2.5Hz, 2H), 2.72 (dt, J= 10.3,1.8Hz,2H),2.27(t,J=2.4Hz,1H),1.98(dd,J=11.3,10.1Hz,2H),1.18(d,J=6.4Hz,6H).
[1357] Step 2: 4-(4-amino-7-(3-(cis-2,6-dimethylmorpholino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 10)
[1358] 4-(4-Amino-7-bromo-2-(4-(2-fluoroacryloylamino)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (62 mg, 0.1 mmol, 1.0 eq), cis-2,6-dimethyl-4-(prop-2-yn-1-yl)morpholine (306 mg, 2 mmol, 20 eq), cuprous iodide (7.62 mg, 0.04 mmol, 0.4 eq), tetrakis(triphenylphosphine)palladium (23.1 mg, 0.02 mmol, 0.2 eq), bis(triphenylphosphine)palladium dichloride (7.02 mg, 0.01 mmole). ol, 0.1 eq) was added to a mixed solvent of triethylamine (3 mL) and N,N-dimethylformamide (2 mL), followed by bubbling nitrogen for 10 seconds. The reaction was carried out in a microwave oven at 115°C for 2.25 hours. After completion of the reaction, the mixture was cooled to room temperature, filtered, and concentrated. The residue was purified by preparative chromatography to give 4-(4-amino-7-(3-(cis-2,6-dimethylmorpholino)prop-1-yn-1-yl)-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (11.3 mg, yield: 16.3%) as a light yellow solid.
[1359] MS m / z:693[M+H] +
[1360] 1 H NMR(400MHz,CH3OH-d4)δ7.88(t,J=9.4Hz,2H),7.74(d,J=8.6Hz,2H),7.39– 7.25(m,2H),7.08–6.95(m,2H),5.84–5.69(m,1H),5.33(dd,J=15.2,3.4Hz,1 H),4.14(q,J=9.4Hz,2H),4.04(s,3H),3.81(s,3H),3.79–3.70(m,2H),3.64( s, 2H), 2.92 (d, J = 11.1Hz, 2H), 2.07 (t, J = 10.8Hz, 2H), 1.19 (d, J = 6.3Hz, 6H).
[1361] HPLC separation conditions:
[1362] Column: Phenomenex C18 80*40mm*3μm;
[1363] Mobile phase: [A (formic acid / water, 1 / 999)-B (acetonitrile)]; B%: 30%-60%, 9 min;
[1364] Flow rate: 25mL / min.
[1365] Example 11: Compound 11
[1366] 4-(7-(3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptane-5-yl)prop-1-yn-1-yl)-4-amino-2-(4-(2-fluoroacryloylamido)phenyl)-1-methyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-methoxy-N-(2,2,2-trifluoroethyl)benzamide (Compound 11)
[1367] Step 1: (1R,4R)-5-(prop-2-yn-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane
[1368] (1R,4R)-2-Aza-5-oxabicyclo[2.2.1]heptane hydrochloride (1.36 g, 10.03 mmol, 1 eq) was added to tetrahydrofuran (10 mL), and 4N sodium hydroxide (15.05 mL, 60.18 mmol, 6 eq) and 3-bromoprop-1-yne (1.25 g, 10.53 mmol, 1.05 eq) were slowly added. The mixture was then reacted at room temperature for 8 hours. After the reaction, ice water was added, the mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography (PE / EtOAc = 30-70%) to give (1R,4R)-5-(prop-2-yn-1-yl)-2-oxa-5-azabicyclo[2.2.1]heptane (0.65 g, yield: 43.4%) as a yellow oil.
[1369] MS m / z:138[M+H] +
[1370] Step 2: 4-(7-(3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)prop-1-yn-1-yl)-4-amino-2-(4-(2-fluoroacryloylamido)ph...
Claims
1. A compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: in: X is CR X or N; R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl; Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl; or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group; Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C 6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl; Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 2a replace; Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 2-a are independently hydrogen or C 1-6 alkyl; m is 0, 1, 2, 3, 4 or 5; Each R 8 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl; Each R 8a and R 8b are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 8-a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group or one or more R 8-b Substituted C 3-8 Cycloalkyl; Each R 8-a and R 8-b are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene; Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 3a replace; Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; n is 0, 1, 2, 3 or 4; L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-; Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl; Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 7 For halogen, cyano, R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl; Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl, -OC 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl; Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 )、-P(O)(R 18 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl; Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, One or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 Deuterium, C 1-6 Alkyl, halogen, cyano, hydroxyl or -N(R 12 )2; Each R 12 are each independently hydrogen or C 1-6 alkyl; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f Each is independently -S(O)2(R 19 ), deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Substituted C 3-8 Cycloalkyl; Each R 9-a 、R 9-b 、R 9-c and R 9-d Deuterium, C 1-6 Alkyl, hydroxyl, halogen, cyano, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2; Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl; Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl; Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 17 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 18 are independently hydrogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 19 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2, 3 or 4; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: in: X is CR X or N; R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl; Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl; or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group; Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C 6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl; Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 2a replace; Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 2-a are independently hydrogen or C 1-6 alkyl; m is 0, 1, 2, 3, 4 or 5; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene; Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 3a replace; Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; n is 0, 1, 2, 3 or 4; L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-; Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl; Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 7 For halogen, cyano, R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cycloalkyl, 3-10 membered heterocyclic hydrocarbon Base, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl; Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl or -OC 1-6 alkyl; R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl; Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 )、-P(O)(R 18 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl; Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are each independently deuterium, halogen, cyano, hydroxyl, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 are each independently deuterium, halogen, cyano, hydroxyl or -N(R 12 )2; Each R 12 are each independently hydrogen or C 1-6 alkyl; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f Each is independently -S(O)2(R 19 ), deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo, C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1- 6-membered alkyl, 3-12-membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9- d Substituted C 3-8 Cycloalkyl; Each R 9-a 、R 9-b 、R 9-c and R 9-d Deuterium, C 1-6 Alkyl, hydroxyl, halogen, cyano, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2; Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl; Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl; Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 17 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 18 are independently hydrogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 19 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is Independently, 1, 2 or 3.
3. The compound of formula (I) according to claim 2, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: X is CR X or N; R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl; Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl; or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group; Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C 6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl; Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more R 2a replace; Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 2-a are independently hydrogen or C 1-6 alkyl; m is 0, 1, 2, 3, 4 or 5; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene; Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl and 5-10 membered heteroaryl are each independently unsubstituted or substituted by one or more R 3a replace; Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; n is 0, 1, 2, 3 or 4; L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-; Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl; Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 7 For halogen, cyano, R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl; Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl or -OC 1-6 alkyl; R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, or multiple R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl; Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl; Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 are each independently deuterium, halogen, cyano, hydroxyl or -N(R 12 )2; Each R 12 are each independently hydrogen or C 1-6 alkyl; Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Fang alkyl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo, C 1- 6-alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Substituted C 3-8 Cycloalkyl; Each R 9-a 、R 9-b 、R 9-c and R 9-d are each independently deuterium, hydroxyl, halogen, cyano or -NH2; Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl; Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl; Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
4. The compound of formula (I) according to claim 3, its stereoisomer or pharmaceutically acceptable salt thereof, wherein: in: X is CR X or N; R X is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C substituted by one or more halogen 1-6 alkyl; Each R 6 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 6a Substituted C 1-6 Alkyl, one or more R 6b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 6c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 6d Substituted C 6-10 Aryl or one or more R 6e substituted 5-10 membered heteroaryl; or two R 6 Together with the nitrogen atom to which they are commonly connected, they form a 3-10 membered heterocyclic hydrocarbon group or one or more R 6f substituted 3-10 membered heterocyclic hydrocarbon group; Each R 6a 、R 6b 、R 6c 、R 6d 、R 6e and R 6f are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 1 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)N(R 6 )2、-C(O)R 6 、-C(O)OR 6 、-SO2R 6 、-SO2N(R 6 )2. By one or more R 1a Substituted C 1-6 Alkyl, one or more R 1b Replaced -OC 1-6 Alkyl, one or more R 1c Substituted C 2-6 Alkenyl, one or more R 1d Substituted C 2-6 Alkynyl, one or more R 1e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1g Substituted C 6-10 Aryl or one or more R 1h substituted 5-10 membered heteroaryl; Each R 1a 、R 1b 、R 1c 、R 1d 、R 1e 、R 1f 、R 1g and R 1h are independently deuterium, halogen, cyano, hydroxyl, -N(R 6 )2、C 1- 6-alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 1-a Substituted C 1-6 Alkyl, one or more R 1-b Replaced -OC 1-6 Alkyl, one or more R 1-c Substituted C 2-6 Alkenyl, one or more R 1-d Substituted C 2-6 Alkynyl, one or more R 1-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 1-f substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 1-g Substituted C 6-10 Aryl or one or more R 1-h substituted 5-10 membered heteroaryl; Each R 1-a 、R 1-b 、R 1-c 、R 1-d 、R 1-e 、R 1-f 、R 1-g and R 1-h are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring A is C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -N(R 8 )2、-S(O)2(R 8 )、-S(O)2N(R 8 )2、-S(O)(R 8 )、-S(O)N(R 8 )2、-C(O)(R 8 )、-C(O)O(R 8 )、-C(O)N(R 8 )2、-OC(O)(R 8 )、-OC(O)N(R 8 )2、-N(R 8 )C(O)O(R 8 )、-N(R 8 )C(O)(R 8 )、-N(R 8 )C(O)N(R 8 )2、-N(R 8 )S(O)2N(R 8 )2、-N(R 8 )S(O)2(R 8 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 The aryl or 5-10 membered heteroaryl is unsubstituted or substituted by one or more R 2a replace; Each R 2a are independently deuterium, halogen, cyano, -N(R 2-a )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 2-a are independently hydrogen or C 1-6 alkyl; m is 0, 1, 2, 3, 4 or 5; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; Ring B is C 3-8 Cycloalkylene, 3-10 membered heterocycloalkylene, C 6-10 Arylene or 5-10 membered heteroarylene; Each R 3 are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered hetero The aryl group is unsubstituted or substituted with one or more R 3a replace; Each R 3a are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; n is 0, 1, 2, 3 or 4; L is a covalent bond, C 1-6 Alkylene, -N(R L )-、-N(R L )C(O)-、-C(O)N(R L )-、-N(R L )S(O)2-、-S(O)2N(R L )-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)- or -S(O)2-; Each R L are independently hydrogen, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R La Substituted C 1-6 Alkyl, one or more R Lb Substituted C 3-8 Cyclic hydrocarbon group, one or more R Lc substituted 3-10 membered heterocyclic hydrocarbon group, one or more R Ld Substituted C 6-10 Aryl or one or more R Le substituted 5-10 membered heteroaryl; Each R La 、R Lb 、R Lc 、R Ld and R Le are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1-6 alkyl; R 7 For halogen, cyano, R 7a 、R 7b and R 7c are independently hydrogen, deuterium, halogen, cyano, -C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、C 1-6 Alkyl, one or more R 7-a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, one or more R 7-b Substituted C 2-6 Alkenyl, C 2-6 Alkynyl, one or more R 7-c Substituted C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, one or more R 7-d Substituted C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, one or more R 7-f Substituted C 6-10 Aryl, 5-10 membered heteroaryl or one or more R 7-g substituted 5-10 membered heteroaryl; Each R 7-a 、R 7-b 、R 7-c 、R 7-d 、R 7-e 、R 7-f and R 7-g are independently deuterium, halogen, cyano, -N(R 6 )2, hydroxyl, C 1- 6-alkyl or -OC 1-6 alkyl; R 4 is hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -N(R 6 )2、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 4a Substituted C 1-6 Alkyl, one or more R 4b Substituted C 2-6 Alkenyl, one or more R 4c Substituted C 2-6 Alkynyl, one or more R 4d Substituted C 3-8 Cyclic hydrocarbon group, one or more R 4e substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 4f Substituted C 6-10 Aryl or one or more R 4g substituted 5-10 membered heteroaryl; Each R 4a 、R 4b 、R 4c 、R 4d 、R 4e 、R 4f and R 4g are independently deuterium, halogen, cyano, C 1-6 Alkyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, nitro, -O(R 6 )、-S(R 6 )、-N(R 6 )2、-S(O)2(R 6 )、-S(O)2N(R 6 )2、-S(O)(R 6 )、-S(O)N(R 6 )2、-C(O)(R 6 )、-C(O)O(R 6 )、-C(O)N(R 6 )2、-OC(O)(R 6 )、-OC(O)N(R 6 )2、-N(R 6 )C(O)O(R 6 )、-N(R 6 )C(O)(R 6 )、-N(R 6 )C(O)N(R 6 )2、-N(R 6 )S(O)2N(R 6 )2、-N(R 6 )S(O)2(R 6 ), C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl or 5-10 membered heteroaryl; R 5 For hydrogen, deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C( O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5b Replaced -OC 1-6 Alkyl, one or more R 5c Substituted C 2-6 Alkenyl, one or more R 5d Substituted C 2-6 Alkynyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5g Substituted C 6-10 Aryl or one or more R 5h substituted 5-10 membered heteroaryl; Each R 5a 、R 5b 、R 5c 、R 5d 、R 5e 、R 5f 、R 5g and R 5h are independently deuterium, halogen, hydroxyl, cyano, nitro, -NR 9 R 10 、-S(R 9 )、-S(O)2(R 11 )、-S(O)2N(R 9 )2、-S(O)(R 11 )、-S(O)N(R 9 )2、-C(O)(R 11 )、-C(O)O(R 9 )、-C(O)N(R 9 )2、-OC(O)(R 9 )、-OC(O)N(R 9 )2、-N(R 9 )C(O)O(R 9 )、-N(R 9 )C(O)(R 9 )、-N(R 9 )C(O)N(R 9 )2、-N(R 9 )S(O)2N(R 9 )2、-N(R 9 )S(O)2(R 9 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 、C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 5-a Substituted C 1-6 Alkyl, one or more R 5- b Replaced -OC 1-6 Alkyl, one or more R 5-c Substituted C 2-6 Alkenyl, one or more R 5-d Substituted C 2-6 Alkynyl, one or more R 5-e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 5-g Substituted C 6-10 Aryl or one or more R 5-h substituted 5-10 membered heteroaryl; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, one or more R 15a Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15a and R 15b are independently deuterium, halogen, cyano, hydroxyl, -NH2, C 1-6 Alkyl or -OC 1-6 alkyl; Each R 5-a 、R 5-b 、R 5-c 、R 5-d 、R 5-e 、R 5-f 、R 5-g and R 5-h are independently deuterium, halogen, cyano, hydroxyl, oxo (=O), -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5-a-1 Substituted C 1-6 Alkyl, one or more R 5-a-2 Replaced -OC 1-6 Alkyl, one or more R 5-a-3 Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-a-1 、R 5-a-2 、R 5-a-3 and R 5-a-4 are each independently deuterium, halogen, cyano, hydroxyl or -N(R 12 )2; Each R 12 are each independently hydrogen or C 1-6 alkyl; Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group, one or more R 9d Substituted C 6-10 Aryl or one or more R 9e substituted 5-10 membered heteroaryl; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a 、R 9b 、R 9c 、R 9d 、R 9e and R 9f are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl, oxo, C 1- 6-alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, one or more R 9-b Replaced -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9-c Substituted 3-12 membered heterocyclic hydrocarbon group, C 3-8 Cyclic hydrocarbon group or one or more R 9-d Replaced C 3-8 Cycloalkyl; Each R 9-a 、R 9-b 、R 9-c and R 9-d are each independently deuterium, hydroxyl, halogen, cyano or -NH2; Each R 11 are independently hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-10 membered heterocyclic hydrocarbon group, C 6-10 Aryl, 5-10 membered heteroaryl, substituted by one or more R 11a Substituted C 1-6 Alkyl, one or more R 11b Substituted C 3-8 Cyclic hydrocarbon group, one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group, one or more R 11d Substituted C 6-10 Aryl or one or more R 11e substituted 5-10 membered heteroaryl; Each R 11a 、R 11b 、R 11c 、R 11d and R 11e are independently deuterium, halogen, cyano, -NH2, hydroxyl, C 1-6 Alkyl or -OC 1- 6-alkyl; Each R 13 are independently hydrogen, C 1-6 Alkyl, C 3-8 Cycloalkyl or 3-10 membered heterocycloalkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
5. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: It meets one or more of the following conditions: (1) Each C 6-10 Aryl is independently phenyl or naphthyl, for example phenyl; (2) Each C 6-10 Arylene is independently phenylene or naphthylene, for example phenylene, for example (3) each halogen is independently fluorine, chlorine, bromine or iodine, for example fluorine or chlorine, for example fluorine; (4) Each C 1-6 Alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl or sec-butyl, for example methyl, ethyl, isopropyl or isobutyl; (5) Each -OC 1-6 Alkyl is independently -O-methyl, -O-ethyl, -O-n-propyl, -O-isopropyl, -O-n-butyl, -O-tert-butyl, -O-isobutyl or -O-sec-butyl, for example -O-methyl, -O-ethyl or -O-isobutyl, for example -O-methyl; (6) each 3-12 membered heterocyclic hydrocarbon group is independently a 3-10 membered heterocyclic hydrocarbon group, and the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group; The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2 or 3. The polycyclic ring may be a cyclic ring, a spirocyclic ring or a bridged ring, such as piperazinyl, piperidinyl, Another example like Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2, 3 or 4. The polycyclic ring may be a cyclic ring, a spirocyclic ring or a bridged ring, for example Further example Preferably, each 3-12 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic hydrocarbon group, and the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocyclic alkyl group or a 3-10 membered heterocyclic alkenyl group; The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two, or more of N, O, or S, and the number of heteroatoms is 1, 2, or 3; More preferably, each 3-12 membered heterocyclic hydrocarbon group is independently a 3-10 membered heterocyclic hydrocarbon group, and the 3-10 membered heterocyclic hydrocarbon group is preferably a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group; The 3-10 membered heterocycloalkyl group is preferably a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group is preferably a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3; (7) Each C 3-8 The cycloalkyl groups are independently C 3-8 Cycloalkyl or C 3-8 Cycloalkenyl, such as C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl is preferably C 3-8 Monocyclic cycloalkyl or C 6-8 Polycyclic cycloalkyl, more preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, such as cyclopropyl; the C 3-8 Cycloalkenyl is preferably C 3-8 Monocyclic cycloalkenyl or C 6-8 polycyclic cycloalkenyl; (8) Each C 1-6 The alkylene group is independently methylene, ethylene, n-propylene, isopropylene, n-butylene, tert-butylene, isobutylene or sec-butylene, preferably methylene; (9) Each C 2-6 Alkenyl is independently ethenyl, propenyl, butenyl or pentenyl; (10) Each C 2-6 Alkynyl is independently ethynyl, propynyl, butynyl or pentynyl, for example (11) Each 5-10 membered heteroaryl group is independently a 5-6 membered heteroaryl group having a heteroatom species of N and a heteroatom number of 1, 2 or 3. Monocyclic heteroaryl or 8-10 membered polycyclic heteroaryl, such as pyridyl, (12) Each 5-10 membered heteroarylene group is independently a 5-6 membered monocyclic heteroarylene group or an 8-10 membered polycyclic heteroarylene group, wherein the heteroatom species is N and the number of heteroatoms is 1, 2 or 3; (13) Each C 3-8 The cycloalkylene groups are independently C 3-8 Cycloalkylene or C 3-8 Cycloalkenylene, the C 3-8 Cycloalkylene is preferably C3-8 monocyclic cycloalkylene or C 6-8 Polycyclic cycloalkylene, the C 3-8 Cycloalkenylene is preferably C 3-8 Monocyclic cycloalkenylene or C 6-8 polycyclic cycloalkenylene; (14) Each 3-10 membered heterocycloalkylene group is independently a 3-10 membered heterocycloalkylene group or a 3-10 membered heterocycloalkenylene group, wherein the 3-10 membered heterocycloalkylene group is preferably a 3-6 membered monocyclic heterocycloalkylene group or a 6-10 membered polycyclic heterocycloalkylene group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3; and the 3-10 membered heterocycloalkenylene group is preferably a 3-6 membered monocyclic heterocycloalkenylene group or a 6-10 membered polycyclic heterocycloalkenylene group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3; (15) Each-SC 1-6 Alkyl is independently methylmercapto, ethylmercapto, n-propylmercapto, isopropylmercapto, n-butylmercapto, isobutylmercapto, sec-butylmercapto or tert-butylmercapto; and (16) each 3-10 membered heterocycloalkyl group is independently a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group; The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2 or 3. The polycyclic ring may be a cyclic ring, a spirocyclic ring or a bridged ring, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2, 3 or 4. The polycyclic ring may be a cyclic ring, a spirocyclic ring or a bridged ring, for example Further example Preferably, each 3-10 membered heterocycloalkyl group may independently be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group; The 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two, or more of N, O, or S, and the number of heteroatoms is 1, 2, or 3; More preferably, each 3-10 membered heterocycloalkyl group is independently a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group; The 3-10 membered heterocycloalkyl group is preferably a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic heterocycloalkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group is preferably a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3; Preferably, the compound represented by formula (I), its stereoisomers or pharmaceutically acceptable salts thereof meet the following conditions: R 7b 、R 7c 、R 7-a and R 11 In the embodiment, each 3-10 membered heterocyclic hydrocarbon group is independently a 3-10 membered heterocyclic alkyl group or a 3-10 membered heterocyclic alkenyl group, and the 3-10 membered heterocyclic alkyl group may be a 3-6 membered monocyclic heterocyclic alkyl group or a 6-10 membered polycyclic heterocyclic alkyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2 or 3, and the polycyclic ring may be a cyclic, spirocyclic or bridged ring, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one or both of N and O, and the number of heteroatoms is 1, 2, or 3. Further example Preferably, R 7b and R 7c In the embodiment, each 3-10 membered heterocyclic hydrocarbon group is independently a 3-10 membered heterocyclic alkyl group or a 3-10 membered heterocyclic alkenyl group, wherein the 3-10 membered heterocyclic alkyl group is preferably a 3-6 membered monocyclic heterocyclic alkyl group or a 6-10 membered polycyclic heterocyclic alkyl group having one or both of N and O as heteroatoms and 1, 2 or 3 heteroatoms, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group is preferably a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3; and / or, R 5 、R 5a 、R 5-b 、R 5-f 、R 9 、R 9a 、R 9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group is independently a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group may be The heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2 or 3, and the 3-6 membered monocyclic heterocycloalkyl or 6-10 membered polycyclic heterocycloalkyl, the polycyclic ring may be a cyclic ring, a spirocyclic ring or a bridged ring, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2, 3 or 4. The polycyclic ring may be a cyclic ring, a spirocyclic ring or a bridged ring, for example Further example Preferably, R 5 、R 5a 、R 5-f 、R 9 、R 9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group may independently be a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group may be a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group may be a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic (e.g., cyclic, spiro or bridged) heterocycloalkyl group, wherein the heteroatom species is one, two or more of N, O or S, and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group may be a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic (e.g., cyclic, spirocyclic, or bridged) heterocycloalkenyl group, wherein the heteroatom species is one, two, or more of N, O, or S, and the number of heteroatoms is 1, 2, or 3; More preferably, R 5 、R 5a 、R 5-f 、R 9 、R 9f 、R 10 and R 15 In the embodiment, each 3-12 membered heterocyclic hydrocarbon group is independently a 3-10 membered heterocyclic hydrocarbon group, the 3-10 membered heterocyclic hydrocarbon group is preferably a 3-10 membered heterocycloalkyl group or a 3-10 membered heterocycloalkenyl group, the 3-10 membered heterocycloalkyl group is preferably a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic heterocycloalkyl group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3, such as piperazinyl, piperidinyl, For example Further example The 3-10 membered heterocycloalkenyl group is preferably a 3-6 membered monocyclic heterocycloalkenyl group or a 6-10 membered polycyclic heterocycloalkenyl group in which the heteroatom species is one or both of N and O and the number of heteroatoms is 1, 2 or 3.
6. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: It meets one or more of the following conditions: (1)X is CR X ; (2)R X is hydrogen; (3)R 1 -N(R 6 )2; (4) Each R 6 are independently hydrogen; (5) Ring A is C 6-10 Aryl or 5-10 membered heteroaryl, preferably C 6-10 aryl; (6) Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; preferably each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2; More preferably, each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; further preferably each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2; further preferably each R 2 Independently -OC 1-6 Alkyl or -C(O)N(R 8 )2; (7) m is 1, 2 or 3, preferably 2 or 3, more preferably 2; (8) Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; (9) Each R 8a are independently halogen or hydroxy, preferably halogen; (10) Ring B is C 6-10 Arylene or 5-10 membered heteroarylene, preferably C 6-10 arylene; (11) n is 0, 1 or 2, preferably 0; (12)L is -N(R L )C(O)-; (13)R L is hydrogen or C 1-6 Alkyl, preferably hydrogen; (14)R 7 for (15)R 7a is hydrogen, halogen or C 1-6 Alkyl, preferably halogen; (16)R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, preferably hydrogen or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, more preferably hydrogen; (17)R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, preferably hydrogen or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group, more preferably hydrogen; (18) Each R 7-e are independently halogen, hydroxy or C 1-6 Alkyl, preferably C 1-6 alkyl; (19)R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 Alkyl, preferably C 1-6 alkyl; (20) Each R 4a are independently halogen or cyano; (21)R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; preferably one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; more preferably substituted by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; further preferably one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; further preferably substituted by one or more R 5a Substituted C 1-6 Alkyl or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; (22) Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; preferably hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; more preferably hydroxyl, -NR 9 R 10 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group; further preferably -NR 9 R 10 or a 3-12 membered heterocyclic hydrocarbon group; (23) Each R 5-b are independently halogen, hydroxy or -OC 1-6 Alkyl, preferably hydroxy or -OC 1-6 alkyl; (24) Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl, preferably 3-12 membered heterocycloalkyl; (25) Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, preferably halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, more preferably halogen, hydroxy or C 1-6 alkyl; (26) Each R 5-a-1 are independently halogen or hydroxy, preferably hydroxy; (27) Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 , preferably halogen or -NR 9 R 10 , more preferably -NR 9 R 10 ; (28) Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 , preferably hydroxyl or -NR 9 R 10 , more preferably -NR 9 R 10 ; (29) Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 Alkyl, preferably hydrogen or C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f Substituted 3-12 membered heterocyclic hydrocarbon group, preferably R 9 and R 10 Together with the nitrogen atom to which they are commonly attached, they form a 3-12 membered heterocyclic hydrocarbon group; (30) Each R 9a are independently halogen or hydroxy, preferably hydroxy; (31) Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cyclic hydrocarbon groups, preferably halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group, more preferably halogen, hydroxyl or C 1-6 alkyl; (32) Each R 9-a are independently hydroxy, halogen or -NH2, preferably hydroxy; (33) Each R 11 Independently C 1-6 alkyl; (34) Each R 12 are independently hydrogen; (35) Each R 13 are independently hydrogen or C 1-6 alkyl; (36) Each R 14 are independently hydrogen; and (37) each R 2a are independently deuterium, halogen or hydroxy, preferably deuterium or halogen; Preferably, the compound represented by formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, satisfies one or more of the following conditions: (a) When R 5a is a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 5-f a substituted 3-12 membered heterocyclic hydrocarbon group, wherein the 3-12 membered heterocyclic hydrocarbon group is a 3-6 membered monocyclic heterocycloalkyl group or a 6-10 membered polycyclic heterocycloalkyl group; (b) When R 5a is a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 5-f A substituted 3-12 membered heterocyclic hydrocarbon group, wherein the heteroatoms in the 3-12 membered heterocyclic hydrocarbon group are selected from one or both of N and O, and the number of heteroatoms is 1 or 2; and (c) when R 5a is a 3-12 membered heterocyclic hydrocarbon group or is replaced by one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group, when at least one hetero atom in the 3-12 membered heterocyclic hydrocarbon group is N, the 3-12 membered heterocyclic hydrocarbon group is connected to R 5 C 1-6 Alkyl linkage.
7. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: It meets one or more of the following conditions: (1)R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; For example, R 5 -C(O)(R 11 )、-C(O)N(R 9 )2、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; further, for example, R 5 -C(O)(R 11 )、-C(O)N(R 9 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; (2) Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; For example, each R 9 and R 10 Each independently represents hydrogen, hydroxy, 3-12 membered heterocyclic hydrocarbon, one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group or C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; (3) Each R 9a are independently halogen, hydroxy, 3-12 membered heterocyclic hydrocarbon or -N(R 14 )2; (4) Each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 1-6 Alkyl, -S(O)2(R 19 ), C 3-8 Cycloalkyl, oxo, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; for example, each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 3-8 Cycloalkyl, oxo, C 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; (5) Each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ), halogen, -NHR 16 、-N(R 16 )2 or -NH2, for example, each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ) or -N(R 16 )2, preferably, each R 9-a Each independently is C 1-6 Alkyl or hydroxyl; (6) Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c Substituted 3-10 membered heterocyclic hydrocarbon group; for example, each R 11 is independently a 3-10 membered heterocyclic hydrocarbon group or is replaced by one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; (7) Each R 9c Independently C 1-6 alkyl; (8) Each R 11c are independently -NH2, hydroxyl or C 1-6 Alkyl; for example, each R 11c are independently hydroxy or C 1-6 Alkyl, such as C 1-6 alkyl; (9) Each R 16 Independently C 1-6 alkyl; (10) Each R 17 Independently C 1-6 alkyl; (11) Each R 18 Independently C 1-6 alkyl; (12) Each R 19 Independently C 1-6 alkyl; (13) The stereoisomers refer to configurational isomers, conformational isomers or mixtures thereof, such as enantiomers, diastereomers or mixtures thereof; (14) When the compound represented by formula (I) contains a chiral center, the compound represented by formula (I) is a stereoisomer or a mixture thereof. For example, when it contains one chiral center, the compound represented by formula (I) is an R configuration and / or an S configuration.
8. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: It meets one or more of the following conditions: (1) Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl, -N(R 8 )2 or -C(O)N(R 8 )2, where C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; preferably each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, where -OC 1-6 Alkyl is unsubstituted or substituted with one or more R 2a replace; (2) Each R 8 are independently hydrogen, C 1-6 Alkyl, one or more R 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl; preferably, each R 8 are independently hydrogen, 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl; Preferably, each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl; (3) Each R 8a and R 8b Each independently represents deuterium, halogen, hydroxyl, one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cycloalkyl; preferably, each R 8a are independently deuterium, halogen, or one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cyclic hydrocarbon group, each R 8b are independently halogen or are replaced by one or more R 8-a Substituted C 1-6 alkyl; Preferably, each R 8a are independently deuterium, halogen or hydroxy; preferably, each R 8a are independently deuterium or halogen; (4) Each R 8-a and R 8-b is a halogen; (5)R 3 Halogen or C 1-6 alkyl; (6) n is 0 or 1; (7)R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, preferably R 7b is hydrogen, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; (8)R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e Substituted 3-10 membered heterocyclic hydrocarbon group, preferably R 7c is hydrogen, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; (9) Each R 7-a and R 7-e are independently halogen, hydroxy, C 1-6 alkyl or 3-10 membered heterocyclic hydrocarbon group; preferably, each R 7- a and R 7-e Each independently is C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group; Preferably, each R 7-a and R 7-e are each independently halogen, hydroxyl or C 1-6 Alkyl; More preferably, each R 7-a and R 7-e Each independently is C 1-6 alkyl; (10)R 5 -C(O)(R 11 )、-C(O)N(R 9 )2、-P(O)(R 18 )2, 3-12 membered heterocyclic hydrocarbon group, one or more R 5a Substituted C 1- 6 alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group; for example, R 5 -C(O)(R 11 )、-C(O)N(R 9 )2, 3-12 membered heterocyclic hydrocarbon group, one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; (11) Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; (12) Each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; (13) Each R 5-a-4 C 1-6 alkyl; (14) Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; (15) Each R 15b are independently halogen or C 1-6 alkyl; (16) Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 Alkyl, preferably halogen, hydroxy, -N(R 12 )2 or C 1-6 alkyl; (17) Each R 5f For hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; (18) Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; (19) Each R 9a are independently halogen, hydroxy, -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; preferably, each R 9a are independently -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; (20) Each R 9-c Independently C 1-6 alkyl; (21) Each R 9b are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl or C 1-6 alkyl; (22) Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -S(O)2(R 19 ), by one or Multiple R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl; (23) Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2; Preferably, each R 9-a are independently hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2; (24) Each R 12 Independently C 1-6 alkyl; (25) Each R 14 Independently C 1-6 alkyl; and (26) each R 2a independently deuterium.
9. The compound of formula (I) according to any one of claims 1 to 8, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The definitions of the groups in the compound represented by formula (I), its stereoisomers or pharmaceutically acceptable salts thereof are as described in Scheme 1, Scheme 2, Scheme 3, Scheme 4, Scheme 5, Scheme 6, Scheme 7, Scheme 8, Scheme 9, Scheme 10, Scheme 11, Scheme 12 or Scheme 13. Solution 1: X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2; m is 1, 2, or 3; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen or hydroxy; Ring B is C 6-10 Arylene or 5-10 membered heteroarylene; n is 0, 1, or 2; L is -N(R L )C(O)-; R L is hydrogen or C 1-6 alkyl; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-e are independently halogen, hydroxy or C 1-6 alkyl; R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 alkyl; Each R 4a are independently halogen or cyano; R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cycloalkyl, 3-12 heterocyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently halogen, hydroxy or -OC 1-6 alkyl; Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 are independently halogen or hydroxy; Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently halogen or hydroxy; Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl; Each R 9-a are independently hydroxy, halogen or -NH2; Each R 11 Independently C 1-6 alkyl; Each R 12 are independently hydrogen; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 2 X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 aryl; Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2; m is 2; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen; Ring B is C 6-10 arylene; n is 0; L is -N(R L )C(O)-; R L is hydrogen; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-e Independently C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 For one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently hydroxy or -OC 1-6 alkyl; Each R 15 are independently 3-12 membered heterocyclic hydrocarbon groups; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 are independently hydroxyl groups; Each R 5e are independently -NR 9 R 10 ; Each R 5f are independently hydroxy or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently hydroxyl groups; Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; Each R 9-a are independently hydroxyl groups; Each R 11 Independently C 1-6 alkyl; Each R 12 are independently hydrogen; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 3 X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 aryl; Each R 2 Independently -OC 1-6 Alkyl or -C(O)N(R 8 )2; m is 2; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen, such as fluorine; Ring B is C 6-10 arylene; n is 0; L is -N(R L )C(O)-; R L is hydrogen; R 7 for R 7a is a halogen, such as fluorine; R 7b is hydrogen; R 7c is hydrogen; R 4 C 1-6 Alkyl groups, such as methyl; R 5 For one or more R 5a Substituted C 1-6 Alkyl or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5a are independently -NR 9 R 10 or a 3-12 membered heterocyclic hydrocarbon group; Each R 5f are independently -NR 9 R 10 ; Each R 9 and R 10 are each independently hydrogen or C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly attached, they form a 3-12 membered heterocyclic hydrocarbon group; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S. The number of sub-elements is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Solution 4 X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 1, 2, or 3; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen or hydroxy; Each R 2a are independently deuterium, halogen or hydroxyl; Ring B is C 6-10 Arylene or 5-10 membered heteroarylene; n is 0, 1, or 2; L is -N(R L )C(O)-; R L is hydrogen or C 1-6 alkyl; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-e are independently halogen, hydroxy or C 1-6 alkyl; R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 alkyl; Each R 4a are independently halogen or cyano; R 5 For one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently halogen, hydroxy or -OC 1-6 alkyl; Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 are independently halogen or hydroxy; Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently halogen or hydroxy; Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl; Each R 9-a are independently hydroxy, halogen or -NH2; Each R 11 Independently C 1-6 alkyl; Each R 12 are independently hydrogen; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Solution 5 X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 2 or 3; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen; Each R 2a are independently deuterium or halogen; Ring B is C 6-10 arylene; n is 0; L is -N(R L )C(O)-; R L is hydrogen; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-e Independently C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 For one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently hydroxy or -OC 1-6 alkyl; Each R 15 are independently 3-12 membered heterocyclic hydrocarbon groups; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 are independently hydroxyl groups; Each R 5e are independently halogen or -NR 9 R 10 ; Each R 5f are independently hydroxy or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 9a Substituted C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently hydroxyl groups; Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; Each R 9-a are independently hydroxyl groups; Each R 11 Independently C 1-6 alkyl; Each R 12 are independently hydrogen; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 6 X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 aryl; Each R 2 Independently -OC 1-6 Alkyl or -C(O)N(R 8 )2; m is 2; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen, such as fluorine; Ring B is C 6-10 arylene; n is 0; L is -N(R L )C(O)-; R L is hydrogen; R 7 for R 7a is a halogen, such as fluorine; R 7b is hydrogen; R 7c is hydrogen; R 4 C 1-6 Alkyl groups, such as methyl; R 5 For one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5a are independently hydroxyl, -NR 9 R 10 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5e are independently -NR 9 R 10 ; Each R 5f are independently -NR 9 R 10 ; Each R 5-f are independently halogen, hydroxy or C 1-6 alkyl; Each R 9 and R 10 are each independently hydrogen or C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9f are independently halogen, hydroxy or C 1-6 alkyl; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 7: X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 1, 2, or 3; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen or hydroxy; Each R 2a are independently deuterium, halogen or hydroxyl; Ring B is C 6-10 Arylene or 5-10 membered heteroarylene; n is 0, 1, or 2; L is -N(R L )C(O)-; R L is hydrogen or C 1-6 alkyl; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-e are independently halogen, hydroxy or C 1-6 alkyl; R 4 C 1-6 Alkyl or one or more R 4a Substituted C 1-6 alkyl; Each R 4a are independently halogen or cyano; R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently halogen, hydroxy, -NR 9 R 10 、-S(O)2(R 11 ),-OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently halogen, hydroxy or -OC 1-6 alkyl; Each R 15 Independently C 3-8 Cycloalkyl or 3-12 membered heterocycloalkyl; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 are independently halogen or hydroxy; Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently halogen, hydroxy, 3-12 membered heterocyclic hydrocarbon or -N(R 14 )2; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, hydroxy, oxo, -N(R 14 )2、C 1-6 Alkyl, -S(O)2(R 19 ),-OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl; Each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ), halogen, -NHR 16 、-N(R 16 )2 or -NH2; Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c are independently -NH2, hydroxyl or C 1-6 alkyl; Each R 12 are independently hydrogen; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 alkyl; Each R 17 Independently C 1-6 alkyl; Each R 19 Independently C 1-6 alkyl; Each R 18 Independently C 1-6 alkyl; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 8: X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkynyl or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 2 or 3; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen; Each R 2a are independently deuterium or halogen; Ring B is C 6-10 arylene; n is 0; L is -N(R L )C(O)-; R L is hydrogen; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c is hydrogen or is replaced by one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-e Independently C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ),-OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently hydroxy or -OC 1-6 alkyl; Each R 15 are independently 3-12 membered heterocyclic hydrocarbon groups; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 are independently hydroxyl groups; Each R 5e are independently halogen or -NR 9 R 10 ; Each R 5f are independently hydroxy or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently halogen, hydroxy, 3-12 membered heterocyclic hydrocarbon or -N(R 14 )2; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 1-6 Alkyl, -S(O)2(R 19 ), C 3-8 Cycloalkyl, oxo, -OC 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; Each R 9-a Independently C 1-6 Alkyl, hydroxy, -S(O)2(R 17 ) or -N(R 16 )2; Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c are independently -NH2, hydroxyl or C 1-6 alkyl; Each R 12 are independently hydrogen; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 alkyl; Each R 17 Independently C 1-6 alkyl; Each R 19 Independently C 1-6 alkyl; Each R 18 Independently C 1-6 alkyl; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 9: X is CR X ; R X is hydrogen; R 1 -N(R 6 )2; Each R 6 are independently hydrogen; Ring A is C 6-10 aryl; Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2; m is 2; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently halogen; Ring B is C 6-10 arylene; n is 0; L is -N(R L )C(O)-; R L is hydrogen; R 7 for R 7a is a halogen; R 7b is hydrogen; R 7c is hydrogen; R 4 C 1-6 alkyl; R 5 -C(O)(R 11 )、-C(O)N(R 9 )2. By one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group or one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5a are independently hydroxyl, -NR 9 R 10 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5e are independently -NR 9 R 10 ; Each R 5f are independently -NR 9 R 10 ; Each R 5-f are independently halogen, hydroxy or C 1-6 alkyl; Each R 9 and R 10 Each independently represents hydrogen, hydroxy, 3-12 membered heterocyclic hydrocarbon, one or more R 9c Substituted 3-12 membered heterocyclic hydrocarbon group or C 1-6 alkyl; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, hydroxy, -N(R 14 )2、C 3-8 Cycloalkyl, oxo, C 1-6 Alkyl, one or more R 9-a Substituted C 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; Each R 9-a Each independently is C 1-6 Alkyl or hydroxyl; Each R 11 is independently a 3-10 membered heterocyclic hydrocarbon group or is replaced by one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c Independently C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Preferably, in each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 10: X is CH; R 1 is -NH2; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 2 or 3; Each R 8 are independently hydrogen, C 1-6 Alkyl, one or more R 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3- 8-cyclic hydrocarbon group; Each R 8a and R 8b Each independently represents deuterium, halogen, hydroxyl, one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cycloalkyl; Each R 8-a and R 8-b are each independently halogen; Each R 2a are independently deuterium or halogen; Ring B is C 6-10 arylene; R 3 Halogen or C 1-6 alkyl; n is 0 or 1; L is -NHC(O)-; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-a and R 7-e are independently halogen, hydroxy, C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group; R 4 C 1-6 alkyl; R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-4 substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-a-4 C 1-6 alkyl; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15b are independently halogen or C 1-6 alkyl; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon, 3-12 membered Heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 is halogen or hydroxy; Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently halogen, hydroxy, -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9-c Independently C 1-6 alkyl; Each R 9b are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl or C 1-6 alkyl; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -S(O)2(R 19 ), by one or more R 9- a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, -OC 1-6 Alkyl or C 3-8 Cycloalkyl; Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2; Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c are independently hydroxy or C 1-6 alkyl; Each R 12 are independently hydrogen or C 1-6 alkyl; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 alkyl; Each R 17 Independently C 1-6 alkyl; Each R 18 Independently C 1-6 alkyl; Each R 19 Independently C 1-6 alkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2, 3 or 4; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 11: X is CH; R 1 is -NH2; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, wherein said -OC 1-6 Each alkyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 2 or 3; Each R 8 are independently hydrogen, 8a Substituted C 1-6 Alkyl or one or more R 8b Substituted C 3-8 Cycloalkyl; Each R 8a are independently deuterium, halogen, or one or more R 8-a Substituted C 1-6 Alkyl or one or more R 8-b Substituted C 3-8 Cyclic hydrocarbon group, each R 8b are independently halogen or are replaced by one or more R 8-a Substituted C 1-6 alkyl; Each R 8-a and R 8-b are each independently halogen; Each R 2a for deuterium; Ring B is C 6-10 arylene; R 3 Halogen or C 1-6 alkyl; n is 0 or 1; L is -NHC(O)-; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b is hydrogen, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c is hydrogen, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-a and R 7-e Each independently is C 1-6 Alkyl or 3-10 membered heterocyclic hydrocarbon group; R 4 C 1-6 alkyl; R 5 -C(O)(R 11 ), by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15b are independently halogen or C 1-6 alkyl; Each R 5-f are independently halogen, hydroxy, -N(R 12 )2 or C 1-6 alkyl; Each R 5e are independently halogen or -NR 9 R 10 ; Each R 5f are independently hydroxy or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9a Substituted C 1- 6 alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f Replaced 3-12 1-membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9-c Independently C 1-6 alkyl; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, one or more R 9-a Substituted C 1- 6-membered alkyl, 3-12-membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl; Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2; Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c Independently C 1-6 alkyl; Each R 12 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 alkyl; Each R 17 Independently C 1-6 alkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2, 3 or 4; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 12: X is CH; R 1 is -NH2; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2、-S(O)2(R 8 ) or -C(O)N(R 8 )2, wherein said C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 2 or 3; Each R 8 are independently hydrogen, C 1-6 Alkyl or one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently deuterium, halogen or hydroxyl; Each R 2a are independently deuterium or halogen; Ring B is C 6-10 arylene; R 3 Halogen or C 1-6 alkyl; n is 0 or 1; L is -NHC(O)-; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c For hydrogen, halogen, C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-a and R 7-e are each independently halogen, hydroxyl or C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 -C(O)(R 11 )、-P(O)(R 18 )2. By one or more R 5a Substituted C 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group, one or more R 5-b Replaced -OC 1-6 Alkyl or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 5-b are independently halogen, hydroxy, -OC 1-6 Alkyl or 3-12 membered heterocyclic hydrocarbon group; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15b are independently halogen or C 1-6 alkyl; Each R 5-f are independently halogen, hydroxy, oxo, -N(R 12 )2、C 1-6 Alkyl, -OC 1-6 Alkyl, C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5-a-1 Substituted C 1-6 alkyl; Each R 5-a-1 is halogen or hydroxy; Each R 5e are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 5f are independently halogen, hydroxy, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, -C(O)N(R 13 )2、C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 9a Substituted C 1-6 Alkyl, one or more R 9b Substituted C 3-8 Cyclic hydrocarbon group or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently halogen, hydroxy, -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9-c Independently C 1-6 alkyl; Each R 9b are independently deuterium, halogen, cyano, -N(R 14 )2, hydroxyl or C 1-6 alkyl; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, -S(O)2(R 19 ), by one or more R 9- a Substituted C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, -OC 1-6 Alkyl or C 3-8 Cycloalkyl; Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 )、-NH2、-NH(R 16 ) or -N(R 16 )2; Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c are independently hydroxy or C 1-6 alkyl; Each R 12 are independently hydrogen or C 1-6 alkyl; Each R 13 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 alkyl; Each R 17 Independently C 1-6 alkyl; Each R 18 Independently C 1-6 alkyl; Each R 19 Independently C 1-6 alkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; Option 13: X is CH; R 1 is -NH2; Ring A is C 6-10 Aryl or 5-10 membered heteroaryl; Each R 2 are independently halogen, -OC 1-6 Alkyl or -C(O)N(R 8 )2, wherein said -OC 1-6 Each alkyl group is independently unsubstituted or substituted with one or more R 2a replace; m is 2 or 3; Each R 8 are independently hydrogen or replaced by one or more R 8a Substituted C 1-6 alkyl; Each R 8a are independently deuterium or halogen; Each R 2a for deuterium; Ring B is C 6-10 arylene; R 3 Halogen or C 1-6 alkyl; n is 0 or 1; L is -NHC(O)-; R 7 for R 7a is hydrogen, halogen or C 1-6 alkyl; R 7b is hydrogen, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; R 7c is hydrogen, one or more R 7-a Substituted C 1-6 Alkyl or one or more R 7-e substituted 3-10 membered heterocyclic hydrocarbon group; Each R 7-a and R 7-e Each independently is C 1-6 alkyl; R 4 C 1-6 alkyl; R 5 -C(O)(R 11 ), by one or more R 5a Substituted C 1-6 Alkyl, one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group, one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group or -C(O)N(R 9 )2; Each R 5a are independently hydroxyl, -NR 9 R 10 、-S(O)2(R 11 ), C 1-6 Alkyl, -OC 1-6 Alkyl, -OR 15 , 3-12 membered heterocyclic hydrocarbon group or one or more R 5-f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15 Independently C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 15b substituted 3-12 membered heterocyclic hydrocarbon group; Each R 15b are independently halogen or C 1-6 alkyl; Each R 5-f are independently halogen, hydroxy, -N(R 12 )2 or C 1-6 alkyl; Each R 5e are independently halogen or NR 9 R 10 ; Each R 5f are independently hydroxy or -NR 9 R 10 ; Each R 9 and R 10 are independently hydrogen, hydroxyl, C 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 9a Substituted C 1- 6 alkyl or one or more R 9c substituted 3-12 membered heterocyclic hydrocarbon group; or R 9 and R 10 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; or two R 9 Together with the nitrogen atom to which they are commonly connected, they form a 3-12 membered heterocyclic hydrocarbon group or one or more R 9f substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9a are independently -N(R 14 ) 2, 3-12 membered heterocyclic hydrocarbon group or one or more R 9-c substituted 3-12 membered heterocyclic hydrocarbon group; Each R 9-c Independently C 1-6 alkyl; Each R 9c Independently C 1-6 alkyl; Each R 9f are independently halogen, -N(R 14 )2, hydroxyl, oxo (=O), C 1-6 Alkyl, one or more R 9-a Substituted C 1- 6-membered alkyl, 3-12-membered heterocyclic hydrocarbon or C 3-8 Cycloalkyl; Each R 9-a Independently C 1-6 Alkyl, hydroxy, halogen, -S(O)2(R 17 ) or -N(R 16 )2; Each R 11 Independently C 1-6 Alkyl, 3-10 membered heterocyclic hydrocarbon or one or more R 11c substituted 3-10 membered heterocyclic hydrocarbon group; Each R 11c Independently C 1-6 alkyl; Each R 12 are independently hydrogen or C 1-6 alkyl; Each R 14 are independently hydrogen or C 1-6 alkyl; Each R 16 Independently C 1-6 alkyl; Each R 17 Independently C 1-6 alkyl; In each "heterocyclic hydrocarbon group", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3; In each "heteroaryl", the heteroatom species are independently selected from one, two or more of N, O and S, and the number of heteroatoms is independently 1, 2 or 3.
10. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound represented by formula (I) is a compound represented by formula (I-1), (I-2), (I-3) or (I-4): Wherein, m' is 0, 1, 2, 3 or 4; X 1 、X 2 、X 3 and X 4 are each independently N, -CH or -CR 2’ ; Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a Substituted; preferably, each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a More preferably, each R 2’ Independently -OC 1-6 alkyl; X, R 1 、R 2 、R 2a 、R 3 、R 4 、R 5 、R 7 、R 7a 、R 7b 、R 7c 、R 8 , m, n, ring A, ring B and L are as defined in any one of claims 1 to 9; Preferably, the compound represented by formula (I) is a compound represented by formula (I-5): Among them, R 2-1 For halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a substituted; preferably, R 2-1 For halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a substituted; more preferably, R 2-1 For-OC 1-6 alkyl; R 2-2 is hydrogen or halogen; X, R 1 、R 2a 、R 3 、R 4 、R 5 、R 7 、R 8 , n, ring B and L are as defined in any one of claims 1 to 9.
11. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound represented by formula (I) is a compound represented by formula (I-6): Among them, X, R 1 、R 2 、R 3 、R 7 、R 4 、R 9 , L, Ring A, Ring B, m and n are as defined in any one of claims 1 to 9; Preferably, the compound represented by formula (I) is a compound represented by formula (I-7) or formula (I-8): Wherein, m' is 0, 1, 2, 3 or 4; X, R 1 、R 2 、R 3 、R 7a 、R 7b 、R 7c 、R 4 、R 9 , L, R 7 , Ring A, Ring B, m and n are defined as any one of claims 1 to 9; More preferably, the compound represented by formula (I) is a compound represented by formula (I-6), formula (I-7) or formula (I-8): Wherein, m' is 0, 1, 2, 3 or 4; X, R 1 、R 2 、R 7a 、R 7b 、R 7c 、R 4 、R 9 、R 18 and R 11 The definition as described in any one of claims 1 to 9.
12. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound represented by formula (I) is a compound represented by formula (I-12): Among them, X 1 、X 2 、X 3 and X 4 are each independently N, CH or CR 2’ ; Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; X, R 1 、R 2a 、R 3 、R 4 、R 5 、R 7 、R 8 and n is defined as in any one of claims 1 to 9; Preferably, the compound represented by formula (I-12) satisfies one or both of the following conditions: (1) Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; and (2)X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ ; or, X 1 and X 4 are each independently N or CH, X 3 and X 2 CR 2’ ; Preferably, X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ ; Preferably, the compound represented by formula (I) is a compound represented by formula (I-13), formula (I-14), formula (I-15), formula (I-16), formula (I-17) or formula (I-18): Among them, X 1 、X 2 、X 3 and X 4 are each independently N, CH or CR 2’ ; Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -N(R 8 )2 or -S(O)2(R 8 ), wherein the C 1-6 Alkyl, -OC 1-6 Alkyl, C 2-6 Alkenyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; R 5-1 For one or more R 5-1-a Substituted C 1-6 Alkyl; each R 5-1-a are independently hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, 3-12 membered heterocyclic hydrocarbon, one or more R 5-f Substituted 3-12 membered heterocyclic hydrocarbon group, NR 9 R 10 or -S(O)2(R 11 ); R 5-2 For one or more R 5e Substituted C 3-8 Cycloalkyl, 3-12 membered heterocyclic hydrocarbon, -P(O)(R 18 )2 or by one or more R 5f substituted 3-12 membered heterocyclic hydrocarbon group; X, R 1 、R 2a 、R 3 、R 4 、R 5e 、R 5f 、R 7a 、R 7b 、R 7c 、R 8 、R 9 、R 10 、R 11 、R 15 、R 18 、R 5-f and n is defined as in any one of claims 1 to 9; Preferably, the compound represented by formula (I-13), formula (I-14), formula (I-15), formula (I-16), formula (I-17) or formula (I-18) satisfies one or more of the following conditions: (1)X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ ; or, X 1 and X 4 are each independently N or CH, X 3 and X 2 CR 2’ ; Preferably, X 1 、X 2 and X 4 are each independently N or CH, X 3 CR 2’ ; (2) Each R 2’ are independently halogen, cyano, C 1-6 Alkyl, -OC 1-6 Alkyl or C 2-6 Alkynyl, wherein the C 1-6 Alkyl, -OC 1-6 Alkyl and C 2-6 Each alkynyl group is independently unsubstituted or substituted with one or more R 2a replace; (3)R 5-1-a For hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl or -S(O)2(R 11 ); and (4)R 5-2 For one or more R 5e Substituted C 3-8 Cyclic hydrocarbon group, 3-12 membered heterocyclic hydrocarbon group or one or more R 5f Substituted 3-12 membered heterocyclic hydrocarbon group.
13. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: It meets one or more of the following conditions: (1) X is CH; (2)R 1 is -NH2; (3) R2 is fluorine, -O-methyl, -O-CD3, -O-CHF2, -O-CF2Cl, cyano, -O-ethyl, chlorine, -CF3, -CHF2, -O-CF3, methyl, Such as fluorine, chlorine, -O-methyl, -O-CD3、 Preferably, R2 is fluoro, -O-methyl, -O-CD3, -O-CHF2, -O-CF2Cl, cyano, -O-ethyl, chlorine, -CF3, -CHF2, -O-CF3, methyl or For example, fluorine, chlorine, -O-methyl or Another example is -O-methyl or (4) Ring A is phenyl or pyridyl, preferably For example (5) Ring B is phenylene, for example (6) L is -N(H)C(O)-; (7)R 7 for Preferred Preferably, R 7 for Preferred For example (8)R 4 is methyl; (9)R 5 for For example Preferably, R 5 for For example, R 5 for Another example is R 5 for Further example R 5 for (10)R 3 is fluorine, chlorine or methyl; and (11) for Preferably, the end marked with * is connected to L; Preferably, the compound represented by formula (I), its stereoisomers or pharmaceutically acceptable salts thereof meet the following conditions: for For example Preferably, for For example Another example and / or, for For example For example Preferably, for Preferred For example 14. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound represented by formula (I) is any of the following compounds:
15. The compound of formula (I) according to any one of claims 1 to 4, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The pharmaceutically acceptable salt of the compound represented by formula (I) is any of the following compounds:
16. A pharmaceutical composition comprising substance A and a pharmaceutically acceptable excipient, wherein substance A is a compound of formula (I) according to any one of claims 1 to 15, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
17. Use of the compound of formula (I) according to any one of claims 1 to 15, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 16 in the preparation of an FGFR2 inhibitor.
18. Use of a compound as represented by formula (I) according to any one of claims 1 to 15, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 16 in the preparation of a medicament for treating and / or preventing a disease associated with FGFR2; preferably, the compound as represented by formula (I), its stereoisomer, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition is in a therapeutically effective amount, and / or the disease associated with FGFR2 is a disease associated with abnormal activation of FGFR2, and / or the disease is cancer, preferably bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, bladder cancer, ovarian cancer, colorectal cancer, endometrial cancer, or urothelial carcinoma, more preferably bile duct cancer, gastric cancer, or endometrial cancer, such as gastric cancer, and more preferably small cell lung cancer.
19. Use of a compound as shown in formula (I) according to any one of claims 1 to 15, its stereoisomer or pharmaceutically acceptable salt, or the pharmaceutical composition according to claim 16 in the preparation of a medicament for treating and / or preventing cancer; preferably, the compound as shown in formula (I), its stereoisomer or pharmaceutically acceptable salt, or the pharmaceutical composition is in a therapeutically effective amount, and / or the cancer is preferably bile duct cancer, liver cancer, breast cancer, prostate cancer, lung cancer, thyroid cancer, gastric cancer, bladder cancer, ovarian cancer, colorectal cancer, endometrial cancer, or urothelial cancer, the cancer is more preferably bile duct cancer, gastric cancer, or endometrial cancer, such as gastric cancer, and the lung cancer is more preferably small cell lung cancer.
20. A method for preparing a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, characterized in that: It is any of the following methods: Method 1: It comprises the following steps: in a solvent, a compound represented by formula (Ia) and a compound represented by formula (Ib) undergo Sonogashira reaction to obtain a compound represented by formula (I); Among them, X 1 is a halogen; X, R 1 、R 2 、R 3 、R 4 、R 5 、R 7 , m, n, ring A, ring B and L are as defined in any one of claims 1 to 15; Preferably, the X 1 is Br; And / or, the solvent is a nitrogen-containing compound solvent, such as N,N-dimethylformamide and / or triethylamine, and another example is a mixed solvent of N,N-dimethylformamide and triethylamine; And / or, the Sonogashira reaction is carried out under the action of a palladium catalyst; the palladium catalyst is preferably a divalent palladium catalyst and / or a zerovalent palladium catalyst, more preferably dichloro[bis(diphenylphosphinophenyl)ether]palladium and / or tetrakis(triphenylphosphine)palladium, for example, a mixture of dichloro[bis(diphenylphosphinophenyl)ether]palladium and tetrakis(triphenylphosphine)palladium; And / or, the Sonogashira reaction is carried out under the action of a base; the base is preferably an organic amine, such as triethylamine; Method 2: comprising the following steps: performing a deprotection reaction on a compound represented by formula (Ic) in a solvent to prepare a compound represented by formula (I); Among them, R 5’ -C(O)-R 11’ 、 By one or more R 5a’ Substituted C 1-6 Alkyl, with one or more -NYR 9 Substituted C 3-8 Cyclic hydrocarbon or one or more -NYR 9 Substituted 3-12 membered heterocyclic hydrocarbon group, each R 5a’ Independently for-NYR 9 or a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys, each Y being independently an amino protecting group; R 9’ is a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys; or R 9 and R 9’ Together with the nitrogen atoms to which they are attached, they form a group consisting of one or more -NYR 14 a substituted 3- to 12-membered heterocyclic hydrocarbon group or a 3- to 12-membered heterocyclic hydrocarbon group substituted by one or more Ys; R 11’ is a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys; R 5 -C(O)NR 11 、-C(O)N(R 9 )2. By one or more R 5a Substituted C 1-6 Alkyl, separated by one or more -NHR 9 Substituted C 3- 8-cyclic hydrocarbon group or one or more -NHR 9 Substituted 3-12 membered heterocyclic hydrocarbon group; each R 5a Independently -NHR 9 or a 3-12 membered heterocyclic hydrocarbon group; X, R 1 、R 2 、R 3 、R 4 、R 7 、R 9 、R 14 , m, n, ring A, ring B and L are as defined in any one of claims 1 to 15; Preferably, R 5’ For one or more R 5a’ Substituted C 1-6 Alkyl, with one or more -NYR 9 Substituted C 3-8 Cyclic hydrocarbon or one or more -NYR 9 Substituted 3-12 membered heterocyclic hydrocarbon group, each R 5a’ Independently for-NYR 9 or a 3-12 membered heterocyclic hydrocarbon group substituted by one or more Ys, each Y being independently an amino protecting group; R 5 For one or more R 5a Substituted C 1-6 Alkyl, separated by one or more -NHR 9 Substituted C 3-8 Cycloalkyl or one or more -NHR 9 Substituted 3-12 membered heterocyclic hydrocarbon group, each R 5a Independently -NHR 9 or a 3-12 membered heterocyclic hydrocarbon group; X, R 1 、R 2 、R 3 、R 4 、R 7 、R 9 , m, n, ring A, ring B and L are as defined in any one of claims 1 to 15; Preferably, the solvent is a halogenated hydrocarbon solvent, such as dichloromethane; and / or, said Y is tert-butyloxycarbonyl; And / or, the deprotection reaction is carried out under the action of an acid, preferably an organic acid, such as trifluoroacetic acid; Method 3: comprising the following steps: condensing a compound represented by formula (Id) with ammonia or an ammonia salt in a solvent to obtain a compound represented by formula (I); Among them, R 5” is hydroxy or halogen; X, R 1 、R 2 、R 3 、R 4 、R 5 、R 7 、R 9 , m, n, ring A, ring B and L are as defined in any one of claims 1 to 15; Preferably, the solvent is a nitrogen-containing compound solvent or a halogenated hydrocarbon solvent, such as N,N-diisopropylethylamine or dichloromethane; and / or, the R 5” is hydroxyl group; And / or, the condensation reaction is carried out under the action of a condensation reagent, and the condensation reagent is preferably 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; further preferably, the condensation reaction is carried out under the action of a condensation reagent and a base, and the base is preferably N,N-diisopropylethylamine; And / or, the ammonia salt is ammonia hydrochloride.
21. A compound of formula (Ia), (Ic) or (Id): in, X 1 , X, R 1 、R 2 、R 3 、R 4 、R 5’ 、R 5” 、R 7 , m, n, Ring A, Ring B and L are as defined in claim 20; Preferably, the compound of formula (Ia), formula (Ic) or formula (Id) is any of the following compounds:
Citation Information
Patent Citations
FGFR inhibitors and methods of use thereof
CN114126620A
PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY
WO2006004703A2
Azaindole derivative
WO2010046013A1
FGFR inhibitors and methods of making and using the same
WO2022109577A1
FGFR inhibitors and methods of use thereof
WO2023046117A1
